A	O
novel	O
SCN5A	O
mutation	O
manifests	O
as	O
a	O
malignant	O
form	O
of	O
long	B-Disease
QT	I-Disease
syndrome	I-Disease
with	O
perinatal	O
onset	O
of	O
tachycardia	B-Disease
/	O
bradycardia	B-Disease
.	O

OBJECTIVE	O
:	O
Congenital	O
long	B-Disease
QT	I-Disease
syndrome	I-Disease
(	O
LQTS	B-Disease
)	O
with	O
in	O
utero	O
onset	O
of	O
the	O
rhythm	O
disturbances	O
is	O
associated	O
with	O
a	O
poor	O
prognosis	O
.	O

In	O
this	O
study	O
we	O
investigated	O
a	O
newborn	O
patient	O
with	O
fetal	O
bradycardia	B-Disease
,	O
2	O
:	O
1	O
atrioventricular	B-Disease
block	I-Disease
and	O
ventricular	B-Disease
tachycardia	I-Disease
soon	O
after	O
birth	O
.	O

METHODS	O
:	O
Mutational	O
analysis	O
and	O
DNA	O
sequencing	O
were	O
conducted	O
in	O
a	O
newborn	O
.	O

The	O
2	O
:	O
1	O
atrioventricular	B-Disease
block	I-Disease
improved	O
to	O
1	O
:	O
1	O
conduction	O
only	O
after	O
intravenous	O
lidocaine	O
infusion	O
or	O
a	O
high	O
dose	O
of	O
mexiletine	O
,	O
which	O
also	O
controlled	O
the	O
ventricular	B-Disease
tachycardia	I-Disease
.	O

RESULTS	O
:	O
A	O
novel	O
,	O
spontaneous	O
LQTS	B-Disease
-	O
3	O
mutation	O
was	O
identified	O
in	O
the	O
transmembrane	O
segment	O
6	O
of	O
domain	O
IV	O
of	O
the	O
Na	O
(	O
v	O
)	O
1	O
.	O
5	O
cardiac	O
sodium	O
channel	O
,	O
with	O
a	O
G	O
-->	O
A	O
substitution	O
at	O
codon	O
1763	O
,	O
which	O
changed	O
a	O
valine	O
(	O
GTG	O
)	O
to	O
a	O
methionine	O
(	O
ATG	O
).	O

The	O
proband	O
was	O
heterozygous	O
but	O
the	O
mutation	O
was	O
absent	O
in	O
the	O
parents	O
and	O
the	O
sister	O
.	O

Expression	O
of	O
this	O
mutant	O
channel	O
in	O
tsA201	O
mammalian	O
cells	O
by	O
site	O
-	O
directed	O
mutagenesis	O
revealed	O
a	O
persistent	O
tetrodotoxin	O
-	O
sensitive	O
but	O
lidocaine	O
-	O
resistant	O
current	O
that	O
was	O
associated	O
with	O
a	O
positive	O
shift	O
of	O
the	O
steady	O
-	O
state	O
inactivation	O
curve	O
,	O
steeper	O
activation	O
curve	O
and	O
faster	O
recovery	O
from	O
inactivation	O
.	O

We	O
also	O
found	O
a	O
similar	O
electrophysiological	O
profile	O
for	O
the	O
neighboring	O
V1764M	O
mutant	O
.	O

But	O
,	O
the	O
other	O
neighboring	O
I1762A	O
mutant	O
had	O
no	O
persistent	O
current	O
and	O
was	O
still	O
associated	O
with	O
a	O
positive	O
shift	O
of	O
inactivation	O
.	O

CONCLUSIONS	O
:	O
These	O
findings	O
suggest	O
that	O
the	O
Na	O
(	O
v	O
)	O
1	O
.	O
5	O
/	O
V1763M	O
channel	O
dysfunction	O
and	O
possible	O
neighboring	O
mutants	O
contribute	O
to	O
a	O
persistent	O
inward	O
current	O
due	O
to	O
altered	O
inactivation	O
kinetics	O
and	O
clinically	O
congenital	O
LQTS	B-Disease
with	O
perinatal	O
onset	O
of	O
arrhythmias	B-Disease
that	O
responded	O
to	O
lidocaine	O
and	O
mexiletine	O
.	O


Allelic	O
expression	O
imbalance	O
of	O
human	O
mu	O
opioid	O
receptor	O
(	O
OPRM1	O
)	O
caused	O
by	O
variant	O
A118G	O
.	O

As	O
a	O
primary	O
target	O
for	O
opioid	O
drugs	O
and	O
peptides	O
,	O
the	O
mu	O
opioid	O
receptor	O
(	O
OPRM1	O
)	O
plays	O
a	O
key	O
role	O
in	O
pain	B-Disease
perception	O
and	O
addiction	O
.	O

Genetic	O
variants	O
of	O
OPRM1	O
have	O
been	O
implicated	O
in	O
predisposition	O
to	O
drug	B-Disease
addiction	I-Disease
,	O
in	O
particular	O
the	O
single	O
nucleotide	O
polymorphism	O
A118G	O
,	O
leading	O
to	O
an	O
N40D	O
substitution	O
,	O
with	O
an	O
allele	O
frequency	O
of	O
10	O
-	O
32	O
%,	O
and	O
uncertain	O
functions	O
.	O

We	O
have	O
measured	O
allele	O
-	O
specific	O
mRNA	O
expression	O
of	O
OPRM1	O
in	O
human	O
autopsy	O
brain	O
tissues	O
,	O
using	O
A118G	O
as	O
a	O
marker	O
.	O

In	O
8	O
heterozygous	O
samples	O
measured	O
,	O
the	O
A118	O
mRNA	O
allele	O
was	O
1	O
.	O
5	O
-	O
2	O
.	O
5	O
-	O
fold	O
more	O
abundant	O
than	O
the	O
G118	O
allele	O
.	O

Transfection	O
into	O
Chinese	O
hamster	O
ovary	O
cells	O
of	O
a	O
cDNA	O
representing	O
only	O
the	O
coding	O
region	O
of	O
OPRM1	O
,	O
carrying	O
adenosine	O
,	O
guanosine	O
,	O
cytidine	O
,	O
and	O
thymidine	O
in	O
position	O
118	O
,	O
resulted	O
in	O
1	O
.	O
5	O
-	O
fold	O
lower	O
mRNA	O
levels	O
only	O
for	O
OPRM1	O
-	O
G118	O
,	O
and	O
more	O
than	O
10	O
-	O
fold	O
lower	O
OPRM1	O
protein	O
levels	O
,	O
measured	O
by	O
Western	O
blotting	O
and	O
receptor	O
binding	O
assay	O
.	O

After	O
transfection	O
and	O
inhibition	O
of	O
transcription	O
with	O
actinomycin	O
D	O
,	O
analysis	O
of	O
mRNA	O
turnover	O
failed	O
to	O
reveal	O
differences	O
in	O
mRNA	O
stability	O
between	O
A118	O
and	O
G118	O
alleles	O
,	O
indicating	O
a	O
defect	O
in	O
transcription	O
or	O
mRNA	O
maturation	O
.	O

These	O
results	O
indicate	O
that	O
OPRM1	O
-	O
G118	O
is	O
a	O
functional	O
variant	O
with	O
deleterious	O
effects	O
on	O
both	O
mRNA	O
and	O
protein	O
yield	O
.	O

Clarifying	O
the	O
functional	O
relevance	O
of	O
polymorphisms	O
associated	O
with	O
susceptibility	O
to	O
a	O
complex	O
disorder	O
such	O
as	O
drug	B-Disease
addiction	I-Disease
provides	O
a	O
foundation	O
for	O
clinical	O
association	O
studies	O
.	O


Genetic	O
polymorphisms	O
in	O
the	O
carbonyl	O
reductase	O
3	O
gene	O
CBR3	O
and	O
the	O
NAD	O
(	O
P	O
)	O
H	O
:	O
quinone	O
oxidoreductase	O
1	O
gene	O
NQO1	O
in	O
patients	O
who	O
developed	O
anthracycline	O
-	O
related	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
after	O
childhood	O
cancer	B-Disease
.	O

BACKGROUND	O
:	O
Exposure	O
to	O
anthracyclines	O
as	O
part	O
of	O
cancer	B-Disease
therapy	O
has	O
been	O
associated	O
with	O
the	O
development	O
of	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
(	O
CHF	B-Disease
).	O

The	O
potential	O
role	O
of	O
genetic	O
risk	O
factors	O
in	O
anthracycline	O
-	O
related	O
CHF	B-Disease
remains	O
to	O
be	O
defined	O
.	O

Thus	O
,	O
in	O
this	O
study	O
,	O
the	O
authors	O
examined	O
whether	O
common	O
polymorphisms	O
in	O
candidate	O
genes	O
involved	O
in	O
the	O
pharmacodynamics	O
of	O
anthracyclines	O
(	O
in	O
particular	O
,	O
the	O
nicotinamide	O
adenine	O
dinucleotide	O
phosphate	O
:	O
quinone	O
oxidoreductase	O
1	O
gene	O
NQO1	O
and	O
the	O
carbonyl	O
reductase	O
3	O
gene	O
CBR3	O
)	O
had	O
an	O
impact	O
on	O
the	O
risk	O
of	O
anthracycline	O
-	O
related	O
CHF	B-Disease
.	O

METHODS	O
:	O
A	O
nested	O
case	O
-	O
control	O
study	O
was	O
conducted	O
within	O
a	O
cohort	O
of	O
1979	O
patients	O
enrolled	O
in	O
the	O
Childhood	O
Cancer	O
Survivor	O
Study	O
who	O
received	O
treatment	O
with	O
anthracyclines	O
and	O
had	O
available	O
DNA	O
.	O

Thirty	O
patients	O
with	O
CHF	B-Disease
(	O
cases	O
)	O
and	O
115	O
matched	O
controls	O
were	O
genotyped	O
for	O
polymorphisms	O
in	O
NQO1	O
(	O
NQO1	O
*	O
2	O
)	O
and	O
CBR3	O
(	O
the	O
CBR3	O
valine	O
[	O
V	O
]	O
to	O
methionine	O
[	O
M	O
]	O
substitution	O
at	O
position	O
244	O
[	O
V244M	O
]).	O

Enzyme	O
activity	O
assays	O
with	O
recombinant	O
CBR3	O
isoforms	O
(	O
CBR3	O
V244	O
and	O
CBR3	O
M244	O
)	O
and	O
the	O
anthracycline	O
substrate	O
doxorubicin	O
were	O
used	O
to	O
investigate	O
the	O
functional	O
impact	O
of	O
the	O
CBR3	O
V244M	O
polymorphism	O
.	O

RESULTS	O
:	O
Multivariate	O
analyses	O
adjusted	O
for	O
sex	O
and	O
primary	O
disease	O
recurrence	O
were	O
used	O
to	O
test	O
for	O
associations	O
between	O
the	O
candidate	O
genetic	O
polymorphisms	O
(	O
NQO1	O
*	O
2	O
and	O
CBR3	O
V244M	O
)	O
and	O
the	O
risk	O
of	O
CHF	B-Disease
.	O

Analyses	O
indicated	O
no	O
association	O
between	O
the	O
NQO1	O
*	O
2	O
polymorphism	O
and	O
the	O
risk	O
of	O
anthracycline	O
-	O
related	O
CHF	B-Disease
(	O
odds	O
ratio	O
[	O
OR	O
],	O
1	O
.	O
4	O
;	O
P	O
=.	O
97	O
).	O

There	O
was	O
a	O
trend	O
toward	O
an	O
association	O
between	O
the	O
CBR3	O
V244M	O
polymorphism	O
and	O
the	O
risk	O
of	O
CHF	B-Disease
(	O
OR	O
,	O
8	O
.	O
16	O
;	O
P	O
=.	O
56	O
for	O
G	O
/	O
G	O
vs	O
A	O
/	O
A	O
;	O
OR	O
,	O
5	O
.	O
44	O
;	O
P	O
=.	O
92	O
for	O
G	O
/	O
A	O
vs	O
A	O
/	O
A	O
).	O

In	O
line	O
,	O
recombinant	O
CBR3	O
V244	O
(	O
G	O
allele	O
)	O
synthesized	O
2	O
.	O
6	O
-	O
fold	O
more	O
cardiotoxic	B-Disease
doxorubicinol	O
per	O
unit	O
of	O
time	O
than	O
CBR3	O
M244	O
(	O
A	O
allele	O
;	O
CBR3	O
V244	O
[	O
8	O
.	O
26	O
+/-	O
3	O
.	O
57	O
nmol	O
/	O
hour	O
.	O
mg	O
]	O
vs	O
CBR3	O
M244	O
[	O
3	O
.	O
22	O
+/-	O
0	O
.	O
67	O
nmol	O
/	O
hour	O
.	O
mg	O
];	O
P	O
=.	O
1	O
).	O

CONCLUSIONS	O
:	O
The	O
functional	O
CBR3	O
V244M	O
polymorphism	O
may	O
have	O
an	O
impact	O
on	O
the	O
risk	O
of	O
anthracycline	O
-	O
related	O
CHF	B-Disease
among	O
childhood	O
cancer	B-Disease
survivors	O
by	O
modulating	O
the	O
intracardiac	O
formation	O
of	O
cardiotoxic	B-Disease
anthracycline	O
alcohol	O
metabolites	O
.	O

Larger	O
confirmatory	O
case	O
-	O
control	O
studies	O
are	O
warranted	O
.	O


Debrisoquine	O
phenotype	O
and	O
the	O
pharmacokinetics	O
and	O
beta	O
-	O
2	O
receptor	O
pharmacodynamics	O
of	O
metoprolol	O
and	O
its	O
enantiomers	O
.	O

The	O
metabolism	O
of	O
the	O
cardioselective	O
beta	O
-	O
blocker	O
metoprolol	O
is	O
under	O
genetic	O
control	O
of	O
the	O
debrisoquine	O
/	O
sparteine	O
type	O
.	O

The	O
two	O
metabolic	O
phenotypes	O
,	O
extensive	O
(	O
EM	O
)	O
and	O
poor	O
metabolizers	O
(	O
PM	O
),	O
show	O
different	O
stereoselective	O
metabolism	O
,	O
resulting	O
in	O
apparently	O
higher	O
beta	O
-	O
1	O
adrenoceptor	O
antagonistic	O
potency	O
of	O
racemic	O
metoprolol	O
in	O
EMs	O
.	O

We	O
investigated	O
if	O
the	O
latter	O
also	O
applies	O
to	O
the	O
beta	O
-	O
2	O
adrenoceptor	O
antagonism	O
by	O
metoprolol	O
.	O

The	O
drug	O
effect	O
studied	O
was	O
the	O
antagonism	O
by	O
metoprolol	O
of	O
terbutaline	O
-	O
induced	O
hypokalemia	B-Disease
.	O

By	O
using	O
pharmacokinetic	O
pharmacodynamic	O
modeling	O
the	O
pharmacodynamics	O
of	O
racemic	O
metoprolol	O
and	O
the	O
active	O
S	O
-	O
isomer	O
,	O
were	O
quantitated	O
in	O
EMs	O
and	O
PMs	O
in	O
terms	O
of	O
IC50	O
values	O
,	O
representing	O
metoprolol	O
plasma	O
concentrations	O
resulting	O
in	O
half	O
-	O
maximum	O
receptor	O
occupancy	O
.	O

Six	O
EMs	O
received	O
0	O
.	O
5	O
mg	O
of	O
terbutaline	O
s	O
.	O
c	O
.	O

on	O
two	O
different	O
occasions	O
:	O
1	O
)	O
1	O
hr	O
after	O
administration	O
of	O
a	O
placebo	O
and	O
2	O
)	O
1	O
hr	O
after	O
150	O
mg	O
of	O
metoprolol	O
p	O
.	O
o	O
.	O

Five	O
PMs	O
were	O
studied	O
according	O
to	O
the	O
same	O
protocol	O
,	O
except	O
for	O
a	O
higher	O
terbutaline	O
dose	O
(	O
0	O
.	O
75	O
mg	O
)	O
on	O
day	O
2	O
.	O

Blood	O
samples	O
for	O
the	O
analysis	O
of	O
plasma	O
potassium	O
,	O
terbutaline	O
,	O
metoprolol	O
(	O
racemic	O
,	O
R	O
-	O
and	O
S	O
-	O
isomer	O
),	O
and	O
alpha	O
-	O
hydroxymetoprolol	O
concentrations	O
were	O
taken	O
at	O
regular	O
time	O
intervals	O
,	O
during	O
8	O
hr	O
after	O
metoprolol	O
.	O

In	O
PMs	O
,	O
metoprolol	O
increased	O
the	O
terbutaline	O
area	O
under	O
the	O
plasma	O
concentration	O
vs	O
.	O

time	O
curve	O
(+	O
67	O
%).	O

Higher	O
metoprolol	O
/	O
alpha	O
-	O
hydroxymetoprolol	O
ratios	O
in	O
PMs	O
were	O
predictive	O
for	O
higher	O
R	O
-/	O
S	O
-	O
isomer	O
ratios	O
of	O
unchanged	O
drug	O
.	O

There	O
was	O
a	O
difference	O
in	O
metoprolol	O
potency	O
with	O
higher	O
racemic	O
metoprolol	O
IC50	O
values	O
in	O
PMs	O
(	O
72	O
+/-	O
7	O
ng	O
.	O
ml	O
-	O
1	O
)	O
than	O
EMs	O
(	O
42	O
+/-	O
8	O
ng	O
.	O
ml	O
-	O
1	O
,	O
P	O
less	O
than	O
.	O
1	O
).	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O


The	O
first	O
founder	O
DGUOK	O
mutation	O
associated	O
with	O
hepatocerebral	B-Disease
mitochondrial	I-Disease
DNA	I-Disease
depletion	I-Disease
syndrome	I-Disease
.	O

Deoxyguanosine	B-Disease
kinase	I-Disease
(	I-Disease
dGK	I-Disease
)	I-Disease
deficiency	I-Disease
is	O
a	O
frequent	O
cause	O
of	O
mitochondrial	B-Disease
DNA	I-Disease
depletion	I-Disease
associated	O
with	O
a	O
hepatocerebral	O
phenotype	O
.	O

In	O
this	O
study	O
,	O
we	O
describe	O
a	O
new	O
splice	O
site	O
mutation	O
in	O
the	O
DGUOK	O
gene	O
and	O
the	O
clinical	O
,	O
radiologic	O
,	O
and	O
genetic	O
features	O
of	O
these	O
DGUOK	O
patients	O
.	O

This	O
new	O
DGUOK	O
homozygous	O
mutation	O
(	O
c	O
.	O
444	O
-	O
62C	O
>	O
A	O
)	O
was	O
identified	O
in	O
three	O
patients	O
from	O
two	O
North	O
-	O
African	O
consanguineous	O
families	O
with	O
combined	O
respiratory	B-Disease
chain	I-Disease
deficiencies	I-Disease
and	O
mitochondrial	B-Disease
DNA	I-Disease
depletion	I-Disease
in	O
the	O
liver	O
.	O

Brain	O
MRIs	O
are	O
normal	O
in	O
DGUOK	O
patients	O
in	O
the	O
literature	O
.	O

Interestingly	O
,	O
we	O
found	O
subtentorial	B-Disease
abnormal	I-Disease
myelination	I-Disease
and	O
moderate	B-Disease
hyperintensity	I-Disease
in	O
the	O
bilateral	O
pallidi	O
in	O
our	O
patients	O
.	O

This	O
new	O
mutation	O
creates	O
a	O
cryptic	O
splice	O
site	O
in	O
intron	O
3	O
(	O
in	O
position	O
-	O
62	O
)	O
and	O
is	O
predicted	O
to	O
result	O
in	O
a	O
larger	O
protein	O
with	O
an	O
in	O
-	O
frame	O
insertion	O
of	O
20	O
amino	O
acids	O
.	O

In	O
silico	O
analysis	O
of	O
the	O
putative	O
impact	O
of	O
the	O
insertion	O
shows	O
serious	O
clashes	O
in	O
protein	O
conformation	O
:	O
this	O
insertion	O
disrupts	O
the	O
alpha5	O
helix	O
of	O
the	O
dGK	O
kinase	O
domain	O
,	O
rendering	O
the	O
protein	O
unable	O
to	O
bind	O
purine	O
deoxyribonucleosides	O
.	O

In	O
addition	O
,	O
a	O
common	O
haplotype	O
that	O
segregated	O
with	O
the	O
disease	O
in	O
both	O
families	O
was	O
detected	O
by	O
haplotype	O
reconstruction	O
with	O
10	O
markers	O
(	O
microsatellites	O
and	O
SNPs	O
),	O
which	O
span	O
4	O
.	O
6	O
Mb	O
of	O
DNA	O
covering	O
the	O
DGUOK	O
locus	O
.	O

In	O
conclusion	O
,	O
we	O
report	O
a	O
new	O
DGUOK	O
splice	O
site	O
mutation	O
that	O
provide	O
insight	O
into	O
a	O
critical	O
protein	O
domain	O
(	O
dGK	O
kinase	O
domain	O
)	O
and	O
the	O
first	O
founder	O
mutation	O
in	O
a	O
North	O
-	O
African	O
population	O
.	O


Adenosine	O
A	O
(	O
2A	O
)	O
receptor	O
gene	O
(	O
ADORA2A	O
)	O
variants	O
may	O
increase	O
autistic	B-Disease
symptoms	I-Disease
and	O
anxiety	B-Disease
in	O
autism	B-Disease
spectrum	I-Disease
disorder	I-Disease
.	O

Autism	B-Disease
spectrum	I-Disease
disorders	I-Disease
(	O
ASDs	B-Disease
)	O
are	O
heterogeneous	O
disorders	O
presenting	O
with	O
increased	O
rates	O
of	O
anxiety	B-Disease
.	O

The	O
adenosine	O
A	O
(	O
2A	O
)	O
receptor	O
gene	O
(	O
ADORA2A	O
)	O
is	O
associated	O
with	O
panic	B-Disease
disorder	I-Disease
and	O
is	O
located	O
on	O
chromosome	O
22q11	O
.	O
23	O
.	O

Its	O
gene	O
product	O
,	O
the	O
adenosine	O
A	O
(	O
2A	O
)	O
receptor	O
,	O
is	O
strongly	O
expressed	O
in	O
the	O
caudate	O
nucleus	O
,	O
which	O
also	O
is	O
involved	O
in	O
ASD	B-Disease
.	O

As	O
autistic	B-Disease
symptoms	I-Disease
are	O
increased	O
in	O
individuals	O
with	O
22q11	B-Disease
.	I-Disease
2	I-Disease
deletion	I-Disease
syndrome	I-Disease
,	O
and	O
large	O
22q11	B-Disease
.	I-Disease
2	I-Disease
deletions	I-Disease
and	O
duplications	O
have	O
been	O
observed	O
in	O
ASD	B-Disease
individuals	O
,	O
in	O
this	O
study	O
,	O
98	O
individuals	O
with	O
ASD	B-Disease
and	O
234	O
control	O
individuals	O
were	O
genotyped	O
for	O
eight	O
single	O
-	O
nucleotide	O
polymorphisms	O
in	O
ADORA2A	O
.	O

Nominal	O
association	O
with	O
the	O
disorder	O
was	O
observed	O
for	O
rs2236624	O
-	O
CC	O
,	O
and	O
phenotypic	O
variability	O
in	O
ASD	B-Disease
symptoms	O
was	O
influenced	O
by	O
rs3761422	O
,	O
rs5751876	O
and	O
rs35320474	O
.	O

In	O
addition	O
,	O
association	O
of	O
ADORA2A	O
variants	O
with	O
anxiety	B-Disease
was	O
replicated	O
for	O
individuals	O
with	O
ASD	B-Disease
.	O

Findings	O
point	O
toward	O
a	O
possible	O
mediating	O
role	O
of	O
ADORA2A	O
variants	O
on	O
phenotypic	O
expression	O
in	O
ASD	B-Disease
that	O
need	O
to	O
be	O
replicated	O
in	O
a	O
larger	O
sample	O
.	O


High	O
frequency	O
of	O
lamivudine	O
resistance	O
mutations	O
in	O
Brazilian	O
patients	O
co	B-Disease
-	I-Disease
infected	I-Disease
with	I-Disease
HIV	I-Disease
and	I-Disease
hepatitis	I-Disease
B	I-Disease
.	O

This	O
study	O
analyzed	O
the	O
genotype	O
distribution	O
and	O
frequency	O
of	O
lamivudine	O
(	O
LAM	O
)	O
and	O
tenofovir	O
(	O
TDF	O
)	O
resistance	O
mutations	O
in	O
a	O
group	O
of	O
patients	O
co	B-Disease
-	I-Disease
infected	I-Disease
with	I-Disease
HIV	I-Disease
and	I-Disease
hepatitis	I-Disease
B	I-Disease
virus	I-Disease
(	O
HBV	O
).	O

A	O
cross	O
-	O
sectional	O
study	O
of	O
847	O
patients	O
with	O
HIV	O
was	O
conducted	O
.	O

Patients	O
provided	O
blood	O
samples	O
for	O
HBsAg	O
detection	O
.	O

The	O
load	O
of	O
HBV	O
was	O
determined	O
using	O
an	O
in	O
-	O
house	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
.	O

HBV	O
genotypes	O
/	O
subgenotypes	O
,	O
antiviral	O
resistance	O
,	O
basal	O
core	O
promoter	O
(	O
BCP	O
),	O
and	O
precore	O
mutations	O
were	O
detected	O
by	O
DNA	O
sequencing	O
.	O

Twenty	O
-	O
eight	O
patients	O
with	O
co	O
-	O
infection	B-Disease
were	O
identified	O
.	O

The	O
distribution	O
of	O
HBV	O
genotypes	O
among	O
these	O
patients	O
was	O
A	O
(	O
n	O
=	O
9	O
;	O
50	O
%),	O
D	O
(	O
n	O
=	O
4	O
;	O
22	O
.	O
2	O
%),	O
G	O
(	O
n	O
=	O
3	O
;	O
16	O
.	O
7	O
%),	O
and	O
F	O
(	O
n	O
=	O
2	O
;	O
11	O
.	O
1	O
%).	O

Eighteen	O
patients	O
were	O
treated	O
with	O
LAM	O
and	O
six	O
patients	O
were	O
treated	O
with	O
LAM	O
plus	O
TDF	O
.	O

The	O
length	O
of	O
exposure	O
to	O
LAM	O
and	O
TDF	O
varied	O
from	O
4	O
to	O
216	O
months	O
.	O

LAM	O
resistance	O
substitutions	O
(	O
rtL180M	O
+	O
rtM204V	O
)	O
were	O
detected	O
in	O
10	O
(	O
50	O
%)	O
of	O
the	O
20	O
patients	O
with	O
viremia	B-Disease
.	O

This	O
pattern	O
and	O
an	O
accompanying	O
rtV173L	O
mutation	O
was	O
found	O
in	O
four	O
patients	O
.	O

Three	O
patients	O
with	O
the	O
triple	O
polymerase	O
substitution	O
pattern	O
(	O
rtV173L	O
+	O
rtL180M	O
+	O
rtM204V	O
)	O
had	O
associated	O
changes	O
in	O
the	O
envelope	O
gene	O
(	O
sE164D	O
+	O
sI195M	O
).	O

Mutations	O
in	O
the	O
BCP	O
region	O
(	O
A1762T	O
,	O
G1764A	O
)	O
and	O
in	O
the	O
precore	O
region	O
(	O
G1896A	O
,	O
G1899A	O
)	O
were	O
also	O
found	O
.	O

No	O
putative	O
TDF	O
resistance	O
substitution	O
was	O
detected	O
.	O

The	O
data	O
suggest	O
that	O
prolonged	O
LAM	O
use	O
is	O
associated	O
with	O
the	O
emergence	O
of	O
particular	O
changes	O
in	O
the	O
HBV	O
genome	O
,	O
including	O
substitutions	O
that	O
may	O
elicit	O
a	O
vaccine	O
escape	O
phenotype	O
.	O

No	O
putative	O
TDF	O
resistance	O
change	O
was	O
detected	O
after	O
prolonged	O
use	O
of	O
TDF	O
.	O


Identification	O
of	O
a	O
novel	O
FBN1	O
gene	O
mutation	O
in	O
a	O
Chinese	O
family	O
with	O
Marfan	B-Disease
syndrome	I-Disease
.	O

PURPOSE	O
:	O
To	O
identify	O
the	O
mutation	O
in	O
the	O
fibrillin	O
-	O
1	O
gene	O
(	O
FBN1	O
)	O
in	O
a	O
Chinese	O
family	O
with	O
Marfan	B-Disease
syndrome	I-Disease
(	O
MFS	B-Disease
).	O

METHODS	O
:	O
Patients	O
and	O
family	O
members	O
were	O
given	O
complete	O
physical	O
,	O
ophthalmic	O
,	O
and	O
cardiovascular	O
examinations	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
leukocytes	O
of	O
venous	O
blood	O
of	O
six	O
individuals	O
in	O
the	O
family	O
and	O
170	O
healthy	O
Chinese	O
individuals	O
.	O

All	O
of	O
the	O
65	O
coding	O
exons	O
and	O
their	O
flanking	O
intronic	O
boundaries	O
of	O
FBN1	O
were	O
amplified	O
in	O
the	O
proband	O
by	O
polymerase	O
chain	O
reaction	O
and	O
followed	O
by	O
direct	O
sequencing	O
.	O

The	O
mutation	O
identified	O
in	O
the	O
proband	O
was	O
screened	O
in	O
the	O
other	O
family	O
members	O
and	O
the	O
170	O
healthy	O
Chinese	O
individuals	O
by	O
direct	O
sequencing	O
.	O

Protein	O
conservation	O
analysis	O
was	O
performed	O
in	O
six	O
species	O
using	O
an	O
online	O
ClustalW	O
tool	O
.	O

Protein	O
structure	O
was	O
modeled	O
based	O
on	O
the	O
Protein	O
data	O
bank	O
and	O
mutated	O
in	O
DeepView	O
v4	O
.	O
0	O
.	O
1	O
to	O
predict	O
the	O
functional	O
consequences	O
of	O
the	O
mutation	O
.	O

RESULTS	O
:	O
A	O
novel	O
heterozygous	O
c	O
.	O
3703T	O
>	O
C	O
change	O
in	O
exon	O
29	O
of	O
FBN1	O
was	O
detected	O
in	O
the	O
proband	O
,	O
which	O
resulted	O
in	O
the	O
substitution	O
of	O
serine	O
by	O
proline	O
at	O
codon	O
1235	O
(	O
p	O
.	O
S1235P	O
).	O

This	O
mutation	O
was	O
also	O
present	O
in	O
two	O
family	O
members	O
but	O
absent	O
in	O
the	O
other	O
,	O
unaffected	O
family	O
members	O
and	O
the	O
170	O
healthy	O
Chinese	O
individuals	O
.	O

The	O
mutant	O
residue	O
located	O
in	O
the	O
calcium	O
binding	O
epidermal	O
growth	O
factor	O
-	O
like	O
#	O
15	O
domain	O
is	O
highly	O
conserved	O
among	O
mammalian	O
species	O
and	O
could	O
probably	O
induce	O
conformation	O
change	O
of	O
the	O
domain	O
.	O

CONCLUSIONS	O
:	O
We	O
indentified	O
a	O
novel	O
p	O
.	O
S1235P	O
mutation	O
in	O
FBN1	O
,	O
which	O
is	O
the	O
causative	O
mutation	O
for	O
MFS	B-Disease
in	O
this	O
family	O
.	O

Our	O
result	O
expands	O
the	O
mutation	O
spectrum	O
of	O
FBN1	O
and	O
contributes	O
to	O
the	O
study	O
of	O
the	O
molecular	O
pathogenesis	O
of	O
Marfan	B-Disease
syndrome	I-Disease
.	O


Molecular	O
and	O
phenotypic	O
analysis	O
of	O
patients	O
with	O
deletions	O
within	O
the	O
deletion	O
-	O
rich	O
region	O
of	O
the	O
Duchenne	O
muscular	O
dystrophy	O
(	O
DMD	O
)	O
gene	O
.	O

Eighty	O
unrelated	O
individuals	O
with	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	B-Disease
)	O
or	O
Becker	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
BMD	B-Disease
)	O
were	O
found	O
to	O
have	O
deletions	O
in	O
the	O
major	O
deletion	O
-	O
rich	O
region	O
of	O
the	O
DMD	O
locus	O
.	O

This	O
region	O
includes	O
the	O
last	O
five	O
exons	O
detected	O
by	O
cDNA5b	O
-	O
7	O
,	O
all	O
exons	O
detected	O
by	O
cDNA8	O
,	O
and	O
the	O
first	O
two	O
exons	O
detected	O
by	O
cDNA9	O
.	O

These	O
80	O
individuals	O
account	O
for	O
approximately	O
75	O
%	O
of	O
109	O
deletions	O
of	O
the	O
gene	O
,	O
detected	O
among	O
181	O
patients	O
analyzed	O
with	O
the	O
entire	O
dystrophin	O
cDNA	O
.	O

Endpoints	O
for	O
many	O
of	O
these	O
deletions	O
were	O
further	O
characterized	O
using	O
two	O
genomic	O
probes	O
,	O
p20	O
(	O
DXS269	O
;	O
Wapenaar	O
et	O
al	O
.)	O

and	O
GMGX11	O
(	O
DXS239	O
;	O
present	O
paper	O
).	O

Clinical	O
findings	O
are	O
presented	O
for	O
all	O
80	O
patients	O
allowing	O
a	O
correlation	O
of	O
phenotypic	O
severity	O
with	O
the	O
genotype	O
.	O

Thirty	O
-	O
eight	O
independent	O
patients	O
were	O
old	O
enough	O
to	O
be	O
classified	O
as	O
DMD	B-Disease
,	O
BMD	B-Disease
,	O
or	O
intermediate	O
phenotype	O
and	O
had	O
deletions	O
of	O
exons	O
with	O
sequenced	O
intron	O
/	O
exon	O
boundaries	O
.	O

Of	O
these	O
,	O
eight	O
BMD	B-Disease
patients	O
and	O
one	O
intermediate	O
patient	O
had	O
gene	O
deletions	O
predicted	O
to	O
leave	O
the	O
reading	O
frame	O
intact	O
,	O
while	O
21	O
DMD	B-Disease
patients	O
,	O
7	O
intermediate	O
patients	O
,	O
and	O
1	O
BMD	B-Disease
patient	O
had	O
gene	O
deletions	O
predicted	O
to	O
disrupt	O
the	O
reading	O
frame	O
.	O

Thus	O
,	O
with	O
two	O
exceptions	O
,	O
frameshift	O
deletions	O
of	O
the	O
gene	O
resulted	O
in	O
more	O
severe	O
phenotype	O
than	O
did	O
in	O
-	O
frame	O
deletions	O
.	O

This	O
is	O
in	O
agreement	O
with	O
recent	O
findings	O
by	O
Baumbach	O
et	O
al	O
.	O

and	O
Koenig	O
et	O
al	O
.	O

but	O
is	O
in	O
contrast	O
to	O
findings	O
,	O
by	O
Malhotra	O
et	O
al	O
.	O

at	O
the	O
5	O
'	O
end	O
of	O
the	O
gene	O
.	O


Absence	O
of	O
PKC	O
-	O
alpha	O
attenuates	O
lithium	O
-	O
induced	O
nephrogenic	B-Disease
diabetes	I-Disease
insipidus	I-Disease
.	O

Lithium	O
,	O
an	O
effective	O
antipsychotic	O
,	O
induces	O
nephrogenic	B-Disease
diabetes	I-Disease
insipidus	I-Disease
(	O
NDI	B-Disease
)	O
in	O
40	O
%	O
of	O
patients	O
.	O

The	O
decreased	O
capacity	O
to	O
concentrate	O
urine	O
is	O
likely	O
due	O
to	O
lithium	O
acutely	O
disrupting	O
the	O
cAMP	O
pathway	O
and	O
chronically	O
reducing	O
urea	O
transporter	O
(	O
UT	O
-	O
A1	O
)	O
and	O
water	O
channel	O
(	O
AQP2	O
)	O
expression	O
in	O
the	O
inner	O
medulla	O
.	O

Targeting	O
an	O
alternative	O
signaling	O
pathway	O
,	O
such	O
as	O
PKC	O
-	O
mediated	O
signaling	O
,	O
may	O
be	O
an	O
effective	O
method	O
of	O
treating	O
lithium	O
-	O
induced	O
polyuria	B-Disease
.	O

PKC	O
-	O
alpha	O
null	O
mice	O
(	O
PKCa	O
KO	O
)	O
and	O
strain	O
-	O
matched	O
wild	O
type	O
(	O
WT	O
)	O
controls	O
were	O
treated	O
with	O
lithium	O
for	O
0	O
,	O
3	O
or	O
5	O
days	O
.	O

WT	O
mice	O
had	O
increased	O
urine	O
output	O
and	O
lowered	O
urine	O
osmolality	O
after	O
3	O
and	O
5	O
days	O
of	O
treatment	O
whereas	O
PKCa	O
KO	O
mice	O
had	O
no	O
change	O
in	O
urine	O
output	O
or	O
concentration	O
.	O

Western	O
blot	O
analysis	O
revealed	O
that	O
AQP2	O
expression	O
in	O
medullary	O
tissues	O
was	O
lowered	O
after	O
3	O
and	O
5	O
days	O
in	O
WT	O
mice	O
;	O
however	O
,	O
AQP2	O
was	O
unchanged	O
in	O
PKCa	O
KO	O
.	O

Similar	O
results	O
were	O
observed	O
with	O
UT	O
-	O
A1	O
expression	O
.	O

Animals	O
were	O
also	O
treated	O
with	O
lithium	O
for	O
6	O
weeks	O
.	O

Lithium	O
-	O
treated	O
WT	O
mice	O
had	O
19	O
-	O
fold	O
increased	O
urine	O
output	O
whereas	O
treated	O
PKCa	O
KO	O
animals	O
had	O
a	O
4	O
-	O
fold	O
increase	O
in	O
output	O
.	O

AQP2	O
and	O
UT	O
-	O
A1	O
expression	O
was	O
lowered	O
in	O
6	O
week	O
lithium	O
-	O
treated	O
WT	O
animals	O
whereas	O
in	O
treated	O
PKCa	O
KO	O
mice	O
,	O
AQP2	O
was	O
only	O
reduced	O
by	O
2	O
-	O
fold	O
and	O
UT	O
-	O
A1	O
expression	O
was	O
unaffected	O
.	O

Urinary	O
sodium	O
,	O
potassium	O
and	O
calcium	O
were	O
elevated	O
in	O
lithium	O
-	O
fed	O
WT	O
but	O
not	O
in	O
lithium	O
-	O
fed	O
PKCa	O
KO	O
mice	O
.	O

Our	O
data	O
show	O
that	O
ablation	O
of	O
PKCa	O
preserves	O
AQP2	O
and	O
UT	O
-	O
A1	O
protein	O
expression	O
and	O
localization	O
in	O
lithium	O
-	O
induced	O
NDI	B-Disease
,	O
and	O
prevents	O
the	O
development	O
of	O
the	O
severe	O
polyuria	B-Disease
associated	O
with	O
lithium	O
therapy	O
.	O


Decreased	O
Whole	O
-	O
Body	O
Fat	O
Mass	O
Produced	O
by	O
Chronic	O
Alcohol	O
Consumption	O
is	O
Associated	O
with	O
Activation	O
of	O
S6K1	O
-	O
Mediated	O
Protein	O
Synthesis	O
and	O
Increased	O
Autophagy	O
in	O
Epididymal	O
White	O
Adipose	O
Tissue	O
.	O

BACKGROUND	O
:	O
Chronic	O
alcohol	O
consumption	O
leads	O
to	O
a	O
loss	O
of	O
white	O
adipose	O
tissue	O
(	O
WAT	O
)	O
but	O
the	O
underlying	O
mechanisms	O
for	O
this	O
lipodystrophy	B-Disease
are	O
not	O
fully	O
elucidated	O
.	O

This	O
study	O
tested	O
the	O
hypothesis	O
that	O
the	O
reduction	O
in	O
WAT	O
mass	O
in	O
chronic	O
alcohol	O
-	O
fed	O
mice	O
is	O
associated	O
with	O
a	O
decreased	O
protein	O
synthesis	O
specifically	O
related	O
to	O
impaired	O
function	O
of	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
).	O

METHODS	O
:	O
Adult	O
male	O
mice	O
were	O
provided	O
an	O
alcohol	O
-	O
containing	O
liquid	O
diet	O
for	O
24	O
weeks	O
or	O
an	O
isonitrogenous	O
isocaloric	O
control	O
diet	O
.	O

In	O
vivo	O
protein	O
synthesis	O
was	O
determined	O
at	O
this	O
time	O
and	O
thereafter	O
epididymal	O
WAT	O
(	O
eWAT	O
)	O
was	O
excised	O
for	O
analysis	O
of	O
signal	O
transduction	O
pathways	O
central	O
to	O
controling	O
protein	O
synthesis	O
and	O
degradation	O
.	O

RESULTS	O
:	O
While	O
chronic	O
alcohol	O
feeding	O
decreased	O
whole	O
-	O
body	O
and	O
eWAT	O
mass	O
,	O
this	O
was	O
associated	O
with	O
a	O
discordant	O
increase	O
in	O
protein	O
synthesis	O
in	O
eWAT	O
.	O

This	O
increase	O
was	O
not	O
associated	O
with	O
a	O
change	O
in	O
mTOR	O
,	O
4E	O
-	O
BP1	O
,	O
Akt	O
,	O
or	O
PRAS40	O
phosphorylation	O
.	O

Instead	O
,	O
a	O
selective	O
increase	O
in	O
phosphorylation	O
of	O
S6K1	O
and	O
its	O
downstream	O
substrates	O
,	O
S6	O
and	O
eIF4B	O
was	O
detected	O
in	O
alcohol	O
-	O
fed	O
mice	O
.	O

Alcohol	O
also	O
increased	O
eEF2K	O
phosphorylation	O
and	O
decreased	O
eEF2	O
phosphorylation	O
consistent	O
with	O
increased	O
translation	O
elongation	O
.	O

Alcohol	O
increased	O
Atg12	O
-	O
5	O
,	O
LC3B	O
-	O
I	O
and	O
-	O
II	O
,	O
and	O
ULK1	O
S555	O
phosphorylation	O
,	O
suggesting	O
increased	O
autophagy	O
,	O
while	O
markers	O
of	O
apoptosis	O
(	O
cleaved	O
caspase	O
-	O
3	O
and	O
-	O
9	O
,	O
and	O
PARP	O
)	O
were	O
unchanged	O
.	O

Lipolytic	O
enzymes	O
(	O
ATGL	O
and	O
HSL	O
phosphorylation	O
)	O
were	O
increased	O
and	O
lipogenic	O
regulators	O
(	O
PPARgamma	O
and	O
C	O
/	O
EBPalpha	O
)	O
were	O
decreased	O
in	O
eWAT	O
by	O
alcohol	O
.	O

Although	O
alcohol	O
increased	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
6	O
,	O
and	O
IL	O
-	O
1beta	O
mRNA	O
,	O
no	O
change	O
in	O
key	O
components	O
of	O
the	O
NLRP3	O
inflammasome	O
(	O
NLRP3	O
,	O
ACS	O
,	O
and	O
cleaved	O
caspase	O
-	O
1	O
)	O
was	O
detected	O
suggesting	O
alcohol	O
did	O
not	O
increase	O
pyroptosis	O
.	O

Plasma	O
insulin	O
did	O
not	O
differ	O
between	O
groups	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
demonstrate	O
that	O
the	O
alcohol	O
-	O
induced	O
decrease	O
in	O
whole	O
-	O
body	O
fat	O
mass	O
resulted	O
in	O
part	O
from	O
activation	O
of	O
autophagy	O
in	O
eWAT	O
as	O
protein	O
synthesis	O
was	O
increased	O
and	O
mediated	O
by	O
the	O
specific	O
increase	O
in	O
the	O
activity	O
of	O
S6K1	O
.	O


Nefiracetam	O
(	O
DM	O
-	O
9384	O
)	O
reverses	O
apomorphine	O
-	O
induced	O
amnesia	B-Disease
of	O
a	O
passive	O
avoidance	O
response	O
:	O
delayed	O
emergence	O
of	O
the	O
memory	O
retention	O
effects	O
.	O

Nefiracetam	O
is	O
a	O
novel	O
pyrrolidone	O
derivative	O
which	O
attenuates	O
scopolamine	O
-	O
induced	O
learning	B-Disease
and	I-Disease
post	I-Disease
-	I-Disease
training	I-Disease
consolidation	I-Disease
deficits	I-Disease
.	O

Given	O
that	O
apomorphine	O
inhibits	O
passive	O
avoidance	O
retention	O
when	O
given	O
during	O
training	O
or	O
in	O
a	O
defined	O
10	O
-	O
12h	O
post	O
-	O
training	O
period	O
,	O
we	O
evaluated	O
the	O
ability	O
of	O
nefiracetam	O
to	O
attenuate	O
amnesia	B-Disease
induced	O
by	O
dopaminergic	O
agonism	O
.	O

A	O
step	O
-	O
down	O
passive	O
avoidance	O
paradigm	O
was	O
employed	O
and	O
nefiracetam	O
(	O
3	O
mg	O
/	O
kg	O
)	O
and	O
apomorphine	O
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
were	O
given	O
alone	O
or	O
in	O
combination	O
during	O
training	O
and	O
at	O
the	O
10	O
-	O
12h	O
post	O
-	O
training	O
period	O
of	O
consolidation	O
.	O

Co	O
-	O
administration	O
of	O
nefiracetam	O
and	O
apomorphine	O
during	O
training	O
or	O
10h	O
thereafter	O
produced	O
no	O
significant	O
anti	O
-	O
amnesic	B-Disease
effect	O
.	O

However	O
,	O
administration	O
of	O
nefiracetam	O
during	O
training	O
completely	O
reversed	O
the	O
amnesia	B-Disease
induced	O
by	O
apomorphine	O
at	O
the	O
10h	O
post	O
-	O
training	O
time	O
and	O
the	O
converse	O
was	O
also	O
TRUE	O
.	O

These	O
effects	O
were	O
not	O
mediated	O
by	O
a	O
dopaminergic	O
mechanism	O
as	O
nefiracetam	O
,	O
at	O
millimolar	O
concentrations	O
,	O
failed	O
to	O
displace	O
either	O
[	O
3H	O
]	O
SCH	O
23390	O
or	O
[	O
3H	O
]	O
spiperone	O
binding	O
from	O
D1	O
or	O
D2	O
dopamine	O
receptor	O
subtypes	O
,	O
respectively	O
.	O

It	O
is	O
suggested	O
that	O
nefiracetam	O
augments	O
molecular	O
processes	O
in	O
the	O
early	O
stages	O
of	O
events	O
which	O
ultimately	O
lead	O
to	O
consolidation	O
of	O
memory	O
.	O


Pethidine	O
-	O
associated	O
seizure	B-Disease
in	O
a	O
healthy	O
adolescent	O
receiving	O
pethidine	O
for	O
postoperative	B-Disease
pain	I-Disease
control	O
.	O

A	O
healthy	O
17	O
-	O
year	O
-	O
old	O
male	O
received	O
standard	O
intermittent	O
doses	O
of	O
pethidine	O
via	O
a	O
patient	O
-	O
controlled	O
analgesia	O
(	O
PCA	O
)	O
pump	O
for	O
management	O
of	O
postoperative	B-Disease
pain	I-Disease
control	O
.	O

Twenty	O
-	O
three	O
h	O
postoperatively	O
he	O
developed	O
a	O
brief	O
self	O
-	O
limited	O
seizure	B-Disease
.	O

Both	O
plasma	O
pethidine	O
and	O
norpethidine	O
were	O
elevated	O
in	O
the	O
range	O
associated	O
with	O
clinical	O
manifestations	O
of	O
central	O
nervous	O
system	O
excitation	O
.	O

No	O
other	O
risk	O
factors	O
for	O
CNS	O
toxicity	B-Disease
were	O
identified	O
.	O

This	O
method	O
allowed	O
frequent	O
self	O
-	O
dosing	O
of	O
pethidine	O
at	O
short	O
time	O
intervals	O
and	O
rapid	O
accumulation	O
of	O
pethidine	O
and	O
norpethidine	O
.	O

The	O
routine	O
use	O
of	O
pethidine	O
via	O
PCA	O
even	O
for	O
a	O
brief	O
postoperative	B-Disease
analgesia	I-Disease
should	O
be	O
reconsidered	O
.	O


Recovery	O
of	O
tacrolimus	O
-	O
associated	O
brachial	B-Disease
neuritis	I-Disease
after	O
conversion	O
to	O
everolimus	O
in	O
a	O
pediatric	O
renal	O
transplant	O
recipient	O
--	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

TAC	O
has	O
been	O
shown	O
to	O
be	O
a	O
potent	O
immunosuppressive	O
agent	O
for	O
solid	O
organ	O
transplantation	O
in	O
pediatrics	O
.	O

Neurotoxicity	B-Disease
is	O
a	O
potentially	O
serious	O
toxic	O
effect	O
.	O

It	O
is	O
characterized	O
by	O
encephalopathy	B-Disease
,	O
headaches	B-Disease
,	O
seizures	B-Disease
,	O
or	O
neurological	B-Disease
deficits	I-Disease
.	O

Here	O
,	O
we	O
describe	O
an	O
eight	O
-	O
and	O
-	O
a	O
-	O
half	O
-	O
yr	O
-	O
old	O
male	O
renal	O
transplant	O
recipient	O
with	O
right	O
BN	O
.	O

MRI	O
demonstrated	O
hyperintense	O
T2	O
signals	O
in	O
the	O
cervical	O
cord	O
and	O
right	O
brachial	O
plexus	O
roots	O
indicative	O
of	O
both	O
myelitis	B-Disease
and	O
right	O
brachial	B-Disease
plexitis	I-Disease
.	O

Symptoms	O
persisted	O
for	O
three	O
months	O
despite	O
TAC	O
dose	O
reduction	O
,	O
administration	O
of	O
IVIG	O
and	O
four	O
doses	O
of	O
methylprednisolone	O
pulse	O
therapy	O
.	O

Improvement	O
and	O
eventually	O
full	O
recovery	O
only	O
occurred	O
after	O
TAC	O
was	O
completely	O
discontinued	O
and	O
successfully	O
replaced	O
by	O
everolimus	O
.	O


MOL1	O
is	O
required	O
for	O
cambium	O
homeostasis	O
in	O
Arabidopsis	O
.	O

Plants	O
maintain	O
pools	O
of	O
pluripotent	O
stem	O
cells	O
which	O
allow	O
them	O
to	O
constantly	O
produce	O
new	O
tissues	O
and	O
organs	O
.	O

Stem	O
cell	O
homeostasis	O
in	O
shoot	O
and	O
root	O
tips	O
depends	O
on	O
negative	O
regulation	O
by	O
ligand	O
-	O
receptor	O
pairs	O
of	O
the	O
CLE	O
peptide	O
and	O
leucine	O
-	O
rich	O
repeat	O
receptor	O
-	O
like	O
kinase	O
(	O
LRR	O
-	O
RLK	O
)	O
families	O
.	O

However	O
,	O
regulation	O
of	O
the	O
cambium	O
,	O
the	O
stem	O
cell	O
niche	O
required	O
for	O
lateral	O
growth	O
of	O
shoots	O
and	O
roots	O
,	O
is	O
poorly	O
characterized	O
.	O

Here	O
we	O
show	O
that	O
the	O
LRR	O
-	O
RLK	O
MOL1	O
is	O
necessary	O
for	O
cambium	O
homeostasis	O
in	O
Arabidopsis	O
thaliana	O
.	O

By	O
employing	O
promoter	O
reporter	O
lines	O
,	O
we	O
reveal	O
that	O
MOL1	O
is	O
active	O
in	O
a	O
domain	O
that	O
is	O
distinct	O
from	O
the	O
domain	O
of	O
the	O
positively	O
acting	O
CLE41	O
/	O
PXY	O
signaling	O
module	O
.	O

In	O
particular	O
,	O
we	O
show	O
that	O
MOL1	O
acts	O
in	O
an	O
opposing	O
manner	O
to	O
the	O
CLE41	O
/	O
PXY	O
module	O
and	O
that	O
changing	O
the	O
domain	O
or	O
level	O
of	O
MOL1	O
expression	O
both	O
result	O
in	O
disturbed	O
cambium	O
organization	O
.	O

Underlining	O
discrete	O
roles	O
of	O
MOL1	O
and	O
PXY	O
,	O
both	O
LRR	O
-	O
RLKs	O
are	O
not	O
able	O
to	O
replace	O
each	O
other	O
when	O
their	O
expression	O
domains	O
are	O
interchanged	O
.	O

Furthermore	O
,	O
MOL1	O
but	O
not	O
PXY	O
is	O
able	O
to	O
rescue	O
CLV1	O
deficiency	O
in	O
the	O
shoot	O
apical	O
meristem	O
.	O

By	O
identifying	O
genes	O
mis	O
-	O
expressed	O
in	O
mol1	O
mutants	O
,	O
we	O
demonstrate	O
that	O
MOL1	O
represses	O
genes	O
associated	O
with	O
stress	O
-	O
related	O
ethylene	O
and	O
jasmonic	O
acid	O
hormone	O
signaling	O
pathways	O
which	O
have	O
known	O
roles	O
in	O
coordinating	O
lateral	O
growth	O
of	O
the	O
Arabidopsis	O
stem	O
.	O

Our	O
findings	O
provide	O
evidence	O
that	O
common	O
regulatory	O
mechanisms	O
in	O
different	O
plant	O
stem	O
cell	O
niches	O
are	O
adapted	O
to	O
specific	O
niche	O
anatomies	O
and	O
emphasize	O
the	O
importance	O
of	O
a	O
complex	O
spatial	O
organization	O
of	O
intercellular	O
signaling	O
cascades	O
for	O
a	O
strictly	O
bidirectional	O
tissue	O
production	O
.	O


In	O
vivo	O
evidences	O
suggesting	O
the	O
role	O
of	O
oxidative	O
stress	O
in	O
pathogenesis	O
of	O
vancomycin	O
-	O
induced	O
nephrotoxicity	B-Disease
:	O
protection	O
by	O
erdosteine	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
examine	O
vancomycin	O
(	O
VCM	O
)-	O
induced	O
oxidative	O
stress	O
that	O
promotes	O
production	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
and	O
to	O
investigate	O
the	O
role	O
of	O
erdosteine	O
,	O
an	O
expectorant	O
agent	O
,	O
which	O
has	O
also	O
antioxidant	O
properties	O
,	O
on	O
kidney	O
tissue	O
against	O
the	O
possible	O
VCM	O
-	O
induced	O
renal	B-Disease
impairment	I-Disease
in	O
rats	O
.	O

Rats	O
were	O
divided	O
into	O
three	O
groups	O
:	O
sham	O
,	O
VCM	O
and	O
VCM	O
plus	O
erdosteine	O
.	O

VCM	O
was	O
administrated	O
intraperitoneally	O
(	O
i	O
.	O
p	O
.)	O

with	O
200mgkg	O
(-	O
1	O
)	O
twice	O
daily	O
for	O
7	O
days	O
.	O

Erdosteine	O
was	O
administered	O
orally	O
.	O

VCM	O
administration	O
to	O
control	O
rats	O
significantly	O
increased	O
renal	O
malondialdehyde	O
(	O
MDA	O
)	O
and	O
urinary	O
N	O
-	O
acetyl	O
-	O
beta	O
-	O
d	O
-	O
glucosaminidase	O
(	O
NAG	O
,	O
a	O
marker	O
of	O
renal	B-Disease
tubular	I-Disease
injury	I-Disease
)	O
excretion	O
but	O
decreased	O
superoxide	O
dismutase	O
(	O
SOD	O
)	O
and	O
catalase	O
(	O
CAT	O
)	O
activities	O
.	O

Erdosteine	O
administration	O
with	O
VCM	O
injections	O
caused	O
significantly	O
decreased	O
renal	O
MDA	O
and	O
urinary	O
NAG	O
excretion	O
,	O
and	O
increased	O
SOD	O
activity	O
,	O
but	O
not	O
CAT	O
activity	O
in	O
renal	O
tissue	O
when	O
compared	O
with	O
VCM	O
alone	O
.	O

Erdosteine	O
showed	O
histopathological	O
protection	O
against	O
VCM	O
-	O
induced	O
nephrotoxicity	B-Disease
.	O

There	O
were	O
a	O
significant	O
dilatation	O
of	O
tubular	O
lumens	O
,	O
extensive	O
epithelial	O
cell	O
vacuolization	O
,	O
atrophy	B-Disease
,	O
desquamation	B-Disease
,	O
and	O
necrosis	B-Disease
in	O
VCM	O
-	O
treated	O
rats	O
more	O
than	O
those	O
of	O
the	O
control	O
and	O
the	O
erdosteine	O
groups	O
.	O

Erdosteine	O
caused	O
a	O
marked	O
reduction	O
in	O
the	O
extent	O
of	O
tubular	O
damage	O
.	O

It	O
is	O
concluded	O
that	O
oxidative	O
tubular	O
damage	O
plays	O
an	O
important	O
role	O
in	O
the	O
VCM	O
-	O
induced	O
nephrotoxicity	B-Disease
and	O
the	O
modulation	O
of	O
oxidative	O
stress	O
with	O
erdosteine	O
reduces	O
the	O
VCM	O
-	O
induced	O
kidney	B-Disease
damage	I-Disease
both	O
at	O
the	O
biochemical	O
and	O
histological	O
levels	O
.	O


Mutation	O
screening	O
of	O
the	O
GUCA1B	O
gene	O
in	O
patients	O
with	O
autosomal	O
dominant	O
cone	B-Disease
and	I-Disease
cone	I-Disease
rod	I-Disease
dystrophy	I-Disease
.	O

Background	O
:	O
Heterozygous	O
mutations	O
in	O
GUCA1A	O
(	O
MIM	O
#	O
600364	O
)	O
have	O
been	O
identified	O
to	O
cause	O
autosomal	O
dominantly	O
inherited	O
cone	B-Disease
dystrophy	I-Disease
,	O
cone	B-Disease
rod	I-Disease
dystrophy	I-Disease
and	O
macular	B-Disease
dystrophy	I-Disease
.	O

However	O
,	O
the	O
role	O
of	O
GUCA1B	O
gene	O
mutations	O
in	O
inherited	O
retinal	B-Disease
disease	I-Disease
has	O
been	O
controversial	O
.	O

We	O
therefore	O
performed	O
a	O
mutation	O
analysis	O
of	O
the	O
GUCA1B	O
gene	O
in	O
a	O
clinically	O
well	O
characterized	O
group	O
of	O
patients	O
of	O
European	O
and	O
North	O
-	O
American	O
geographical	O
origin	O
with	O
autosomal	O
dominantly	O
inherited	O
cone	B-Disease
dystrophy	I-Disease
and	O
cone	B-Disease
rod	I-Disease
dystrophy	I-Disease
.	O

Material	O
and	O
Methods	O
:	O
Twenty	O
-	O
four	O
unrelated	O
patients	O
diagnosed	O
with	O
cone	B-Disease
dystrophy	I-Disease
or	O
cone	B-Disease
rod	I-Disease
dystrophy	I-Disease
according	O
to	O
standard	O
diagnostic	O
criteria	O
and	O
a	O
family	O
history	O
consistent	O
with	O
an	O
autosomal	O
dominant	O
mode	O
of	O
inheritance	O
were	O
included	O
in	O
the	O
study	O
.	O

Mutation	O
analysis	O
of	O
all	O
coding	O
exons	O
of	O
the	O
GUCA1B	O
gene	O
was	O
performed	O
by	O
polymerase	O
chain	O
reaction	O
amplification	O
of	O
genomic	O
DNA	O
and	O
subsequent	O
DNA	O
sequencing	O
.	O

Results	O
:	O
Three	O
different	O
sequence	O
variants	O
,	O
c	O
.-	O
17T	O
>	O
C	O
,	O
c	O
.	O
171T	O
>	O
C	O
,	O
c	O
.	O
465G	O
>	O
T	O
were	O
identified	O
.	O

The	O
sequence	O
variant	O
c	O
.	O
465G	O
>	O
T	O
encodes	O
a	O
conservative	O
amino	O
acid	O
substitution	O
,	O
p	O
.	O
Glu155Asp	O
,	O
located	O
in	O
EF	O
-	O
hand	O
4	O
,	O
the	O
calcium	O
binding	O
site	O
of	O
GCAP2	O
protein	O
.	O

All	O
sequence	O
variants	O
were	O
previously	O
reported	O
in	O
healthy	O
subjects	O
.	O

Conclusion	O
:	O
The	O
absence	O
of	O
clearly	O
pathogenic	O
mutations	O
in	O
the	O
selected	O
patient	O
group	O
suggests	O
that	O
the	O
GUCA1B	O
gene	O
is	O
a	O
minor	O
cause	O
for	O
retinal	B-Disease
degenerations	I-Disease
in	O
Europeans	O
or	O
North	O
-	O
Americans	O
.	O


Cardioprotective	O
effect	O
of	O
tincture	O
of	O
Crataegus	O
on	O
isoproterenol	O
-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
in	O
rats	O
.	O

Tincture	O
of	O
Crataegus	O
(	O
TCR	O
),	O
an	O
alcoholic	O
extract	O
of	O
the	O
berries	O
of	O
hawthorn	O
(	O
Crataegus	O
oxycantha	O
),	O
is	O
used	O
in	O
herbal	O
and	O
homeopathic	O
medicine	O
.	O

The	O
present	O
study	O
was	O
done	O
to	O
investigate	O
the	O
protective	O
effect	O
of	O
TCR	O
on	O
experimentally	O
induced	O
myocardial	B-Disease
infarction	I-Disease
in	O
rats	O
.	O

Pretreatment	O
of	O
TCR	O
,	O
at	O
a	O
dose	O
of	O
0	O
.	O
5	O
mL	O
/	O
100	O
g	O
bodyweight	O
per	O
day	O
,	O
orally	O
for	O
30	O
days	O
,	O
prevented	O
the	O
increase	O
in	O
lipid	O
peroxidation	O
and	O
activity	O
of	O
marker	O
enzymes	O
observed	O
in	O
isoproterenol	O
-	O
induced	O
rats	O
(	O
85	O
mg	O
kg	O
(-	O
1	O
)	O
s	O
.	O
c	O
.	O
for	O
2	O
days	O
at	O
an	O
interval	O
of	O
24	O
h	O
).	O

TCR	O
prevented	O
the	O
isoproterenol	O
-	O
induced	O
decrease	O
in	O
antioxidant	O
enzymes	O
in	O
the	O
heart	O
and	O
increased	O
the	O
rate	O
of	O
ADP	O
-	O
stimulated	O
oxygen	O
uptake	O
and	O
respiratory	O
coupling	O
ratio	O
.	O

TCR	O
protected	O
against	O
pathological	O
changes	O
induced	O
by	O
isoproterenol	O
in	O
rat	O
heart	O
.	O

The	O
results	O
show	O
that	O
pretreatment	O
with	O
TCR	O
may	O
be	O
useful	O
in	O
preventing	O
the	O
damage	O
induced	O
by	O
isoproterenol	O
in	O
rat	O
heart	O
.	O


A	O
novel	O
splicing	O
mutation	O
in	O
SLC12A3	O
associated	O
with	O
Gitelman	B-Disease
syndrome	I-Disease
and	O
idiopathic	B-Disease
intracranial	I-Disease
hypertension	I-Disease
.	O

We	O
report	O
a	O
case	O
of	O
Gitelman	B-Disease
syndrome	I-Disease
(	O
GS	B-Disease
)	O
in	O
a	O
dizygotic	O
twin	O
who	O
presented	O
at	O
12	O
years	O
of	O
age	O
with	O
growth	B-Disease
delay	I-Disease
,	O
metabolic	B-Disease
alkalosis	I-Disease
,	O
hypomagnesemia	B-Disease
and	O
hypokalemia	B-Disease
with	O
inappropriate	O
kaliuresis	O
,	O
and	O
idiopathic	B-Disease
intracranial	I-Disease
hypertension	I-Disease
with	O
bilateral	B-Disease
papilledema	I-Disease
(	O
pseudotumor	B-Disease
cerebri	I-Disease
).	O

The	O
patient	O
,	O
her	O
twin	O
sister	O
,	O
and	O
her	O
mother	O
also	O
presented	O
with	O
cerebral	B-Disease
cavernous	I-Disease
malformations	I-Disease
.	O

Based	O
on	O
the	O
early	O
onset	O
and	O
normocalciuria	O
,	O
Bartter	B-Disease
syndrome	I-Disease
was	O
diagnosed	O
first	O
.	O

However	O
,	O
mutation	O
analysis	O
showed	O
that	O
the	O
proband	O
is	O
a	O
compound	O
heterozygote	O
for	O
2	O
mutations	O
in	O
SLC12A3	O
:	O
a	O
substitution	O
of	O
serine	O
by	O
leucine	O
at	O
amino	O
acid	O
position	O
555	O
(	O
p	O
.	O
Ser555Leu	O
)	O
and	O
a	O
novel	O
guanine	O
to	O
cytosine	O
transition	O
at	O
the	O
5	O
'	O
splice	O
site	O
of	O
intron	O
22	O
(	O
c	O
.	O
2633	O
+	O
1G	O
>	O
C	O
),	O
providing	O
the	O
molecular	O
diagnosis	O
of	O
GS	B-Disease
.	O

These	O
mutations	O
were	O
not	O
detected	O
in	O
200	O
normal	O
chromosomes	O
and	O
cosegregated	O
within	O
the	O
family	O
.	O

Analysis	O
of	O
complementary	O
DNA	O
showed	O
that	O
the	O
heterozygous	O
nucleotide	O
change	O
c	O
.	O
2633	O
+	O
1G	O
>	O
C	O
caused	O
the	O
appearance	O
of	O
2	O
RNA	O
molecules	O
,	O
1	O
normal	O
transcript	O
and	O
1	O
skipping	O
the	O
entire	O
exon	O
22	O
(	O
r	O
.	O
2521_2634del	O
).	O

Supplementation	O
with	O
potassium	O
and	O
magnesium	O
improved	O
clinical	O
symptoms	O
and	O
resulted	O
in	O
catch	O
-	O
up	O
growth	O
,	O
but	O
vision	O
remained	O
impaired	O
.	O

Three	O
similar	O
associations	O
of	O
Bartter	B-Disease
syndrome	I-Disease
/	O
GS	B-Disease
with	O
pseudotumor	B-Disease
cerebri	I-Disease
were	O
found	O
in	O
the	O
literature	O
,	O
suggesting	O
that	O
electrolyte	B-Disease
abnormalities	I-Disease
and	O
secondary	B-Disease
aldosteronism	I-Disease
may	O
have	O
a	O
role	O
in	O
idiopathic	B-Disease
intracranial	I-Disease
hypertension	I-Disease
.	O

This	O
study	O
provides	O
further	O
evidence	O
for	O
the	O
phenotypical	O
heterogeneity	O
of	O
GS	B-Disease
and	O
its	O
association	O
with	O
severe	O
manifestations	O
in	O
children	O
.	O

It	O
also	O
shows	O
the	O
independent	O
segregation	O
of	O
familial	B-Disease
cavernomatosis	I-Disease
and	O
GS	B-Disease
.	O


Association	O
between	O
polymorphisms	O
in	O
SLC30A8	O
,	O
HHEX	O
,	O
CDKN2A	O
/	O
B	O
,	O
IGF2BP2	O
,	O
FTO	O
,	O
WFS1	O
,	O
CDKAL1	O
,	O
KCNQ1	O
and	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
in	O
the	O
Korean	O
population	O
.	O

According	O
to	O
recent	O
genome	O
-	O
wide	O
association	O
studies	O
,	O
a	O
number	O
of	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
are	O
reported	O
to	O
be	O
associated	O
with	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
mellitus	I-Disease
(	O
T2DM	B-Disease
).	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
association	O
among	O
the	O
polymorphisms	O
of	O
SLC30A8	O
,	O
HHEX	O
,	O
CDKN2A	O
/	O
B	O
,	O
IGF2BP2	O
,	O
FTO	O
,	O
WFS1	O
,	O
CDKAL1	O
and	O
KCNQ1	O
and	O
the	O
risk	O
of	O
T2DM	B-Disease
in	O
the	O
Korean	O
population	O
.	O

This	O
study	O
was	O
based	O
on	O
a	O
multicenter	O
case	O
-	O
control	O
study	O
,	O
including	O
908	O
patients	O
with	O
T2DM	B-Disease
and	O
502	O
non	O
-	O
diabetic	B-Disease
controls	O
.	O

We	O
genotyped	O
rs13266634	O
,	O
rs1111875	O
,	O
rs10811661	O
,	O
rs4402960	O
,	O
rs8050136	O
,	O
rs734312	O
,	O
rs7754840	O
and	O
rs2237892	O
and	O
measured	O
the	O
body	O
weight	O
,	O
body	O
mass	O
index	O
and	O
fasting	O
plasma	O
glucose	O
in	O
all	O
patients	O
and	O
controls	O
.	O

The	O
strongest	O
association	O
was	O
found	O
in	O
a	O
variant	O
of	O
CDKAL1	O
[	O
rs7754840	O
,	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
1	O
.	O
77	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
50	O
-	O
2	O
.	O
10	O
,	O
p	O
=	O
5	O
.	O
0	O
x	O
10	O
(-	O
11	O
)].	O

The	O
G	O
allele	O
of	O
rs1111875	O
(	O
OR	O
=	O
1	O
.	O
43	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
18	O
-	O
1	O
.	O
72	O
,	O
p	O
=	O
1	O
.	O
8	O
x	O
10	O
(-	O
4	O
))	O
in	O
HHEX	O
),	O
the	O
T	O
allele	O
of	O
rs10811661	O
(	O
OR	O
=	O
1	O
.	O
47	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
23	O
-	O
1	O
.	O
75	O
,	O
p	O
=	O
2	O
.	O
1	O
x	O
10	O
(-	O
5	O
))	O
in	O
CDKN2A	O
/	O
B	O
)	O
and	O
the	O
C	O
allele	O
of	O
rs2237892	O
(	O
OR	O
=	O
1	O
.	O
31	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
10	O
-	O
1	O
.	O
56	O
,	O
p	O
=	O
0	O
.	O
3	O
)	O
in	O
KCNQ1	O
showed	O
significant	O
associations	O
with	O
T2DM	B-Disease
.	O

Rs13266634	O
(	O
OR	O
=	O
1	O
.	O
19	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
0	O
-	O
1	O
.	O
42	O
,	O
p	O
=	O
0	O
.	O
45	O
)	O
in	O
SLC30A8	O
showed	O
a	O
nominal	O
association	O
with	O
the	O
risk	O
of	O
T2DM	B-Disease
,	O
whereas	O
SNPs	O
in	O
IGF2BP2	O
,	O
FTO	O
and	O
WFS1	O
were	O
not	O
associated	O
.	O

In	O
conclusion	O
,	O
we	O
have	O
shown	O
that	O
SNPs	O
in	O
HHEX	O
,	O
CDKN2A	O
/	O
B	O
,	O
CDKAL1	O
,	O
KCNQ1	O
and	O
SLC30A8	O
confer	O
a	O
risk	O
of	O
T2DM	B-Disease
in	O
the	O
Korean	O
population	O
.	O


Serotonin	O
6	O
receptor	O
gene	O
is	O
associated	O
with	O
methamphetamine	O
-	O
induced	O
psychosis	B-Disease
in	O
a	O
Japanese	O
population	O
.	O

BACKGROUND	O
:	O
Altered	O
serotonergic	O
neural	O
transmission	O
is	O
hypothesized	O
to	O
be	O
a	O
susceptibility	O
factor	O
for	O
psychotic	B-Disease
disorders	I-Disease
such	O
as	O
schizophrenia	B-Disease
.	O

The	O
serotonin	O
6	O
(	O
5	O
-	O
HT6	O
)	O
receptor	O
is	O
therapeutically	O
targeted	O
by	O
several	O
second	O
generation	O
antipsychotics	O
,	O
such	O
as	O
clozapine	O
and	O
olanzapine	O
,	O
and	O
d	O
-	O
amphetamine	O
-	O
induced	O
hyperactivity	B-Disease
in	O
rats	O
is	O
corrected	O
with	O
the	O
use	O
of	O
a	O
selective	O
5	O
-	O
HT6	O
receptor	O
antagonist	O
.	O

In	O
addition	O
,	O
the	O
disrupted	O
prepulse	O
inhibition	O
induced	O
by	O
d	O
-	O
amphetamine	O
or	O
phencyclidine	O
was	O
restored	O
by	O
5	O
-	O
HT6	O
receptor	O
antagonist	O
in	O
an	O
animal	O
study	O
using	O
rats	O
.	O

These	O
animal	O
models	O
were	O
considered	O
to	O
reflect	O
the	O
positive	O
symptoms	O
of	O
schizophrenia	B-Disease
,	O
and	O
the	O
above	O
evidence	O
suggests	O
that	O
altered	O
5	O
-	O
HT6	O
receptors	O
are	O
involved	O
in	O
the	O
pathophysiology	O
of	O
psychotic	B-Disease
disorders	I-Disease
.	O

The	O
symptoms	O
of	O
methamphetamine	O
(	O
METH	O
)-	O
induced	O
psychosis	B-Disease
are	O
similar	O
to	O
those	O
of	O
paranoid	B-Disease
type	I-Disease
schizophrenia	I-Disease
.	O

Therefore	O
,	O
we	O
conducted	O
an	O
analysis	O
of	O
the	O
association	O
of	O
the	O
5	O
-	O
HT6	O
gene	O
(	O
HTR6	O
)	O
with	O
METH	O
-	O
induced	O
psychosis	B-Disease
.	O

METHOD	O
:	O
Using	O
five	O
tagging	O
SNPs	O
(	O
rs6693503	O
,	O
rs1805054	O
,	O
rs4912138	O
,	O
rs3790757	O
and	O
rs9659997	O
),	O
we	O
conducted	O
a	O
genetic	O
association	O
analysis	O
of	O
case	O
-	O
control	O
samples	O
(	O
197	O
METH	O
-	O
induced	O
psychosis	B-Disease
patients	O
and	O
337	O
controls	O
)	O
in	O
the	O
Japanese	O
population	O
.	O

The	O
age	O
and	O
sex	O
of	O
the	O
control	O
subjects	O
did	O
not	O
differ	O
from	O
those	O
of	O
the	O
methamphetamine	O
dependence	O
patients	O
.	O

RESULTS	O
:	O
rs6693503	O
was	O
associated	O
with	O
METH	O
-	O
induced	O
psychosis	B-Disease
patients	O
in	O
the	O
allele	O
/	O
genotype	O
-	O
wise	O
analysis	O
.	O

Moreover	O
,	O
this	O
association	O
remained	O
significant	O
after	O
Bonferroni	O
correction	O
.	O

In	O
the	O
haplotype	O
-	O
wise	O
analysis	O
,	O
we	O
detected	O
an	O
association	O
between	O
two	O
markers	O
(	O
rs6693503	O
and	O
rs1805054	O
)	O
and	O
three	O
markers	O
(	O
rs6693503	O
,	O
rs1805054	O
and	O
rs4912138	O
)	O
in	O
HTR6	O
and	O
METH	O
-	O
induced	O
psychosis	B-Disease
patients	O
,	O
respectively	O
.	O

CONCLUSION	O
:	O
HTR6	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathophysiology	O
of	O
METH	O
-	O
induced	O
psychosis	B-Disease
in	O
the	O
Japanese	O
population	O
.	O


Reciprocal	O
effects	O
of	O
NNK	O
and	O
SLURP	O
-	O
1	O
on	O
oncogene	O
expression	O
in	O
target	O
epithelial	O
cells	O
.	O

AIMS	O
:	O
To	O
elucidate	O
how	O
the	O
nicotinic	O
acetylcholine	O
receptors	O
expressed	O
on	O
bronchial	O
and	O
oral	O
epithelial	O
cells	O
targeted	O
by	O
the	O
tobacco	O
nitrosamine	O
(	O
4	O
-(	O
methylnitrosamino	O
)-	O
1	O
-(	O
3	O
-	O
pyridyl	O
)-	O
1	O
-	O
butanone	O
)	O
(	O
NNK	O
)	O
facilitate	O
carcinogenic	B-Disease
transformation	O
.	O

MAIN	O
METHODS	O
:	O
Since	O
NNK	O
-	O
dependent	O
transformation	O
can	O
be	O
abolished	O
by	O
the	O
nicotinergic	O
secreted	O
mammalian	O
Ly	O
-	O
6	O
/	O
urokinase	O
plasminogen	O
activator	O
receptor	O
related	O
protein	O
-	O
1	O
(	O
SLURP	O
-	O
1	O
),	O
we	O
compared	O
effects	O
of	O
NNK	O
and	O
recombinant	O
(	O
r	O
)	O
SLURP	O
-	O
1	O
on	O
the	O
expression	O
of	O
genes	O
related	O
to	O
tumorigenesis	B-Disease
in	O
human	O
immortalized	O
bronchial	O
and	O
oral	O
epithelial	O
cell	O
lines	O
BEP2D	O
and	O
Het	O
-	O
1A	O
,	O
respectively	O
.	O

KEY	O
FINDINGS	O
:	O
NNK	O
stimulated	O
expression	O
of	O
oncogenic	O
genes	O
,	O
including	O
MYB	O
and	O
PIK3CA	O
in	O
BEP2D	O
,	O
ETS1	O
,	O
NRAS	O
and	O
SRC	O
in	O
Het	O
-	O
1A	O
,	O
and	O
AKT1	O
,	O
KIT	O
and	O
RB1	O
in	O
both	O
cell	O
types	O
,	O
which	O
could	O
be	O
abolished	O
in	O
the	O
presence	O
of	O
rSLURP	O
-	O
1	O
.	O

Other	O
cancer	B-Disease
-	O
related	O
genes	O
whose	O
upregulation	O
by	O
NNK	O
was	O
abolishable	O
by	O
rSLURP	O
-	O
1	O
were	O
the	O
growth	O
factors	O
EGF	O
in	O
BEP2D	O
cells	O
and	O
HGF	O
in	O
Het	O
-	O
1A	O
cells	O
,	O
and	O
the	O
transcription	O
factors	O
CDKN2A	O
and	O
STAT3	O
(	O
Het	O
-	O
1A	O
only	O
).	O

NNK	O
also	O
upregulated	O
the	O
anti	O
-	O
apoptotic	O
BCL2	O
(	O
Het	O
-	O
1A	O
)	O
and	O
downregulated	O
the	O
pro	O
-	O
apoptotic	O
TNF	O
(	O
Het	O
-	O
1A	O
),	O
BAX	O
and	O
CASP8	O
(	O
BEP2D	O
),	O
all	O
of	O
which	O
could	O
be	O
abolished	O
,	O
in	O
part	O
,	O
by	O
rSLURP	O
-	O
1	O
.	O

NNK	O
decreased	O
expression	O
of	O
the	O
CTNNB1	O
gene	O
encoding	O
the	O
intercellular	O
adhesion	O
molecule	O
beta	O
-	O
catenin	O
(	O
BEP2D	O
),	O
as	O
well	O
as	O
tumor	B-Disease
suppressors	O
CDKN3	O
and	O
FOXD3	O
in	O
BEP2D	O
cells	O
and	O
SERPINB5	O
in	O
Het	O
-	O
1A	O
cells	O
.	O

These	O
pro	O
-	O
oncogenic	O
effects	O
of	O
NNK	O
were	O
abolished	O
by	O
rSLURP	O
-	O
1	O
that	O
also	O
upregulated	O
RUNX3	O
.	O

SIGNIFICANCE	O
:	O
The	O
obtained	O
results	O
identified	O
target	O
genes	O
for	O
both	O
NNK	O
and	O
SLURP	O
-	O
1	O
and	O
shed	O
light	O
on	O
the	O
molecular	O
mechanism	O
of	O
their	O
reciprocal	O
effects	O
on	O
tumorigenic	B-Disease
transformation	O
of	O
bronchial	O
and	O
oral	O
epithelial	O
cells	O
.	O


Long	O
-	O
term	O
exposure	O
of	O
MCF	O
-	O
7	O
breast	B-Disease
cancer	I-Disease
cells	O
to	O
ethanol	O
stimulates	O
oncogenic	O
features	O
.	O

Alcohol	O
consumption	O
is	O
a	O
risk	O
factor	O
for	O
breast	B-Disease
cancer	I-Disease
.	O

Little	O
is	O
known	O
regarding	O
the	O
mechanism	O
,	O
although	O
it	O
is	O
assumed	O
that	O
acetaldehyde	O
or	O
estrogen	O
mediated	O
pathways	O
play	O
a	O
role	O
.	O

We	O
previously	O
showed	O
that	O
long	O
-	O
term	O
exposure	O
to	O
2	O
.	O
5	O
mM	O
ethanol	O
(	O
blood	O
alcohol	O
~	O
0	O
.	O
12	O
%)	O
of	O
MCF	O
-	O
12A	O
,	O
a	O
human	O
normal	O
epithelial	O
breast	O
cell	O
line	O
,	O
induced	O
epithelial	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
and	O
oncogenic	O
transformation	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
in	O
the	O
human	O
breast	B-Disease
cancer	I-Disease
cell	O
line	O
MCF	O
-	O
7	O
,	O
whether	O
a	O
similar	O
exposure	O
to	O
ethanol	O
at	O
concentrations	O
ranging	O
up	O
to	O
peak	O
blood	O
levels	O
in	O
heavy	O
drinkers	O
would	O
increase	O
malignant	O
progression	O
.	O

Short	O
-	O
term	O
(	O
1	O
-	O
week	O
)	O
incubation	O
to	O
ethanol	O
at	O
as	O
low	O
as	O
1	O
-	O
5	O
mM	O
(	O
corresponding	O
to	O
blood	O
alcohol	O
concentration	O
of	O
~	O
0	O
.	O
48	O
-	O
0	O
.	O
24	O
%)	O
upregulated	O
the	O
stem	O
cell	O
related	O
proteins	O
4-Oct	O
and	O
Nanog	O
,	O
but	O
they	O
were	O
reduced	O
after	O
exposure	O
at	O
25	O
mM	O
.	O

Long	O
-	O
term	O
(	O
4	O
-	O
week	O
)	O
exposure	O
to	O
25	O
mM	O
ethanol	O
upregulated	O
the	O
4-Oct	O
and	O
Nanog	O
proteins	O
,	O
as	O
well	O
as	O
the	O
malignancy	B-Disease
marker	O
Ceacam6	O
.	O

DNA	O
microarray	O
analysis	O
in	O
cells	O
exposed	O
for	O
1	O
week	O
showed	O
upregulated	O
expression	O
of	O
metallothionein	O
genes	O
,	O
particularly	O
MT1X	O
.	O

Long	O
-	O
term	O
exposure	O
upregulated	O
expression	O
of	O
some	O
malignancy	B-Disease
related	O
genes	O
(	O
STEAP4	O
,	O
SERPINA3	O
,	O
SAMD9	O
,	O
GDF15	O
,	O
KRT15	O
,	O
ITGB6	O
,	O
TP63	O
,	O
and	O
PGR	O
,	O
as	O
well	O
as	O
the	O
CEACAM	O
,	O
interferon	O
related	O
,	O
and	O
HLA	O
gene	O
families	O
).	O

Some	O
of	O
these	O
findings	O
were	O
validated	O
by	O
RT	O
-	O
PCR	O
.	O

A	O
similar	O
treatment	O
also	O
modulated	O
numerous	O
microRNAs	O
(	O
miRs	O
)	O
including	O
one	O
regulator	O
of	O
4-Oct	O
as	O
well	O
as	O
miRs	O
involved	O
in	O
oncogenesis	O
and	O
/	O
or	O
malignancy	B-Disease
,	O
with	O
only	O
a	O
few	O
estrogen	O
-	O
induced	O
miRs	O
.	O

Long	O
-	O
term	O
25	O
mM	O
ethanol	O
also	O
induced	O
a	O
5	O
.	O
6	O
-	O
fold	O
upregulation	O
of	O
anchorage	O
-	O
independent	O
growth	O
,	O
an	O
indicator	O
of	O
malignant	O
-	O
like	O
features	O
.	O

Exposure	O
to	O
acetaldehyde	O
resulted	O
in	O
little	O
or	O
no	O
effect	O
comparable	O
to	O
that	O
of	O
ethanol	O
.	O

The	O
previously	O
shown	O
alcohol	O
induction	O
of	O
oncogenic	O
transformation	O
of	O
normal	O
breast	O
cells	O
is	O
now	O
complemented	O
by	O
the	O
current	O
results	O
suggesting	O
alcohol	O
'	O
s	O
potential	O
involvement	O
in	O
malignant	O
progression	O
of	O
breast	B-Disease
cancer	I-Disease
.	O


Large	O
contiguous	O
gene	O
deletions	O
in	O
Sjogren	B-Disease
-	I-Disease
Larsson	I-Disease
syndrome	I-Disease
.	O

Sjogren	B-Disease
-	I-Disease
Larsson	I-Disease
syndrome	I-Disease
(	O
SLS	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
characterized	O
by	O
ichthyosis	B-Disease
,	O
mental	B-Disease
retardation	I-Disease
,	O
spasticity	B-Disease
and	O
mutations	O
in	O
the	O
ALDH3A2	O
gene	O
for	O
fatty	O
aldehyde	O
dehydrogenase	O
,	O
an	O
enzyme	O
that	O
catalyzes	O
the	O
oxidation	O
of	O
fatty	O
aldehyde	O
to	O
fatty	O
acid	O
.	O

More	O
than	O
70	O
mutations	O
have	O
been	O
identified	O
in	O
SLS	B-Disease
patients	O
,	O
including	O
small	O
deletions	O
or	O
insertions	O
,	O
missense	O
mutations	O
,	O
splicing	O
defects	O
and	O
complex	O
nucleotide	O
changes	O
.	O

We	O
now	O
describe	O
2	O
SLS	B-Disease
patients	O
whose	O
disease	O
is	O
caused	O
by	O
large	O
contiguous	O
gene	O
deletions	O
of	O
the	O
ALDH3A2	O
locus	O
on	O
17p11	O
.	O
2	O
.	O

The	O
deletions	O
were	O
defined	O
using	O
long	O
distance	O
inverse	O
PCR	O
and	O
microarray	O
-	O
based	O
comparative	O
genomic	O
hybridization	O
.	O

A	O
24	O
-	O
year	O
-	O
old	O
SLS	B-Disease
female	O
was	O
homozygous	O
for	O
a	O
352	O
-	O
kb	O
deletion	O
involving	O
ALDH3A2	O
and	O
4	O
contiguous	O
genes	O
including	O
ALDH3A1	O
,	O
which	O
codes	O
for	O
the	O
major	O
soluble	O
protein	O
in	O
cornea	O
.	O

Although	O
lacking	O
corneal	B-Disease
disease	I-Disease
,	O
she	O
showed	O
severe	O
symptoms	O
of	O
SLS	B-Disease
with	O
uncommon	O
deterioration	O
in	O
oral	O
motor	O
function	O
and	O
loss	O
of	O
ambulation	O
.	O

The	O
other	O
19	O
-	O
month	O
-	O
old	O
female	O
patient	O
was	O
a	O
compound	O
heterozygote	O
for	O
a	O
1	O
.	O
44	O
-	O
Mb	O
contiguous	O
gene	O
deletion	O
and	O
a	O
missense	O
mutation	O
(	O
c	O
.	O
407C	O
>	O
T	O
,	O
P136L	O
)	O
in	O
ALDH3A2	O
.	O

These	O
studies	O
suggest	O
that	O
large	O
gene	O
deletions	O
may	O
account	O
for	O
up	O
to	O
5	O
%	O
of	O
the	O
mutant	O
alleles	O
in	O
SLS	B-Disease
.	O

Geneticists	O
should	O
consider	O
the	O
possibility	O
of	O
compound	O
heterozygosity	O
for	O
large	O
deletions	O
in	O
patients	O
with	O
SLS	B-Disease
and	O
other	O
inborn	B-Disease
errors	I-Disease
of	I-Disease
metabolism	I-Disease
,	O
which	O
has	O
implications	O
for	O
carrier	O
testing	O
and	O
prenatal	O
diagnosis	O
.	O


Serum	O
Amyloid	O
A	O
Induces	O
Inflammation	O
,	O
Proliferation	O
and	O
Cell	O
Death	O
in	O
Activated	O
Hepatic	O
Stellate	O
Cells	O
.	O

Serum	O
amyloid	O
A	O
(	O
SAA	O
)	O
is	O
an	O
evolutionary	O
highly	O
conserved	O
acute	O
phase	O
protein	O
that	O
is	O
predominantly	O
secreted	O
by	O
hepatocytes	O
.	O

However	O
,	O
its	O
role	O
in	O
liver	B-Disease
injury	I-Disease
and	I-Disease
fibrogenesis	I-Disease
has	O
not	O
been	O
elucidated	O
so	O
far	O
.	O

In	O
this	O
study	O
,	O
we	O
determined	O
the	O
effects	O
of	O
SAA	O
on	O
hepatic	O
stellate	O
cells	O
(	O
HSCs	O
),	O
the	O
main	O
fibrogenic	O
cell	O
type	O
of	O
the	O
liver	O
.	O

Serum	O
amyloid	O
A	O
potently	O
activated	O
IkappaB	O
kinase	O
,	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
),	O
Erk	O
and	O
Akt	O
and	O
enhanced	O
NF	O
-	O
kappaB	O
-	O
dependent	O
luciferase	O
activity	O
in	O
primary	O
human	O
and	O
rat	O
HSCs	O
.	O

Serum	O
amyloid	O
A	O
induced	O
the	O
transcription	O
of	O
MCP	O
-	O
1	O
,	O
RANTES	O
and	O
MMP9	O
in	O
an	O
NF	O
-	O
kappaB	O
-	O
and	O
JNK	O
-	O
dependent	O
manner	O
.	O

Blockade	O
of	O
NF	O
-	O
kappaB	O
revealed	O
cytotoxic	B-Disease
effects	O
of	O
SAA	O
in	O
primary	O
HSCs	O
with	O
signs	O
of	O
apoptosis	O
such	O
as	O
caspase	O
3	O
and	O
PARP	O
cleavage	O
and	O
Annexin	O
V	O
staining	O
.	O

Serum	O
amyloid	O
A	O
induced	O
HSC	O
proliferation	O
,	O
which	O
depended	O
on	O
JNK	O
,	O
Erk	O
and	O
Akt	O
activity	O
.	O

In	O
primary	O
hepatocytes	O
,	O
SAA	O
also	O
activated	O
MAP	O
kinases	O
,	O
but	O
did	O
not	O
induce	O
relevant	O
cell	O
death	O
after	O
NF	O
-	O
kappaB	O
inhibition	O
.	O

In	O
two	O
models	O
of	O
hepatic	B-Disease
fibrogenesis	I-Disease
,	O
CCl4	O
treatment	O
and	O
bile	O
duct	O
ligation	O
,	O
hepatic	O
mRNA	O
levels	O
of	O
SAA1	O
and	O
SAA3	O
were	O
strongly	O
increased	O
.	O

In	O
conclusion	O
,	O
SAA	O
may	O
modulate	O
fibrogenic	O
responses	O
in	O
the	O
liver	O
in	O
a	O
positive	O
and	O
negative	O
fashion	O
by	O
inducing	O
inflammation	O
,	O
proliferation	O
and	O
cell	O
death	O
in	O
HSCs	O
.	O


Influence	O
of	O
interleukin	O
12B	O
(	O
IL12B	O
)	O
polymorphisms	O
on	O
spontaneous	O
and	O
treatment	O
-	O
induced	O
recovery	O
from	O
hepatitis	B-Disease
C	I-Disease
virus	I-Disease
infection	I-Disease
.	O

BACKGROUND	O
/	O
AIMS	O
:	O
Interleukin	O
-	O
12	O
(	O
IL	O
-	O
12	O
)	O
governs	O
the	O
Th1	O
-	O
type	O
immune	O
response	O
,	O
affecting	O
the	O
spontaneous	O
and	O
treatment	O
-	O
induced	O
recovery	O
from	O
HCV	B-Disease
-	I-Disease
infection	I-Disease
.	O

We	O
investigated	O
whether	O
the	O
IL12B	O
polymorphisms	O
within	O
the	O
promoter	O
region	O
(	O
4	O
bp	O
insertion	O
/	O
deletion	O
)	O
and	O
the	O
3	O
'-	O
UTR	O
(	O
1188	O
-	O
A	O
/	O
C	O
),	O
which	O
have	O
been	O
reported	O
to	O
influence	O
IL	O
-	O
12	O
synthesis	O
,	O
are	O
associated	O
with	O
the	O
outcome	O
of	O
HCV	B-Disease
infection	I-Disease
.	O

METHODS	O
:	O
We	O
analyzed	O
186	O
individuals	O
with	O
spontaneous	O
HCV	O
clearance	O
,	O
501	O
chronically	O
HCV	B-Disease
infected	I-Disease
patients	O
,	O
and	O
217	O
healthy	O
controls	O
.	O

IL12B	O
3	O
'-	O
UTR	O
and	O
promoter	O
genotyping	O
was	O
performed	O
by	O
Taqman	O
-	O
based	O
assays	O
with	O
allele	O
-	O
specific	O
oligonucleotide	O
probes	O
and	O
PCR	O
-	O
based	O
allele	O
-	O
specific	O
DNA	O
-	O
amplification	O
,	O
respectively	O
.	O

RESULTS	O
:	O
The	O
proportion	O
of	O
IL12B	O
promoter	O
and	O
3	O
'-	O
UTR	O
genotypes	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
different	O
cohorts	O
.	O

However	O
,	O
HCV	B-Disease
genotype	I-Disease
1	I-Disease
-	I-Disease
infected	I-Disease
patients	O
with	O
high	O
baseline	O
viremia	B-Disease
carrying	O
the	O
IL12B	O
3	O
'-	O
UTR	O
1188	O
-	O
C	O
-	O
allele	O
showed	O
significantly	O
higher	O
sustained	O
virologic	O
response	O
(	O
SVR	O
)	O
rates	O
(	O
25	O
.	O
3	O
%	O
vs	O
.	O

46	O
%	O
vs	O
.	O

54	O
.	O
5	O
%	O
for	O
A	O
/	O
A	O
,	O
A	O
/	O
C	O
and	O
C	O
/	O
C	O
)	O
due	O
to	O
reduced	O
relapse	O
rates	O
(	O
24	O
.	O
2	O
%	O
vs	O
.	O

12	O
%	O
vs	O
.	O

zero	O
%	O
for	O
A	O
/	O
A	O
,	O
A	O
/	O
C	O
and	O
C	O
/	O
C	O
).	O

CONCLUSIONS	O
:	O
IL12B	O
3	O
'-	O
UTR	O
1188	O
-	O
C	O
-	O
allele	O
carriers	O
appear	O
to	O
be	O
capable	O
of	O
responding	O
more	O
efficiently	O
to	O
antiviral	O
combination	O
therapy	O
as	O
a	O
consequence	O
of	O
a	O
reduced	O
relapse	O
rate	O
.	O

No	O
association	O
of	O
IL12B	O
polymorphisms	O
and	O
self	O
-	O
limited	O
HCV	B-Disease
infection	I-Disease
could	O
be	O
demonstrated	O
.	O


No	O
Evidence	O
for	O
BRAF	O
as	O
a	O
melanoma	B-Disease
/	O
nevus	B-Disease
susceptibility	O
gene	O
.	O

Somatic	O
mutations	O
of	O
BRAF	O
have	O
been	O
identified	O
in	O
both	O
melanoma	B-Disease
tumors	I-Disease
and	O
benign	O
nevi	B-Disease
.	O

Germ	O
line	O
mutations	O
in	O
BRAF	O
have	O
not	O
been	O
identified	O
as	O
causal	O
in	O
families	O
predisposed	O
to	O
melanoma	B-Disease
.	O

However	O
,	O
a	O
recent	O
study	O
suggested	O
that	O
a	O
BRAF	O
haplotype	O
was	O
associated	O
with	O
risk	O
of	O
sporadic	B-Disease
melanoma	I-Disease
in	O
men	O
.	O

Polymorphisms	O
or	O
other	O
variants	O
in	O
the	O
BRAF	O
gene	O
may	O
therefore	O
act	O
as	O
candidate	O
low	O
-	O
penetrance	O
genes	O
for	O
nevus	B-Disease
/	O
melanoma	B-Disease
susceptibility	O
.	O

We	O
hypothesized	O
that	O
promoter	O
variants	O
would	O
be	O
the	O
most	O
likely	O
candidates	O
for	O
determinants	O
of	O
risk	O
.	O

Using	O
denaturing	O
high	O
-	O
pressure	O
liquid	O
chromatography	O
and	O
sequencing	O
,	O
we	O
screened	O
peripheral	O
blood	O
DNA	O
from	O
184	O
familial	B-Disease
melanoma	I-Disease
cases	O
for	O
BRAF	O
promoter	O
variants	O
.	O

We	O
identified	O
a	O
promoter	O
insertion	O
/	O
deletion	O
in	O
linkage	O
disequilibrium	O
with	O
the	O
previously	O
described	O
BRAF	O
polymorphism	O
in	O
intron	O
11	O
(	O
rs1639679	O
)	O
reported	O
to	O
be	O
associated	O
with	O
melanoma	B-Disease
susceptibility	O
in	O
males	O
.	O

We	O
therefore	O
investigated	O
the	O
contribution	O
of	O
this	O
BRAF	O
polymorphism	O
to	O
melanoma	B-Disease
susceptibility	O
in	O
581	O
consecutively	O
recruited	O
incident	O
cases	O
,	O
258	O
incident	O
cases	O
in	O
a	O
study	O
of	O
late	O
relapse	O
,	O
673	O
female	O
general	O
practitioner	O
controls	O
,	O
and	O
the	O
184	O
familial	O
cases	O
.	O

We	O
found	O
no	O
statistically	O
significant	O
difference	O
in	O
either	O
genotype	O
or	O
allele	O
frequencies	O
between	O
cases	O
and	O
controls	O
overall	O
or	O
between	O
male	O
and	O
female	O
cases	O
for	O
the	O
BRAF	O
polymorphism	O
in	O
the	O
two	O
incident	O
case	O
series	O
.	O

Our	O
results	O
therefore	O
suggest	O
that	O
the	O
BRAF	O
polymorphism	O
is	O
not	O
significantly	O
associated	O
with	O
melanoma	B-Disease
and	O
the	O
promoter	O
insertion	O
/	O
deletion	O
linked	O
with	O
the	O
polymorphism	O
is	O
not	O
a	O
causal	O
variant	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
there	O
was	O
no	O
association	O
between	O
the	O
BRAF	O
genotype	O
and	O
mean	O
total	O
number	O
of	O
banal	O
or	O
atypical	O
nevi	B-Disease
in	O
either	O
the	O
cases	O
or	O
controls	O
.	O


CFI	O
-	O
rs7356506	O
polymorphisms	O
associated	O
with	O
Vogt	B-Disease
-	I-Disease
Koyanagi	I-Disease
-	I-Disease
Harada	I-Disease
syndrome	I-Disease
.	O

PURPOSE	O
:	O
Complement	O
factor	O
I	O
(	O
CFI	O
)	O
plays	O
an	O
important	O
role	O
in	O
complement	O
activation	O
pathways	O
and	O
is	O
known	O
to	O
affect	O
the	O
development	O
of	O
uveitis	B-Disease
.	O

The	O
present	O
study	O
was	O
performed	O
to	O
investigate	O
the	O
existence	O
of	O
an	O
association	O
between	O
CFI	O
genetic	O
polymorphisms	O
and	O
Vogt	B-Disease
-	I-Disease
Koyanagi	I-Disease
-	I-Disease
Harada	I-Disease
(	I-Disease
VKH	I-Disease
)	I-Disease
syndrome	I-Disease
.	O

METHODS	O
:	O
A	O
total	O
of	O
100	O
patients	O
diagnosed	O
with	O
VKH	B-Disease
syndrome	I-Disease
and	O
300	O
healthy	O
controls	O
were	O
recruited	O
for	O
the	O
study	O
.	O

Two	O
milliliters	O
of	O
peripheral	O
blood	O
were	O
collected	O
in	O
a	O
sterile	O
anticoagulative	O
tube	O
.	O

CFI	O
-	O
rs7356506	O
polymorphisms	O
were	O
genotyped	O
using	O
Sequenom	O
MassARRAY	O
technology	O
.	O

Allele	O
and	O
genotype	O
frequencies	O
were	O
compared	O
between	O
patients	O
and	O
controls	O
using	O
a	O
X	O
(	O
2	O
)	O
test	O
.	O

The	O
analyses	O
were	O
stratified	O
for	O
recurrent	O
status	O
,	O
complicated	O
cataract	B-Disease
status	O
,	O
and	O
steroid	O
-	O
sensitive	O
status	O
.	O

RESULTS	O
:	O
No	O
significant	O
association	O
was	O
found	O
between	O
CFI	O
-	O
rs7356506	O
polymorphisms	O
and	O
VKH	B-Disease
syndrome	I-Disease
.	O

However	O
,	O
patients	O
with	O
recurrent	O
VKH	B-Disease
syndrome	I-Disease
had	O
lower	O
frequencies	O
of	O
the	O
G	O
allele	O
and	O
GG	O
homozygosity	O
in	O
CFI	O
-	O
rs7356506	O
when	O
compared	O
to	O
the	O
controls	O
(	O
p	O
=	O
0	O
.	O
16	O
,	O
odds	O
ratio	O
[	O
OR	O
]=	O
0	O
.	O
429	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]=	O
0	O
.	O
212	O
-	O
0	O
.	O
871	O
;	O
p	O
=	O
0	O
.	O
14	O
,	O
OR	O
=	O
0	O
.	O
364	O
,	O
95	O
%	O
CI	O
=	O
0	O
.	O
158	O
-	O
0	O
.	O
837	O
,	O
respectively	O
).	O

Furthermore	O
,	O
there	O
were	O
significant	O
decreases	O
in	O
the	O
frequencies	O
of	O
the	O
G	O
allele	O
and	O
GG	O
homozygosity	O
in	O
CFI	O
-	O
rs7356506	O
in	O
patients	O
with	O
VKH	B-Disease
syndrome	I-Disease
with	O
complicated	O
cataract	B-Disease
compared	O
to	O
the	O
controls	O
(	O
p	O
<	O
0	O
.	O
1	O
,	O
OR	O
=	O
0	O
.	O
357	O
,	O
95	O
%	O
CI	O
=	O
0	O
.	O
197	O
-	O
0	O
.	O
648	O
;	O
p	O
<	O
0	O
.	O
1	O
,	O
OR	O
=	O
0	O
.	O
273	O
,	O
95	O
%	O
CI	O
=	O
0	O
.	O
135	O
-	O
0	O
.	O
551	O
,	O
respectively	O
).	O

Nevertheless	O
,	O
no	O
significant	O
association	O
with	O
patients	O
with	O
VKH	B-Disease
syndrome	I-Disease
in	O
steroid	O
-	O
sensitive	O
statuses	O
was	O
detected	O
for	O
CFI	O
-	O
rs7356506	O
polymorphisms	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
indicate	O
that	O
CFI	O
polymorphisms	O
are	O
not	O
significantly	O
associated	O
with	O
VKH	B-Disease
syndrome	I-Disease
;	O
nevertheless	O
,	O
we	O
identified	O
a	O
trend	O
for	O
the	O
association	O
of	O
CFI	O
-	O
7356506	O
with	O
VKH	B-Disease
syndrome	I-Disease
that	O
depends	O
on	O
the	O
recurrent	O
status	O
and	O
the	O
complicated	O
cataract	B-Disease
status	O
but	O
not	O
on	O
the	O
steroid	O
-	O
sensitive	O
status	O
.	O


Two	O
novel	O
mutations	O
in	O
the	O
MEN1	O
gene	O
in	O
subjects	O
with	O
multiple	B-Disease
endocrine	I-Disease
neoplasia	I-Disease
-	I-Disease
1	I-Disease
.	O

Multiple	B-Disease
endocrine	I-Disease
neoplasia	I-Disease
type	I-Disease
1	I-Disease
(	O
MEN1	B-Disease
)	O
is	O
characterized	O
by	O
parathyroid	O
,	O
enteropancreatic	B-Disease
endocrine	I-Disease
and	I-Disease
pituitary	I-Disease
adenomas	I-Disease
as	O
well	O
as	O
germline	O
mutation	O
of	O
the	O
MEN1	O
gene	O
.	O

We	O
describe	O
2	O
families	O
with	O
MEN1	O
with	O
novel	O
mutations	O
in	O
the	O
MEN1	O
gene	O
.	O

One	O
family	O
was	O
of	O
Turkish	O
origin	O
,	O
and	O
the	O
index	O
patient	O
had	O
primary	B-Disease
hyperparathyroidism	I-Disease
(	O
PHPT	B-Disease
)	O
plus	O
a	O
prolactinoma	B-Disease
;	O
three	O
relatives	O
had	O
PHPT	B-Disease
only	O
.	O

The	O
index	O
patient	O
in	O
the	O
second	O
family	O
was	O
a	O
46	O
-	O
yr	O
-	O
old	O
woman	O
of	O
Chinese	O
origin	O
living	O
in	O
Taiwan	O
.	O

This	O
patient	O
presented	O
with	O
a	O
complaint	O
of	O
epigastric	O
pain	B-Disease
and	O
watery	O
diarrhea	B-Disease
over	O
the	O
past	O
3	O
months	O
,	O
and	O
had	O
undergone	O
subtotal	O
parathyroidectomy	O
and	O
enucleation	O
of	O
pancreatic	B-Disease
islet	I-Disease
cell	I-Disease
tumor	I-Disease
about	O
10	O
yr	O
before	O
.	O

There	O
was	O
also	O
a	O
prolactinoma	B-Disease
.	O

Sequence	O
analysis	O
of	O
the	O
MEN1	O
gene	O
from	O
leukocyte	O
genomic	O
DNA	O
revealed	O
heterozygous	O
mutations	O
in	O
both	O
probands	O
.	O

The	O
Turkish	O
patient	O
and	O
her	O
affected	O
relatives	O
all	O
had	O
a	O
heterozygous	O
A	O
to	O
G	O
transition	O
at	O
codon	O
557	O
(	O
AAG	O
-->	O
GAG	O
)	O
of	O
exon	O
10	O
of	O
MEN1	O
that	O
results	O
in	O
a	O
replacement	O
of	O
lysine	O
by	O
glutamic	O
acid	O
.	O

The	O
Chinese	O
index	O
patient	O
and	O
one	O
of	O
her	O
siblings	O
had	O
a	O
heterozygous	O
mutation	O
at	O
codon	O
418	O
of	O
exon	O
9	O
(	O
GAC	O
-->	O
TAT	O
)	O
that	O
results	O
in	O
a	O
substitution	O
of	O
aspartic	O
acid	O
by	O
tyrosine	O
.	O

In	O
conclusion	O
,	O
we	O
have	O
identified	O
2	O
novel	O
missense	O
mutations	O
in	O
the	O
MEN1	O
gene	O
.	O


Common	O
BRCA2	O
variants	O
and	O
modification	O
of	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
risk	O
in	O
BRCA1	O
mutation	O
carriers	O
.	O

The	O
HH	O
genotype	O
of	O
the	O
nonconservative	O
amino	O
acid	O
substitution	O
polymorphism	O
N372H	O
in	O
the	O
BRCA2	O
gene	O
was	O
reported	O
to	O
be	O
associated	O
with	O
a	O
1	O
.	O
3	O
-	O
to	O
1	O
.	O
5	O
-	O
fold	O
increase	O
in	O
risk	O
of	O
both	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O

As	O
these	O
studies	O
concerned	O
sporadic	O
cancer	B-Disease
cases	O
,	O
we	O
investigated	O
whether	O
N372H	O
and	O
another	O
common	O
variant	O
located	O
in	O
the	O
5	O
'-	O
untranslated	O
region	O
(	O
203G	O
>	O
A	O
)	O
of	O
the	O
BRCA2	O
gene	O
modify	O
breast	B-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
risk	O
in	O
BRCA1	O
mutation	O
carriers	O
.	O

The	O
study	O
includes	O
778	O
women	O
carrying	O
a	O
BRCA1	O
germ	O
-	O
line	O
mutation	O
belonging	O
to	O
403	O
families	O
.	O

The	O
two	O
BRCA2	O
variants	O
were	O
analyzed	O
by	O
the	O
TaqMan	O
allelic	O
discrimination	O
technique	O
.	O

Genotypes	O
were	O
analyzed	O
by	O
disease	O
-	O
free	O
survival	O
analysis	O
using	O
a	O
Cox	O
proportional	O
hazards	O
model	O
.	O

We	O
found	O
no	O
evidence	O
of	O
a	O
significant	O
modification	O
of	O
breast	B-Disease
cancer	I-Disease
penetrance	O
in	O
BRCA1	O
mutation	O
carriers	O
by	O
either	O
polymorphism	O
.	O

In	O
respect	O
of	O
ovarian	B-Disease
cancer	I-Disease
risk	O
,	O
we	O
also	O
saw	O
no	O
effect	O
with	O
the	O
N372H	O
variant	O
but	O
we	O
did	O
observe	O
a	O
borderline	O
association	O
with	O
the	O
5	O
'-	O
untranslated	O
region	O
203A	O
allele	O
(	O
hazard	O
ratio	O
,	O
1	O
.	O
43	O
;	O
CI	O
,	O
1	O
.	O
1	O
-	O
2	O
.	O
0	O
).	O

In	O
contrast	O
to	O
the	O
result	O
of	O
Healey	O
et	O
al	O
.	O

on	O
newborn	O
females	O
and	O
adult	O
female	O
controls	O
,	O
we	O
found	O
no	O
departure	O
from	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
in	O
the	O
distribution	O
of	O
N372H	O
alleles	O
for	O
our	O
female	O
BRCA1	O
carriers	O
.	O

We	O
conclude	O
that	O
if	O
these	O
single	O
-	O
nucleotide	O
polymorphisms	O
do	O
modify	O
the	O
risk	O
of	O
cancer	B-Disease
in	O
BRCA1	O
mutation	O
carriers	O
,	O
their	O
effects	O
are	O
not	O
significantly	O
larger	O
than	O
that	O
of	O
N372H	O
previously	O
observed	O
in	O
the	O
general	O
population	O
.	O


Transgelin	O
increases	O
metastatic	O
potential	O
of	O
colorectal	B-Disease
cancer	I-Disease
cells	O
in	O
vivo	O
and	O
alters	O
expression	O
of	O
genes	O
involved	O
in	O
cell	O
motility	O
.	O

BACKGROUND	O
:	O
Transgelin	O
is	O
an	O
actin	O
-	O
binding	O
protein	O
that	O
promotes	O
motility	O
in	O
normal	O
cells	O
.	O

Although	O
the	O
role	O
of	O
transgelin	O
in	O
cancer	B-Disease
is	O
controversial	O
,	O
a	O
number	O
of	O
studies	O
have	O
shown	O
that	O
elevated	O
levels	O
correlate	O
with	O
aggressive	O
tumor	B-Disease
behavior	O
,	O
advanced	O
stage	O
,	O
and	O
poor	O
prognosis	O
.	O

Here	O
we	O
sought	O
to	O
determine	O
the	O
role	O
of	O
transgelin	O
more	O
directly	O
by	O
determining	O
whether	O
experimental	O
manipulation	O
of	O
transgelin	O
levels	O
in	O
colorectal	B-Disease
cancer	I-Disease
(	O
CRC	B-Disease
)	O
cells	O
led	O
to	O
changes	O
in	O
metastatic	O
potential	O
in	O
vivo	O
.	O

METHODS	O
:	O
Isogenic	O
CRC	B-Disease
cell	O
lines	O
that	O
differ	O
in	O
transgelin	O
expression	O
were	O
characterized	O
using	O
in	O
vitro	O
assays	O
of	O
growth	O
and	O
invasiveness	O
and	O
a	O
mouse	O
tail	O
vein	O
assay	O
of	O
experimental	O
metastasis	O
.	O

Downstream	O
effects	O
of	O
transgelin	O
overexpression	O
were	O
investigated	O
by	O
gene	O
expression	O
profiling	O
and	O
quantitative	O
PCR	O
.	O

RESULTS	O
:	O
Stable	O
overexpression	O
of	O
transgelin	O
in	O
RKO	O
cells	O
,	O
which	O
have	O
low	O
endogenous	O
levels	O
,	O
led	O
to	O
increased	O
invasiveness	O
,	O
growth	O
at	O
low	O
density	O
,	O
and	O
growth	O
in	O
soft	O
agar	O
.	O

Overexpression	O
also	O
led	O
to	O
an	O
increase	O
in	O
the	O
number	O
and	O
size	O
of	O
lung	B-Disease
metastases	I-Disease
in	O
the	O
mouse	O
tail	O
vein	O
injection	O
model	O
.	O

Similarly	O
,	O
attenuation	O
of	O
transgelin	O
expression	O
in	O
HCT116	O
cells	O
,	O
which	O
have	O
high	O
endogenous	O
levels	O
,	O
decreased	O
metastases	B-Disease
in	O
the	O
same	O
model	O
.	O

Investigation	O
of	O
mRNA	O
expression	O
patterns	O
showed	O
that	O
transgelin	O
overexpression	O
altered	O
the	O
levels	O
of	O
approximately	O
250	O
other	O
transcripts	O
,	O
with	O
over	O
-	O
representation	O
of	O
genes	O
that	O
affect	O
function	O
of	O
actin	O
or	O
other	O
cytoskeletal	O
proteins	O
.	O

Changes	O
included	O
increases	O
in	O
HOOK1	O
,	O
SDCCAG8	O
,	O
ENAH	O
/	O
Mena	O
,	O
and	O
TNS1	O
and	O
decreases	O
in	O
EMB	O
,	O
BCL11B	O
,	O
and	O
PTPRD	O
.	O

CONCLUSIONS	O
:	O
Increases	O
or	O
decreases	O
in	O
transgelin	O
levels	O
have	O
reciprocal	O
effects	O
on	O
tumor	B-Disease
cell	O
behavior	O
,	O
with	O
higher	O
expression	O
promoting	O
metastasis	O
.	O

Chronic	O
overexpression	O
influences	O
steady	O
-	O
state	O
levels	O
of	O
mRNAs	O
for	O
metastasis	O
-	O
related	O
genes	O
.	O


Association	O
of	O
sporadic	B-Disease
chondrocalcinosis	I-Disease
with	O
a	O
-	O
4	O
-	O
basepair	O
G	O
-	O
to	O
-	O
A	O
transition	O
in	O
the	O
5	O
'-	O
untranslated	O
region	O
of	O
ANKH	O
that	O
promotes	O
enhanced	O
expression	O
of	O
ANKH	O
protein	O
and	O
excess	O
generation	O
of	O
extracellular	O
inorganic	O
pyrophosphate	O
.	O

OBJECTIVE	O
:	O
Certain	O
mutations	O
in	O
ANKH	O
,	O
which	O
encodes	O
a	O
multiple	O
-	O
pass	O
transmembrane	O
protein	O
that	O
regulates	O
inorganic	O
pyrophosphate	O
(	O
PPi	O
)	O
transport	O
,	O
are	O
linked	O
to	O
autosomal	B-Disease
-	I-Disease
dominant	I-Disease
familial	I-Disease
chondrocalcinosis	I-Disease
.	O

This	O
study	O
investigated	O
the	O
potential	O
for	O
ANKH	O
sequence	O
variants	O
to	O
promote	O
sporadic	O
chondrocalcinosis	B-Disease
.	O

METHODS	O
:	O
ANKH	O
variants	O
identified	O
by	O
genomic	O
sequencing	O
were	O
screened	O
for	O
association	O
with	O
chondrocalcinosis	B-Disease
in	O
128	O
patients	O
with	O
severe	O
sporadic	O
chondrocalcinosis	B-Disease
or	O
pseudogout	B-Disease
and	O
in	O
ethnically	O
matched	O
healthy	O
controls	O
.	O

The	O
effects	O
of	O
specific	O
variants	O
on	O
expression	O
of	O
common	O
markers	O
were	O
evaluated	O
by	O
in	O
vitro	O
transcription	O
/	O
translation	O
.	O

The	O
function	O
of	O
these	O
variants	O
was	O
studied	O
in	O
transfected	O
human	O
immortalized	O
CH	O
-	O
8	O
articular	O
chondrocytes	O
.	O

RESULTS	O
:	O
Sporadic	B-Disease
chondrocalcinosis	I-Disease
was	O
associated	O
with	O
a	O
G	O
-	O
to	O
-	O
A	O
transition	O
in	O
the	O
ANKH	O
5	O
'-	O
untranslated	O
region	O
(	O
5	O
'-	O
UTR	O
)	O
at	O
4	O
bp	O
upstream	O
of	O
the	O
start	O
codon	O
(	O
in	O
homozygotes	O
of	O
the	O
minor	O
allele	O
,	O
genotype	O
relative	O
risk	O
6	O
.	O
0	O
,	O
P	O
=	O
0	O
.	O
6	O
;	O
overall	O
genotype	O
association	O
P	O
=	O
0	O
.	O
2	O
).	O

This	O
-	O
4	O
-	O
bp	O
transition	O
,	O
as	O
well	O
as	O
2	O
mutations	O
previously	O
linked	O
with	O
familial	B-Disease
and	I-Disease
sporadic	I-Disease
chondrocalcinosis	I-Disease
(+	O
14	O
bp	O
C	O
-	O
to	O
-	O
T	O
and	O
C	O
-	O
terminal	O
GAG	O
deletion	O
,	O
respectively	O
),	O
but	O
not	O
the	O
French	O
familial	B-Disease
chondrocalcinosis	I-Disease
kindred	O
143	O
-	O
bp	O
T	O
-	O
to	O
-	O
C	O
mutation	O
,	O
increased	O
reticulocyte	O
ANKH	O
transcription	O
/	O
ANKH	O
translation	O
in	O
vitro	O
.	O

Transfection	O
of	O
complementary	O
DNA	O
for	O
both	O
the	O
wild	O
-	O
type	O
ANKH	O
and	O
the	O
-	O
4	O
-	O
bp	O
ANKH	O
protein	O
variant	O
promoted	O
increased	O
extracellular	O
PPi	O
in	O
CH	O
-	O
8	O
cells	O
,	O
but	O
unexpectedly	O
,	O
these	O
ANKH	O
mutants	O
had	O
divergent	O
effects	O
on	O
the	O
expression	O
of	O
extracellular	O
PPi	O
and	O
the	O
chondrocyte	O
hypertrophy	B-Disease
marker	O
,	O
type	O
X	O
collagen	O
.	O

CONCLUSION	O
:	O
A	O
subset	O
of	O
sporadic	B-Disease
chondrocalcinosis	I-Disease
appears	O
to	O
be	O
heritable	O
via	O
a	O
-	O
4	O
-	O
bp	O
G	O
-	O
to	O
-	O
A	O
ANKH	O
5	O
'-	O
UTR	O
transition	O
that	O
up	O
-	O
regulates	O
expression	O
of	O
ANKH	O
and	O
extracellular	O
PPi	O
in	O
chondrocyte	O
cells	O
.	O

Distinct	O
ANKH	O
mutations	O
associated	O
with	O
heritable	O
chondrocalcinosis	B-Disease
may	O
promote	O
disease	O
by	O
divergent	O
effects	O
on	O
extracellular	O
PPi	O
and	O
chondrocyte	O
hypertrophy	B-Disease
,	O
which	O
is	O
likely	O
to	O
mediate	O
differences	O
in	O
the	O
clinical	O
phenotypes	O
and	O
severity	O
of	O
the	O
disease	O
.	O


Contribution	O
of	O
STAT4	O
gene	O
single	O
-	O
nucleotide	O
polymorphism	O
to	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
in	O
the	O
Polish	O
population	O
.	O

The	O
STAT4	O
has	O
been	O
found	O
to	O
be	O
a	O
susceptible	O
gene	O
in	O
the	O
development	O
of	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
(	O
SLE	B-Disease
)	O
in	O
various	O
populations	O
.	O

There	O
are	O
evident	O
population	O
differences	O
in	O
the	O
context	O
of	O
clinical	O
manifestations	O
of	O
SLE	B-Disease
,	O
therefore	O
we	O
investigated	O
the	O
prevalence	O
of	O
the	O
STAT4	O
G	O
>	O
C	O
(	O
rs7582694	O
)	O
polymorphism	O
in	O
patients	O
with	O
SLE	B-Disease
(	O
n	O
=	O
253	O
)	O
and	O
controls	O
(	O
n	O
=	O
521	O
)	O
in	O
a	O
sample	O
of	O
the	O
Polish	O
population	O
.	O

We	O
found	O
that	O
patients	O
with	O
the	O
STAT4	O
C	O
/	O
G	O
and	O
CC	O
genotypes	O
exhibited	O
a	O
1	O
.	O
583	O
-	O
fold	O
increased	O
risk	O
of	O
SLE	B-Disease
incidence	O
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
168	O
-	O
2	O
.	O
145	O
,	O
p	O
=	O
0	O
.	O
3	O
),	O
with	O
OR	O
for	O
the	O
C	O
/	O
C	O
versus	O
C	O
/	O
G	O
and	O
G	O
/	O
G	O
genotypes	O
was	O
1	O
.	O
967	O
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
152	O
-	O
3	O
.	O
358	O
,	O
p	O
=	O
0	O
.	O
119	O
).	O

The	O
OR	O
for	O
the	O
STAT4	O
C	O
allele	O
frequency	O
showed	O
a	O
1	O
.	O
539	O
-	O
fold	O
increased	O
risk	O
of	O
SLE	B-Disease
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
209	O
-	O
1	O
.	O
959	O
,	O
p	O
=	O
0	O
.	O
4	O
).	O

We	O
also	O
observed	O
an	O
increased	O
frequency	O
of	O
STAT4	O
C	O
/	O
C	O
and	O
C	O
/	O
G	O
genotypes	O
in	O
SLE	B-Disease
patients	O
with	O
renal	B-Disease
symptoms	I-Disease
OR	O
=	O
2	O
.	O
259	O
(	O
1	O
.	O
365	O
-	O
3	O
.	O
738	O
,	O
p	O
=	O
0	O
.	O
14	O
),	O
(	O
p	O
(	O
corr	O
)	O
=	O
0	O
.	O
238	O
)	O
and	O
in	O
SLE	B-Disease
patients	O
with	O
neurologic	O
manifestations	O
OR	O
=	O
2	O
.	O
867	O
(	O
1	O
.	O
467	O
-	O
5	O
.	O
604	O
,	O
p	O
=	O
0	O
.	O
16	O
),	O
(	O
p	O
(	O
corr	O
)	O
=	O
0	O
.	O
272	O
).	O

Moreover	O
,	O
we	O
found	O
a	O
contribution	O
of	O
STAT4	O
C	O
/	O
C	O
and	O
C	O
/	O
G	O
genotypes	O
to	O
the	O
presence	O
of	O
the	O
anti	O
-	O
snRNP	O
Ab	O
OR	O
=	O
3	O
.	O
237	O
(	O
1	O
.	O
667	O
-	O
6	O
.	O
288	O
,	O
p	O
=	O
0	O
.	O
3	O
),	O
(	O
p	O
(	O
corr	O
)	O
=	O
0	O
.	O
51	O
)	O
and	O
the	O
presence	O
of	O
the	O
anti	O
-	O
Scl	O
-	O
70	O
Ab	O
OR	O
=	O
2	O
.	O
665	O
(	O
1	O
.	O
380	O
-	O
5	O
.	O
147	O
,	O
p	O
=	O
0	O
.	O
28	O
),	O
(	O
p	O
(	O
corr	O
)	O
=	O
0	O
.	O
476	O
).	O

Our	O
studies	O
confirmed	O
an	O
association	O
of	O
the	O
STAT4	O
C	O
(	O
rs7582694	O
)	O
variant	O
with	O
the	O
development	O
of	O
SLE	B-Disease
and	O
occurrence	O
of	O
some	O
clinical	O
manifestations	O
of	O
the	O
disease	O
.	O


Leukemia	O
inhibitory	O
factor	O
protects	O
the	O
lung	O
during	O
respiratory	B-Disease
syncytial	I-Disease
viral	I-Disease
infection	I-Disease
.	O

BACKGROUND	O
:	O
Respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
infects	O
the	O
lung	O
epithelium	O
where	O
it	O
stimulates	O
the	O
production	O
of	O
numerous	O
host	O
cytokines	O
that	O
are	O
associated	O
with	O
disease	O
burden	O
and	O
acute	B-Disease
lung	I-Disease
injury	I-Disease
.	O

Characterizing	O
the	O
host	O
cytokine	O
response	O
to	O
RSV	B-Disease
infection	I-Disease
,	O
the	O
regulation	O
of	O
host	O
cytokines	O
and	O
the	O
impact	O
of	O
neutralizing	O
an	O
RSV	O
-	O
inducible	O
cytokine	O
during	O
infection	B-Disease
were	O
undertaken	O
in	O
this	O
study	O
.	O

METHODS	O
:	O
A549	O
,	O
primary	O
human	O
small	O
airway	O
epithelial	O
(	O
SAE	O
)	O
cells	O
and	O
wild	O
-	O
type	O
,	O
TIR	O
-	O
domain	O
-	O
containing	O
adapter	O
-	O
inducing	O
interferon	O
-	O
b	O
(	O
Trif	O
)	O
and	O
mitochondrial	O
antiviral	O
-	O
signaling	O
protein	O
(	O
Mavs	O
)	O
knockout	O
(	O
KO	O
)	O
mice	O
were	O
infected	O
with	O
RSV	O
and	O
cytokine	O
responses	O
were	O
investigated	O
by	O
ELISA	O
,	O
multiplex	O
analysis	O
and	O
qPCR	O
.	O

Neutralizing	O
anti	O
-	O
leukemia	O
inhibitory	O
factor	O
(	O
LIF	O
)	O
IgG	O
or	O
control	O
IgG	O
was	O
administered	O
to	O
a	O
group	O
of	O
wild	O
-	O
type	O
animals	O
prior	O
to	O
RSV	B-Disease
infection	I-Disease
.	O

RESULTS	O
AND	O
DISCUSSION	O
:	O
RSV	B-Disease
-	I-Disease
infected	I-Disease
A549	O
and	O
SAE	O
cells	O
release	O
a	O
network	O
of	O
cytokines	O
,	O
including	O
newly	O
identified	O
RSV	O
-	O
inducible	O
cytokines	O
LIF	O
,	O
migration	O
inhibitory	O
factor	O
(	O
MIF	O
),	O
stem	O
cell	O
factor	O
(	O
SCF	O
),	O
CCL27	O
,	O
CXCL12	O
and	O
stem	O
cell	O
growth	O
factor	O
beta	O
(	O
SCGF	O
-	O
b	O
).	O

These	O
RSV	O
-	O
inducible	O
cytokines	O
were	O
also	O
observed	O
in	O
the	O
airways	O
of	O
mice	O
during	O
an	O
infection	B-Disease
.	O

To	O
identify	O
the	O
regulation	O
of	O
RSV	O
inducible	O
cytokines	O
,	O
Mavs	O
and	O
Trif	O
deficient	O
animals	O
were	O
infected	O
with	O
RSV	O
.	O

In	O
vivo	O
induction	O
of	O
airway	O
IL	O
-	O
1b	O
,	O
IL	O
-	O
4	O
,	O
IL	O
-	O
5	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
12	O
(	O
p40	O
),	O
IFN	O
-	O
g	O
,	O
CCL2	O
,	O
CCL5	O
,	O
CCL3	O
,	O
CXCL1	O
,	O
IP	O
-	O
10	O
/	O
CXCL10	O
,	O
IL	O
-	O
22	O
,	O
MIG	O
/	O
CXCL9	O
and	O
MIF	O
were	O
dependent	O
on	O
Mavs	O
expression	O
in	O
mice	O
.	O

Loss	O
of	O
Trif	O
expression	O
in	O
mice	O
altered	O
the	O
RSV	O
induction	O
of	O
IL	O
-	O
1b	O
,	O
IL	O
-	O
5	O
,	O
CXCL12	O
,	O
MIF	O
,	O
LIF	O
,	O
CXCL12	O
and	O
IFN	O
-	O
g	O
.	O

Silencing	O
of	O
retinoic	O
acid	O
-	O
inducible	O
gene	O
-	O
1	O
(	O
RIG	O
-	O
I	O
)	O
expression	O
in	O
A549	O
cells	O
had	O
a	O
greater	O
impact	O
on	O
RSV	O
-	O
inducible	O
cytokines	O
than	O
melanoma	O
differentiation	O
-	O
associated	O
protein	O
5	O
(	O
MDA5	O
)	O
and	O
laboratory	O
of	O
genetics	O
and	O
physiology	O
2	O
(	O
LGP2	O
),	O
and	O
Trif	O
expression	O
.	O

To	O
evaluate	O
the	O
role	O
of	O
LIF	O
in	O
the	O
airways	O
during	O
RSV	B-Disease
infection	I-Disease
,	O
animals	O
were	O
treated	O
with	O
neutralizing	O
anti	O
-	O
LIF	O
IgG	O
,	O
which	O
enhanced	O
RSV	O
pathology	O
observed	O
with	O
increased	O
airspace	O
protein	O
content	O
,	O
apoptosis	O
and	O
airway	O
hyperresponsiveness	O
compared	O
to	O
control	O
IgG	O
treatment	O
.	O

CONCLUSIONS	O
:	O
RSV	B-Disease
infection	I-Disease
in	O
the	O
epithelium	O
induces	O
a	O
network	O
of	O
immune	O
factors	O
to	O
counter	O
infection	B-Disease
,	O
primarily	O
in	O
a	O
RIG	O
-	O
I	O
dependent	O
manner	O
.	O

Expression	O
of	O
LIF	O
protects	O
the	O
lung	O
from	O
lung	B-Disease
injury	I-Disease
and	O
enhanced	O
pathology	O
during	O
RSV	B-Disease
infection	I-Disease
.	O


Urinary	B-Disease
bladder	I-Disease
cancer	I-Disease
in	O
Wegener	B-Disease
'	I-Disease
s	I-Disease
granulomatosis	I-Disease
:	O
risks	O
and	O
relation	O
to	O
cyclophosphamide	O
.	O

OBJECTIVE	O
:	O
To	O
assess	O
and	O
characterise	O
the	O
risk	O
of	O
bladder	B-Disease
cancer	I-Disease
,	O
and	O
its	O
relation	O
to	O
cyclophosphamide	O
,	O
in	O
patients	O
with	O
Wegener	B-Disease
'	I-Disease
s	I-Disease
granulomatosis	I-Disease
.	O

METHODS	O
:	O
In	O
the	O
population	O
based	O
,	O
nationwide	O
Swedish	O
Inpatient	O
Register	O
a	O
cohort	O
of	O
1065	O
patients	O
with	O
Wegener	B-Disease
'	I-Disease
s	I-Disease
granulomatosis	I-Disease
,	O
1969	O
-	O
95	O
,	O
was	O
identified	O
.	O

Through	O
linkage	O
with	O
the	O
Swedish	O
Cancer	B-Disease
Register	O
,	O
all	O
subjects	O
in	O
this	O
cohort	O
diagnosed	O
with	O
bladder	B-Disease
cancer	I-Disease
were	O
identified	O
.	O

Nested	O
within	O
the	O
cohort	O
,	O
a	O
matched	O
case	O
-	O
control	O
study	O
was	O
performed	O
to	O
estimate	O
the	O
association	O
between	O
cyclophosphamide	O
and	O
bladder	B-Disease
cancer	I-Disease
using	O
odds	O
ratios	O
(	O
ORs	O
)	O
as	O
relative	O
risk	O
.	O

In	O
the	O
cohort	O
the	O
cumulative	O
risk	O
of	O
bladder	B-Disease
cancer	I-Disease
after	O
Wegener	B-Disease
'	I-Disease
s	I-Disease
granulomatosis	I-Disease
,	O
and	O
the	O
relative	O
prevalence	O
of	O
a	O
history	O
of	O
bladder	B-Disease
cancer	I-Disease
at	O
the	O
time	O
of	O
diagnosis	O
of	O
Wegener	B-Disease
'	I-Disease
s	I-Disease
granulomatosis	I-Disease
,	O
were	O
also	O
estimated	O
.	O

RESULTS	O
:	O
The	O
median	O
cumulative	O
doses	O
of	O
cyclophosphamide	O
among	O
cases	O
(	O
n	O
=	O
11	O
)	O
and	O
controls	O
(	O
n	O
=	O
25	O
)	O
were	O
113	O
g	O
and	O
25	O
g	O
,	O
respectively	O
.	O

The	O
risk	O
of	O
bladder	B-Disease
cancer	I-Disease
doubled	O
for	O
every	O
10	O
g	O
increment	O
in	O
cyclophosphamide	O
(	O
OR	O
=	O
2	O
.	O
0	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
0	O
.	O
8	O
to	O
4	O
.	O
9	O
).	O

Treatment	O
duration	O
longer	O
than	O
1	O
year	O
was	O
associated	O
with	O
an	O
eightfold	O
increased	O
risk	O
(	O
OR	O
=	O
7	O
.	O
7	O
,	O
95	O
%	O
CI	O
0	O
.	O
9	O
to	O
69	O
).	O

The	O
absolute	O
risk	O
for	O
bladder	B-Disease
cancer	I-Disease
in	O
the	O
cohort	O
reached	O
10	O
%	O
16	O
years	O
after	O
diagnosis	O
of	O
Wegener	B-Disease
'	I-Disease
s	I-Disease
granulomatosis	I-Disease
,	O
and	O
a	O
history	O
of	O
bladder	B-Disease
cancer	I-Disease
was	O
(	O
non	O
-	O
significantly	O
)	O
twice	O
as	O
common	O
as	O
expected	O
at	O
the	O
time	O
of	O
diagnosis	O
of	O
Wegener	B-Disease
'	I-Disease
s	I-Disease
granulomatosis	I-Disease
.	O

CONCLUSION	O
:	O
The	O
results	O
indicate	O
a	O
dose	O
-	O
response	O
relationship	O
between	O
cyclophosphamide	O
and	O
the	O
risk	O
of	O
bladder	B-Disease
cancer	I-Disease
,	O
high	O
cumulative	O
risks	O
in	O
the	O
entire	O
cohort	O
,	O
and	O
also	O
the	O
possibility	O
of	O
risk	O
factors	O
operating	O
even	O
before	O
Wegener	B-Disease
'	I-Disease
s	I-Disease
granulomatosis	I-Disease
.	O


Co	O
-	O
inheritance	O
of	O
a	O
PKD1	O
mutation	O
and	O
homozygous	O
PKD2	O
variant	O
:	O
a	O
potential	O
modifier	O
in	O
autosomal	B-Disease
dominant	I-Disease
polycystic	I-Disease
kidney	I-Disease
disease	I-Disease
.	O

BACKGROUND	O
:	O
Autosomal	B-Disease
dominant	I-Disease
polycystic	I-Disease
kidney	I-Disease
disease	I-Disease
(	O
ADPKD	B-Disease
),	O
which	O
is	O
caused	O
by	O
mutations	O
in	O
polycystins	O
1	O
(	O
PC1	O
)	O
and	O
2	O
(	O
PC2	O
),	O
is	O
one	O
of	O
the	O
most	O
commonly	O
inherited	O
renal	B-Disease
diseases	I-Disease
,	O
affecting	O
~	O
1	O
:	O
1000	O
Caucasians	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
screened	O
Greek	O
ADPKD	B-Disease
patients	O
with	O
the	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
DGGE	O
)	O
assay	O
and	O
direct	O
sequencing	O
.	O

RESULTS	O
:	O
We	O
identified	O
a	O
patient	O
homozygous	O
for	O
a	O
nucleotide	O
change	O
c	O
.	O
1445T	O
>	O
G	O
,	O
resulting	O
in	O
a	O
novel	O
homozygous	O
substitution	O
of	O
the	O
non	O
-	O
polar	O
hydrophobic	O
phenylalanine	O
to	O
the	O
polar	O
hydrophilic	O
cysteine	O
in	O
exon	O
6	O
at	O
codon	O
482	O
(	O
p	O
.	O
F482C	O
)	O
of	O
the	O
PKD2	O
gene	O
and	O
a	O
de	O
-	O
novo	O
PKD1	O
splice	O
-	O
site	O
variant	O
IVS21	O
-	O
2delAG	O
.	O

We	O
did	O
not	O
find	O
this	O
PKD2	O
variant	O
in	O
a	O
screen	O
of	O
280	O
chromosomes	O
of	O
healthy	O
subjects	O
,	O
supporting	O
its	O
pathogenicity	O
.	O

The	O
proband	O
'	O
s	O
parents	O
did	O
not	O
have	O
the	O
PKD1	O
mutation	O
.	O

Real	O
-	O
time	O
PCR	O
of	O
the	O
PKD2	O
transcript	O
from	O
a	O
skin	O
biopsy	O
revealed	O
20	O
-	O
fold	O
higher	O
expression	O
in	O
the	O
patient	O
than	O
in	O
a	O
healthy	O
subject	O
and	O
was	O
higher	O
in	O
the	O
patient	O
'	O
s	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
than	O
in	O
those	O
of	O
her	O
heterozygote	O
daughter	O
and	O
a	O
healthy	O
subject	O
.	O

The	O
greater	O
gene	O
expression	O
was	O
also	O
supported	O
by	O
Western	O
blotting	O
.	O

Inner	O
medullar	O
collecting	O
duct	O
(	O
IMCD	O
)	O
cells	O
transfected	O
with	O
the	O
mutant	O
PKD2	O
mouse	O
gene	O
presented	O
a	O
perinuclear	O
and	O
diffuse	O
cytoplasmic	O
localization	O
compared	O
with	O
the	O
wild	O
type	O
ER	O
localization	O
.	O

Patch	O
-	O
clamping	O
of	O
PBMCs	O
from	O
the	O
p	O
.	O
F482C	O
homozygous	O
and	O
heterozygous	O
subjects	O
revealed	O
lower	O
polycystin	O
-	O
2	O
channel	O
function	O
than	O
in	O
controls	O
.	O

CONCLUSIONS	O
:	O
We	O
report	O
for	O
the	O
first	O
time	O
a	O
patient	O
with	O
ADPKD	B-Disease
who	O
is	O
heterozygous	O
for	O
a	O
de	O
novo	O
PKD1	O
variant	O
and	O
homozygous	O
for	O
a	O
novel	O
PKD2	O
mutation	O
.	O


Two	O
novel	O
mutations	O
of	O
the	O
TSH	O
-	O
beta	O
subunit	O
gene	O
underlying	O
congenital	B-Disease
central	I-Disease
hypothyroidism	I-Disease
undetectable	O
in	O
neonatal	O
TSH	O
screening	O
.	O

CONTEXT	O
:	O
Patients	O
with	O
TSH	O
-	O
beta	O
subunit	O
defects	O
and	O
congenital	B-Disease
hypothyroidism	I-Disease
are	O
missed	O
by	O
TSH	O
-	O
based	O
neonatal	O
screening	O
.	O

OBJECTIVE	O
:	O
Our	O
objective	O
was	O
to	O
report	O
the	O
molecular	O
consequences	O
of	O
a	O
novel	O
splice	O
-	O
junction	O
mutation	O
and	O
a	O
novel	O
missense	O
mutation	O
in	O
the	O
TSH	O
-	O
beta	O
subunit	O
gene	O
found	O
in	O
two	O
patients	O
with	O
congenital	B-Disease
central	I-Disease
hypothyroidism	I-Disease
and	O
conventional	O
treatment	O
-	O
resistant	O
anemia	B-Disease
.	O

RESULTS	O
:	O
Patient	O
1	O
had	O
a	O
homozygous	O
G	O
to	O
A	O
nucleotide	O
change	O
at	O
the	O
5	O
'	O
donor	O
splice	O
site	O
of	O
exon	O
/	O
intron	O
2	O
.	O

This	O
resulted	O
in	O
a	O
silent	O
change	O
at	O
codon	O
34	O
of	O
the	O
mature	O
protein	O
.	O

In	O
vitro	O
splicing	O
assays	O
showed	O
that	O
the	O
mutant	O
minigene	O
dramatically	O
affected	O
pre	O
-	O
mRNA	O
processing	O
,	O
causing	O
exon	O
2	O
to	O
be	O
completely	O
skipped	O
.	O

The	O
putative	O
product	O
from	O
a	O
new	O
out	O
-	O
of	O
-	O
frame	O
translational	O
start	O
point	O
in	O
exon	O
3	O
is	O
expected	O
to	O
yield	O
a	O
nonsense	O
25	O
-	O
amino	O
-	O
acid	O
peptide	O
.	O

In	O
patient	O
2	O
,	O
sequence	O
analysis	O
revealed	O
a	O
compound	O
heterozygosis	O
for	O
the	O
already	O
reported	O
313delT	O
(	O
C105Vfs114X	O
)	O
mutation	O
and	O
for	O
a	O
second	O
novel	O
mutation	O
in	O
exon	O
3	O
,	O
substituting	O
G	O
for	O
A	O
at	O
cDNA	O
nucleotide	O
position	O
323	O
,	O
resulting	O
in	O
a	O
C88Y	O
change	O
.	O

This	O
cysteine	O
residue	O
is	O
conserved	O
among	O
all	O
dimeric	O
pituitary	O
and	O
placental	O
glycoprotein	O
hormone	O
-	O
beta	O
subunits	O
.	O

Data	O
from	O
in	O
silico	O
analysis	O
confirmed	O
that	O
the	O
C88Y	O
mutation	O
would	O
affect	O
subunit	O
conformation	O
.	O

Indeed	O
,	O
two	O
different	O
bioinformatics	O
approaches	O
,	O
PolyPhen	O
and	O
SIFT	O
analysis	O
,	O
predicted	O
C88Y	O
to	O
be	O
a	O
damaging	O
substitution	O
.	O

CONCLUSIONS	O
:	O
In	O
isolated	O
TSH	B-Disease
deficiency	I-Disease
,	O
the	O
exact	O
molecular	O
diagnosis	O
is	O
mandatory	O
for	O
diagnosis	O
of	O
isolated	B-Disease
pituitary	I-Disease
deficiency	I-Disease
,	O
delineation	O
of	O
prognosis	O
,	O
and	O
genetic	O
counseling	O
.	O

Moreover	O
,	O
diagnosis	O
of	O
central	B-Disease
hypothyroidism	I-Disease
should	O
be	O
considered	O
in	O
the	O
face	O
of	O
severe	O
infant	O
anemia	B-Disease
of	O
uncertain	O
etiology	O
.	O


Mutations	O
in	O
the	O
NDP	O
gene	O
:	O
contribution	O
to	O
Norrie	B-Disease
disease	I-Disease
,	O
familial	B-Disease
exudative	I-Disease
vitreoretinopathy	I-Disease
and	O
retinopathy	B-Disease
of	I-Disease
prematurity	I-Disease
.	O

BACKGROUND	O
:	O
To	O
examine	O
the	O
contribution	O
of	O
mutations	O
within	O
the	O
Norrie	B-Disease
disease	I-Disease
(	O
NDP	O
)	O
gene	O
to	O
the	O
clinically	O
similar	O
retinal	B-Disease
diseases	I-Disease
Norrie	I-Disease
disease	I-Disease
,	O
X	B-Disease
-	I-Disease
linked	I-Disease
familial	I-Disease
exudative	I-Disease
vitreoretinopathy	I-Disease
(	O
FEVR	B-Disease
),	O
Coat	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
and	O
retinopathy	B-Disease
of	I-Disease
prematurity	I-Disease
(	O
ROP	B-Disease
).	O

METHODS	O
:	O
A	O
dataset	O
comprising	O
13	O
Norrie	B-Disease
-	I-Disease
FEVR	I-Disease
,	O
one	O
Coat	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
,	O
31	O
ROP	B-Disease
patients	O
and	O
90	O
ex	O
-	O
premature	O
babies	O
of	O
<	O
32	O
weeks	O
'	O
gestation	O
underwent	O
an	O
ophthalmologic	O
examination	O
and	O
were	O
screened	O
for	O
mutations	O
within	O
the	O
NDP	O
gene	O
by	O
direct	O
DNA	O
sequencing	O
,	O
denaturing	O
high	O
-	O
performance	O
liquid	O
chromatography	O
or	O
gel	O
electrophoresis	O
.	O

Controls	O
were	O
only	O
screened	O
using	O
denaturing	O
high	O
-	O
performance	O
liquid	O
chromatography	O
and	O
gel	O
electrophoresis	O
.	O

Confirmation	O
of	O
mutations	O
identified	O
was	O
obtained	O
by	O
DNA	O
sequencing	O
.	O

RESULTS	O
:	O
Evidence	O
for	O
two	O
novel	O
mutations	O
in	O
the	O
NDP	O
gene	O
was	O
presented	O
:	O
Leu103Val	O
in	O
one	O
FEVR	B-Disease
patient	O
and	O
His43Arg	O
in	O
monozygotic	O
twin	O
Norrie	B-Disease
disease	I-Disease
patients	O
.	O

Furthermore	O
,	O
a	O
previously	O
described	O
14	O
-	O
bp	O
deletion	O
located	O
in	O
the	O
5	O
'	O
unstranslated	O
region	O
of	O
the	O
NDP	O
gene	O
was	O
detected	O
in	O
three	O
cases	O
of	O
regressed	O
ROP	B-Disease
.	O

A	O
second	O
heterozygotic	O
14	O
-	O
bp	O
deletion	O
was	O
detected	O
in	O
an	O
unaffected	O
ex	O
-	O
premature	O
girl	O
.	O

Only	O
two	O
of	O
the	O
13	O
Norrie	B-Disease
-	I-Disease
FEVR	I-Disease
index	O
cases	O
had	O
the	O
full	O
features	O
of	O
Norrie	B-Disease
disease	I-Disease
with	O
deafness	B-Disease
and	O
mental	B-Disease
retardation	I-Disease
.	O

CONCLUSION	O
:	O
Two	O
novel	O
mutations	O
within	O
the	O
coding	O
region	O
of	O
the	O
NDP	O
gene	O
were	O
found	O
,	O
one	O
associated	O
with	O
a	O
severe	O
disease	O
phenotypes	O
of	O
Norrie	B-Disease
disease	I-Disease
and	O
the	O
other	O
with	O
FEVR	B-Disease
.	O

A	O
deletion	O
within	O
the	O
non	O
-	O
coding	O
region	O
was	O
associated	O
with	O
only	O
mild	O
-	O
regressed	O
ROP	B-Disease
,	O
despite	O
the	O
presence	O
of	O
low	O
birthweight	O
,	O
prematurity	B-Disease
and	O
exposure	O
to	O
oxygen	O
.	O

In	O
full	O
-	O
term	O
children	O
with	O
retinal	B-Disease
detachment	I-Disease
only	O
15	O
%	O
appear	O
to	O
have	O
the	O
full	O
features	O
of	O
Norrie	B-Disease
disease	I-Disease
and	O
this	O
is	O
important	O
for	O
counselling	O
parents	O
on	O
the	O
possible	O
long	O
-	O
term	O
outcome	O
.	O


Growth	O
hormone	O
dose	O
in	O
growth	B-Disease
hormone	I-Disease
-	I-Disease
deficient	I-Disease
adults	O
is	O
not	O
associated	O
with	O
IGF	O
-	O
1	O
gene	O
polymorphisms	O
.	O

AIMS	O
:	O
Several	O
SNPs	O
and	O
a	O
microsatellite	O
cytosine	O
-	O
adenine	O
repeat	O
promoter	O
polymorphism	O
of	O
the	O
IGF	O
-	O
1	O
gene	O
have	O
been	O
reported	O
to	O
be	O
associated	O
with	O
circulating	O
IGF	O
-	O
1	O
serum	O
concentrations	O
.	O

Variance	O
in	O
IGF	O
-	O
1	O
concentrations	O
due	O
to	O
genetic	O
variations	O
may	O
affect	O
different	O
response	O
to	O
growth	O
hormone	O
(	O
GH	O
)	O
treatment	O
,	O
resulting	O
in	O
different	O
individually	O
required	O
GH	O
-	O
doses	O
in	O
GH	B-Disease
-	I-Disease
deficient	I-Disease
patients	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
test	O
if	O
the	O
IGF	O
-	O
1	O
gene	O
polymorphisms	O
are	O
associated	O
with	O
the	O
GH	O
-	O
dose	O
of	O
GH	B-Disease
-	I-Disease
deficient	I-Disease
adults	O
.	O

MATERIALS	O
&	O
METHODS	O
:	O
A	O
total	O
of	O
nine	O
tagging	O
SNPs	O
,	O
five	O
additionally	O
selected	O
SNPs	O
and	O
a	O
cytosine	O
-	O
adenine	O
repeat	O
polymorphism	O
were	O
determined	O
in	O
133	O
German	O
adult	O
patients	O
(	O
66	O
men	O
,	O
67	O
women	O
;	O
mean	O
age	O
45	O
.	O
4	O
years	O
+/-	O
13	O
.	O
1	O
standard	O
deviation	O
;	O
majority	O
Caucasian	O
)	O
with	O
GH	B-Disease
-	I-Disease
deficiency	I-Disease
(	O
GHD	B-Disease
)	O
of	O
different	O
origin	O
,	O
derived	O
from	O
the	O
prospective	O
Pfizer	O
International	O
Metabolic	O
Study	O
(	O
KIMS	O
)	O
Pharmacogenetics	O
Study	O
.	O

Patients	O
received	O
GH	O
-	O
treatment	O
for	O
12	O
months	O
with	O
finished	O
dose	O
-	O
titration	O
of	O
GH	O
and	O
centralized	O
IGF	O
-	O
1	O
measurements	O
.	O

GH	O
-	O
dose	O
after	O
1	O
year	O
of	O
treatment	O
,	O
IGF	O
-	O
1	O
concentrations	O
,	O
IGF	O
-	O
1	O
-	O
standard	O
deviation	O
score	O
(	O
SDS	O
),	O
the	O
IGF	O
-	O
1	O
:	O
GH	O
ratio	O
and	O
anthropometric	O
data	O
were	O
analyzed	O
by	O
genotype	O
.	O

RESULTS	O
:	O
Except	O
for	O
rs1019731	O
,	O
which	O
showed	O
a	O
significant	O
difference	O
of	O
IGF	O
-	O
1	O
-	O
SDS	O
by	O
genotypes	O
(	O
p	O
=	O
0	O
.	O
2	O
),	O
all	O
polymorphisms	O
showed	O
no	O
associations	O
with	O
the	O
GH	O
-	O
doses	O
,	O
IGF	O
-	O
1	O
concentrations	O
,	O
IGF	O
-	O
1	O
-	O
SDS	O
and	O
IGF	O
-	O
1	O
:	O
GH	O
ratio	O
after	O
adjusting	O
for	O
the	O
confounding	O
variables	O
gender	O
,	O
age	O
and	O
BMI	O
.	O

CONCLUSION	O
:	O
IGF	O
-	O
1	O
gene	O
polymorphisms	O
were	O
not	O
associated	O
with	O
the	O
responsiveness	O
to	O
exogenous	O
GH	O
in	O
GHD	B-Disease
.	O

Therefore	O
,	O
genetic	O
variations	O
of	O
the	O
IGF	O
-	O
1	O
gene	O
seem	O
not	O
to	O
be	O
major	O
influencing	O
factors	O
of	O
the	O
GH	O
-	O
IGF	O
-	O
axis	O
causing	O
variable	O
response	O
to	O
exogenous	O
GH	O
-	O
treatment	O
.	O


Mutation	O
analysis	O
of	O
FOXF2	O
in	O
patients	O
with	O
disorders	B-Disease
of	I-Disease
sex	I-Disease
development	I-Disease
(	O
DSD	B-Disease
)	O
in	O
combination	O
with	O
cleft	B-Disease
palate	I-Disease
.	O

In	O
contrast	O
to	O
disorders	B-Disease
of	I-Disease
sexual	I-Disease
differentiation	I-Disease
caused	O
by	O
lack	O
of	O
androgen	O
production	O
or	O
inhibited	O
androgen	O
action	O
,	O
defects	O
affecting	O
development	O
of	O
the	O
bipotent	O
genital	O
anlagen	O
have	O
rarely	O
been	O
investigated	O
in	O
humans	O
.	O

We	O
have	O
previously	O
documented	O
that	O
the	O
transcription	O
factor	O
FOXF2	O
is	O
highly	O
expressed	O
in	O
human	O
foreskin	O
.	O

Moreover	O
,	O
Foxf2	O
knockout	O
mice	O
present	O
with	O
cleft	B-Disease
palate	I-Disease
in	O
combination	O
with	O
hypoplasia	B-Disease
of	I-Disease
the	I-Disease
genital	I-Disease
tubercle	I-Disease
.	O

We	O
hypothesized	O
that	O
humans	O
with	O
disorders	B-Disease
of	I-Disease
sex	I-Disease
development	I-Disease
(	O
DSD	B-Disease
)	O
in	O
combination	O
with	O
cleft	B-Disease
palate	I-Disease
could	O
have	O
mutations	O
in	O
the	O
FOXF2	O
gene	O
.	O

Eighteen	O
children	O
with	O
DSD	B-Disease
and	O
cleft	B-Disease
palate	I-Disease
were	O
identified	O
in	O
the	O
L	O
beck	O
DSD	B-Disease
database	O
(	O
about	O
1	O
,	O
500	O
entries	O
).	O

Genomic	O
DNA	O
sequence	O
analysis	O
of	O
the	O
FOXF2	O
gene	O
was	O
performed	O
and	O
compared	O
with	O
10	O
normal	O
female	O
and	O
10	O
normal	O
male	O
controls	O
,	O
respectively	O
.	O

Two	O
heterozygous	O
DNA	O
sequence	O
variations	O
were	O
solely	O
present	O
in	O
one	O
single	O
patient	O
each	O
but	O
in	O
none	O
of	O
the	O
20	O
normal	O
controls	O
:	O
a	O
duplication	O
of	O
GCC	O
(	O
c	O
.	O
97GCC	O
[	O
9	O
]+[	O
10	O
])	O
resulting	O
in	O
an	O
extra	O
alanine	O
within	O
exon	O
1	O
and	O
a	O
25	O
*	O
G	O
>	O
A	O
substitution	O
in	O
the	O
3	O
'-	O
untranslated	O
region	O
.	O

Two	O
patients	O
carried	O
a	O
c	O
.	O
262G	O
>	O
A	O
sequence	O
variation	O
predicting	O
for	O
an	O
Ala88Thr	O
exchange	O
which	O
was	O
also	O
detected	O
in	O
2	O
normal	O
controls	O
.	O

Two	O
silent	O
mutations	O
,	O
c	O
.	O
1272C	O
>	O
T	O
(	O
Ser424Ser	O
)	O
and	O
c	O
.	O
1284T	O
>	O
C	O
(	O
Tyr428Tyr	O
),	O
respectively	O
,	O
occurred	O
in	O
the	O
coding	O
region	O
of	O
exon	O
2	O
,	O
again	O
in	O
both	O
patients	O
and	O
normal	O
controls	O
.	O

In	O
conclusion	O
,	O
the	O
majority	O
of	O
the	O
detected	O
sequence	O
alterations	O
were	O
polymorphisms	O
without	O
obvious	O
functional	O
relevance	O
.	O

However	O
,	O
it	O
cannot	O
be	O
excluded	O
that	O
the	O
2	O
unique	O
DNA	O
sequence	O
alterations	O
could	O
have	O
affected	O
FOXF2	O
on	O
the	O
mRNA	O
or	O
protein	O
level	O
thus	O
contributing	O
to	O
the	O
observed	O
disturbances	O
in	O
genital	O
and	O
palate	O
development	O
.	O


A	O
novel	O
mutation	O
screening	O
system	O
for	O
Ehlers	B-Disease
-	I-Disease
Danlos	I-Disease
Syndrome	I-Disease
,	I-Disease
vascular	I-Disease
type	I-Disease
by	O
high	O
-	O
resolution	O
melting	O
curve	O
analysis	O
in	O
combination	O
with	O
small	O
amplicon	O
genotyping	O
using	O
genomic	O
DNA	O
.	O

Ehlers	B-Disease
-	I-Disease
Danlos	I-Disease
syndrome	I-Disease
,	I-Disease
vascular	I-Disease
type	I-Disease
(	O
vEDS	B-Disease
)	O
(	O
MIM	B-Disease
#	I-Disease
130050	I-Disease
)	O
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
disorder	I-Disease
caused	O
by	O
type	O
III	O
procollagen	O
gene	O
(	O
COL3A1	O
)	O
mutations	O
.	O

Most	O
COL3A1	O
mutations	O
are	O
detected	O
by	O
using	O
total	O
RNA	O
from	O
patient	O
-	O
derived	O
fibroblasts	O
,	O
which	O
requires	O
an	O
invasive	O
skin	O
biopsy	O
.	O

High	O
-	O
resolution	O
melting	O
curve	O
analysis	O
(	O
hrMCA	O
)	O
has	O
recently	O
been	O
developed	O
as	O
a	O
post	O
-	O
PCR	O
mutation	O
scanning	O
method	O
which	O
enables	O
simple	O
,	O
rapid	O
,	O
cost	O
-	O
effective	O
,	O
and	O
highly	O
sensitive	O
mutation	O
screening	O
of	O
large	O
genes	O
.	O

We	O
established	O
a	O
hrMCA	O
method	O
to	O
screen	O
for	O
COL3A1	O
mutations	O
using	O
genomic	O
DNA	O
.	O

PCR	O
primers	O
pairs	O
for	O
COL3A1	O
(	O
52	O
amplicons	O
)	O
were	O
designed	O
to	O
cover	O
all	O
coding	O
regions	O
of	O
the	O
52	O
exons	O
,	O
including	O
the	O
splicing	O
sites	O
.	O

We	O
used	O
15	O
DNA	O
samples	O
(	O
8	O
validation	O
samples	O
and	O
7	O
samples	O
of	O
clinically	O
suspected	O
vEDS	B-Disease
patients	O
)	O
in	O
this	O
study	O
.	O

The	O
eight	O
known	O
COL3A1	O
mutations	O
in	O
validation	O
samples	O
were	O
all	O
successfully	O
detected	O
by	O
the	O
hrMCA	O
.	O

In	O
addition	O
,	O
we	O
identified	O
five	O
novel	O
COL3A1	O
mutations	O
,	O
including	O
one	O
deletion	O
(	O
c	O
.	O
2187delA	O
)	O
and	O
one	O
nonsense	O
mutation	O
(	O
c	O
.	O
2992C	O
>	O
T	O
)	O
that	O
could	O
not	O
be	O
determined	O
by	O
the	O
conventional	O
total	O
RNA	O
method	O
.	O

Furthermore	O
,	O
we	O
established	O
a	O
small	O
amplicon	O
genotyping	O
(	O
SAG	O
)	O
method	O
for	O
detecting	O
three	O
high	O
frequency	O
coding	O
-	O
region	O
SNPs	O
(	O
rs1800255	O
:	O
G	O
>	O
A	O
,	O
rs1801184	O
:	O
T	O
>	O
C	O
,	O
and	O
rs2271683	O
:	O
A	O
>	O
G	O
)	O
in	O
COL3A1	O
to	O
differentiate	O
mutations	O
before	O
sequencing	O
.	O

The	O
use	O
of	O
hrMCA	O
in	O
combination	O
with	O
SAG	O
from	O
genomic	O
DNA	O
enables	O
rapid	O
detection	O
of	O
COL3A1	O
mutations	O
with	O
high	O
efficiency	O
and	O
specificity	O
.	O

A	O
better	O
understanding	O
of	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
COL3A1	O
using	O
this	O
method	O
will	O
lead	O
to	O
improve	O
in	O
diagnosis	O
and	O
treatment	O
.	O


Critical	O
role	O
of	O
neuronal	O
pentraxin	O
1	O
in	O
mitochondria	O
-	O
mediated	O
hypoxic	B-Disease
-	I-Disease
ischemic	I-Disease
neuronal	I-Disease
injury	I-Disease
.	O

Developing	O
brain	O
is	O
highly	O
susceptible	O
to	O
hypoxic	B-Disease
-	I-Disease
ischemic	I-Disease
(	I-Disease
HI	I-Disease
)	I-Disease
injury	I-Disease
leading	O
to	O
severe	O
neurological	B-Disease
disabilities	I-Disease
in	O
surviving	O
infants	O
and	O
children	O
.	O

Previously	O
,	O
we	O
have	O
reported	O
induction	O
of	O
neuronal	O
pentraxin	O
1	O
(	O
NP1	O
),	O
a	O
novel	O
neuronal	O
protein	O
of	O
long	O
-	O
pentraxin	O
family	O
,	O
following	O
HI	B-Disease
neuronal	I-Disease
injury	I-Disease
.	O

Here	O
,	O
we	O
investigated	O
how	O
this	O
specific	O
signal	O
is	O
propagated	O
to	O
cause	O
the	O
HI	B-Disease
neuronal	I-Disease
death	I-Disease
.	O

We	O
used	O
wild	O
-	O
type	O
(	O
WT	O
)	O
and	O
NP1	O
knockout	O
(	O
NP1	O
-	O
KO	O
)	O
mouse	O
hippocampal	O
cultures	O
,	O
modeled	O
in	O
vitro	O
following	O
exposure	O
to	O
oxygen	O
glucose	O
deprivation	O
(	O
OGD	O
),	O
and	O
in	O
vivo	O
neonatal	O
(	O
P9	O
-	O
10	O
)	O
mouse	O
model	O
of	O
HI	B-Disease
brain	I-Disease
injury	I-Disease
.	O

Our	O
results	O
show	O
induction	O
of	O
NP1	O
in	O
primary	O
hippocampal	O
neurons	O
following	O
OGD	O
exposure	O
(	O
4	O
-	O
8	O
h	O
)	O
and	O
in	O
the	O
ipsilateral	O
hippocampal	O
CA1	O
and	O
CA3	O
regions	O
at	O
24	O
-	O
48	O
h	O
post	O
-	O
HI	O
compared	O
to	O
the	O
contralateral	O
side	O
.	O

We	O
also	O
found	O
increased	O
PTEN	O
activity	O
concurrent	O
with	O
OGD	O
time	O
-	O
dependent	O
(	O
4	O
-	O
8	O
h	O
)	O
dephosphorylation	O
of	O
Akt	O
(	O
Ser473	O
)	O
and	O
GSK	O
-	O
3b	O
(	O
Ser9	O
).	O

OGD	O
also	O
caused	O
a	O
time	O
-	O
dependent	O
decrease	O
in	O
the	O
phosphorylation	O
of	O
Bad	O
(	O
Ser136	O
),	O
and	O
Bax	O
protein	O
levels	O
.	O

Immunofluorescence	O
staining	O
and	O
subcellular	O
fractionation	O
analyses	O
revealed	O
increased	O
mitochondrial	O
translocation	O
of	O
Bad	O
and	O
Bax	O
proteins	O
from	O
cytoplasm	O
following	O
OGD	O
(	O
4	O
h	O
)	O
and	O
simultaneously	O
increased	O
release	O
of	O
Cyt	O
C	O
from	O
mitochondria	O
followed	O
by	O
activation	O
of	O
caspase	O
-	O
3	O
.	O

NP1	O
protein	O
was	O
immunoprecipitated	O
with	O
Bad	O
and	O
Bax	O
proteins	O
;	O
OGD	O
caused	O
increased	O
interactions	O
of	O
NP1	O
with	O
Bad	O
and	O
Bax	O
,	O
thereby	O
,	O
facilitating	O
their	O
mitochondrial	O
translocation	O
and	O
dissipation	O
of	O
mitochondrial	O
membrane	O
potential	O
(	O
D	O
(	O
m	O
)).	O

This	O
NP1	O
induction	O
preceded	O
the	O
increased	O
mitochondrial	O
release	O
of	O
cytochrome	O
C	O
(	O
Cyt	O
C	O
)	O
into	O
the	O
cytosol	O
,	O
activation	O
of	O
caspase	O
-	O
3	O
and	O
OGD	O
time	O
-	O
dependent	O
cell	O
death	O
in	O
WT	O
primary	O
hippocampal	O
neurons	O
.	O

In	O
contrast	O
,	O
in	O
NP1	O
-	O
KO	O
neurons	O
there	O
was	O
no	O
translocation	O
of	O
Bad	O
and	O
Bax	O
from	O
cytosol	O
to	O
the	O
mitochondria	O
,	O
and	O
no	O
evidence	O
of	O
D	O
(	O
m	O
)	O
loss	O
,	O
increased	O
Cyt	O
C	O
release	O
and	O
caspase	O
-	O
3	O
activation	O
following	O
OGD	O
;	O
which	O
resulted	O
in	O
significantly	O
reduced	O
neuronal	B-Disease
death	I-Disease
.	O

Our	O
results	O
indicate	O
a	O
regulatory	O
role	O
of	O
NP1	O
in	O
Bad	O
/	O
Bax	O
-	O
dependent	O
mitochondrial	O
release	O
of	O
Cyt	O
C	O
and	O
caspase	O
-	O
3	O
activation	O
.	O

Together	O
our	O
findings	O
demonstrate	O
a	O
novel	O
mechanism	O
by	O
which	O
NP1	O
regulates	O
mitochondria	O
-	O
driven	O
hippocampal	O
cell	O
death	O
;	O
suggesting	O
NP1	O
as	O
a	O
potential	O
therapeutic	O
target	O
against	O
HI	B-Disease
brain	I-Disease
injury	I-Disease
in	O
neonates	O
.	O


Neuroprotective	O
effect	O
of	O
neuroserpin	O
in	O
oxygen	O
-	O
glucose	O
deprivation	O
-	O
and	O
reoxygenation	O
-	O
treated	O
rat	O
astrocytes	O
in	O
vitro	O
.	O

Neuroserpin	O
(	O
NSP	O
)	O
reportedly	O
exerts	O
neuroprotective	O
effects	O
in	O
cerebral	B-Disease
ischemic	I-Disease
animal	O
models	O
and	O
patients	O
;	O
however	O
,	O
the	O
mechanism	O
of	O
protection	O
is	O
poorly	O
understood	O
.	O

We	O
thus	O
attempted	O
to	O
confirm	O
neuroprotective	O
effects	O
of	O
NSP	O
on	O
astrocytes	O
in	O
the	O
ischemic	B-Disease
state	O
and	O
then	O
explored	O
the	O
relative	O
mechanisms	O
.	O

Astrocytes	O
from	O
neonatal	O
rats	O
were	O
treated	O
with	O
oxygen	O
-	O
glucose	O
deprivation	O
(	O
OGD	O
)	O
followed	O
by	O
reoxygenation	O
(	O
OGD	O
/	O
R	O
).	O

To	O
confirm	O
the	O
neuroprotective	O
effects	O
of	O
NSP	O
,	O
we	O
measured	O
the	O
cell	O
survival	O
rate	O
,	O
relative	O
lactate	O
dehydrogenase	O
(	O
LDH	O
)	O
release	O
;	O
we	O
also	O
performed	O
morphological	O
methods	O
,	O
namely	O
Hoechst	O
33342	O
staining	O
and	O
Annexin	O
V	O
assay	O
.	O

To	O
explore	O
the	O
potential	O
mechanisms	O
of	O
NSP	O
,	O
the	O
release	O
of	O
nitric	O
oxide	O
(	O
NO	O
)	O
and	O
TNF	O
-	O
alpha	O
related	O
to	O
NSP	O
administration	O
were	O
measured	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

The	O
proteins	O
related	O
to	O
the	O
NF	O
-	O
kappaB	O
,	O
ERK1	O
/	O
2	O
,	O
and	O
PI3K	O
/	O
Akt	O
pathways	O
were	O
investigated	O
by	O
Western	O
blotting	O
.	O

To	O
verify	O
the	O
cause	O
-	O
and	O
-	O
effect	O
relationship	O
between	O
neuroprotection	O
and	O
the	O
NF	O
-	O
kappaB	O
pathway	O
,	O
a	O
NF	O
-	O
kappaB	O
pathway	O
inhibitor	O
sc3060	O
was	O
employed	O
to	O
observe	O
the	O
effects	O
of	O
NSP	O
-	O
induced	O
neuroprotection	O
.	O

We	O
found	O
that	O
NSP	O
significantly	O
increased	O
the	O
cell	O
survival	O
rate	O
and	O
reduced	O
LDH	O
release	O
in	O
OGD	O
/	O
R	O
-	O
treated	O
astrocytes	O
.	O

It	O
also	O
reduced	O
NO	O
/	O
TNF	O
-	O
alpha	O
release	O
.	O

Western	O
blotting	O
showed	O
that	O
the	O
protein	O
levels	O
of	O
p	O
-	O
IKKBalpha	O
/	O
beta	O
and	O
P65	O
were	O
upregulated	O
by	O
the	O
OGD	O
/	O
R	O
treatment	O
and	O
such	O
effects	O
were	O
significantly	O
inhibited	O
by	O
NSP	O
administration	O
.	O

The	O
NSP	O
-	O
induced	O
inhibition	O
could	O
be	O
significantly	O
reversed	O
by	O
administration	O
of	O
the	O
NF	O
-	O
kappaB	O
pathway	O
inhibitor	O
sc3060	O
,	O
whereas	O
,	O
expressions	O
of	O
p	O
-	O
ERK1	O
,	O
p	O
-	O
ERK2	O
,	O
and	O
p	O
-	O
AKT	O
were	O
upregulated	O
by	O
the	O
OGD	O
/	O
R	O
treatment	O
;	O
however	O
,	O
their	O
levels	O
were	O
unchanged	O
by	O
NSP	O
administration	O
.	O

Our	O
results	O
thus	O
verified	O
the	O
neuroprotective	O
effects	O
of	O
NSP	O
in	O
ischemic	B-Disease
astrocytes	O
.	O

The	O
potential	O
mechanisms	O
include	O
inhibition	O
of	O
the	O
release	O
of	O
NO	O
/	O
TNF	O
-	O
alpha	O
and	O
repression	O
of	O
the	O
NF	O
-	O
kappaB	O
signaling	O
pathways	O
.	O

Our	O
data	O
also	O
indicated	O
that	O
NSP	O
has	O
little	O
influence	O
on	O
the	O
MAPK	O
and	O
PI3K	O
/	O
Akt	O
pathways	O
.	O


Interleukin	O
6	O
(	O
IL	O
-	O
6	O
)	O
and	O
Tumor	O
Necrosis	O
Factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
Single	O
Nucleotide	O
Polymorphisms	O
(	O
SNPs	O
),	O
Inflammation	B-Disease
and	O
Metabolism	O
in	O
Gestational	B-Disease
Diabetes	I-Disease
Mellitus	I-Disease
in	O
Inner	O
Mongolia	O
.	O

BACKGROUND	O
Gestational	B-Disease
diabetes	I-Disease
mellitus	I-Disease
(	O
GDM	B-Disease
)	O
is	O
common	O
all	O
over	O
the	O
world	O
.	O

GDM	B-Disease
women	O
are	O
with	O
inflammatory	B-Disease
and	O
metabolisms	B-Disease
abnormalities	I-Disease
.	O

However	O
,	O
few	O
studies	O
have	O
focused	O
on	O
the	O
association	O
of	O
IL	O
-	O
65	O
-	O
72C	O
/	O
G	O
and	O
TNF	O
-	O
alpha	O
-	O
857C	O
/	O
T	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
),	O
inflammatory	B-Disease
biomarkers	O
,	O
and	O
metabolic	O
indexes	O
in	O
women	O
with	O
GDM	B-Disease
,	O
especially	O
in	O
the	O
Inner	O
Mongolia	O
population	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
associations	O
of	O
IL	O
-	O
65	O
-	O
72C	O
/	O
G	O
and	O
TNF	O
-	O
alpha	O
-	O
857C	O
/	O
T	O
SNPs	O
,	O
and	O
inflammation	B-Disease
and	O
metabolic	O
biomarkers	O
in	O
women	O
with	O
GDM	B-Disease
pregnancies	O
.	O

MATERIAL	O
AND	O
METHODS	O
Blood	O
samples	O
and	O
placentas	O
from	O
140	O
women	O
with	O
GDM	B-Disease
and	O
140	O
women	O
with	O
healthy	O
pregnancies	O
were	O
collected	O
.	O

Matrix	O
-	O
assisted	O
laser	O
desorption	O
ionization	O
time	O
of	O
flight	O
mass	O
spectrometry	O
(	O
MALDI	O
-	O
TOF	O
-	O
MS	O
)	O
and	O
MassARRAY	O
-	O
IPLEX	O
were	O
performed	O
to	O
analyze	O
IL	O
-	O
65	O
-	O
72C	O
/	O
G	O
and	O
TNF	O
-	O
alpha	O
-	O
857C	O
/	O
T	O
SNPs	O
.	O

Enzyme	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
was	O
performed	O
to	O
analyze	O
inflammatory	B-Disease
biomarkers	O
and	O
adipokines	O
.	O

RESULTS	O
Distribution	O
frequency	O
of	O
TNF	O
-	O
alpha	O
-	O
857CT	O
(	O
OR	O
=	O
3	O
.	O
316	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
92	O
-	O
8	O
.	O
304	O
,	O
p	O
=	O
0	O
.	O
25	O
)	O
in	O
women	O
with	O
GDM	B-Disease
pregnancies	O
were	O
obviously	O
higher	O
than	O
that	O
in	O
women	O
with	O
healthy	O
pregnancies	O
.	O

Women	O
with	O
GDM	B-Disease
were	O
of	O
older	O
maternal	O
age	O
,	O
had	O
higher	O
BMI	O
,	O
were	O
more	O
nulliparous	O
,	O
and	O
had	O
T2DM	B-Disease
and	O
GDM	B-Disease
history	O
,	O
compared	O
to	O
women	O
with	O
healthy	O
pregnancies	O
(	O
p	O
<	O
0	O
.	O
5	O
).	O

Inflammatory	B-Disease
biomarkers	O
in	O
serum	O
(	O
hs	O
-	O
CRP	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
IL	O
-	O
6	O
/	O
IL	O
-	O
10	O
ratio	O
)	O
and	O
placental	O
(	O
NF	O
-	O
kappaB	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
IL	O
-	O
6	O
/	O
IL	O
-	O
10	O
ratio	O
,	O
IL	O
-	O
1b	O
,	O
TNF	O
-	O
alpha	O
)	O
were	O
significantly	O
different	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
between	O
women	O
with	O
GDM	B-Disease
and	O
women	O
with	O
healthy	O
pregnancies	O
.	O

Differences	O
were	O
found	O
for	O
serum	O
FBG	O
,	O
FINS	O
,	O
HOMA	O
-	O
IR	O
,	O
and	O
HOMA	O
-	O
beta	O
,	O
and	O
placental	O
IRS	O
-	O
1	O
,	O
IRS	O
-	O
2	O
,	O
leptin	O
,	O
adiponectin	O
,	O
visfatin	O
,	O
RBP	O
-	O
4	O
,	O
chemerin	O
,	O
nesfatin	O
-	O
1	O
,	O
FATP	O
-	O
4	O
,	O
EL	O
,	O
LPL	O
,	O
FABP	O
-	O
1	O
,	O
FABP	O
-	O
3	O
,	O
FABP	O
-	O
4	O
,	O
and	O
FABP	O
-	O
5	O
.	O

CONCLUSIONS	O
TNF	O
-	O
alpha	O
-	O
857C	O
/	O
T	O
SNP	O
,	O
hs	O
-	O
CRP	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
and	O
IL	O
-	O
6	O
/	O
IL	O
-	O
10	O
were	O
associated	O
with	O
GDM	B-Disease
in	O
women	O
from	O
Inner	O
Mongolia	O
,	O
as	O
was	O
serious	O
inflammation	B-Disease
and	O
disordered	B-Disease
lipid	I-Disease
and	I-Disease
glucose	I-Disease
metabolisms	I-Disease
.	O


Fine	O
mapping	O
and	O
identification	O
of	O
a	O
candidate	O
gene	O
SSH1	O
in	O
disseminated	B-Disease
superficial	I-Disease
actinic	I-Disease
porokeratosis	I-Disease
.	O

Disseminated	B-Disease
superficial	I-Disease
actinic	I-Disease
porokeratosis	I-Disease
(	O
DSAP	B-Disease
)	O
is	O
an	O
uncommon	O
autosomal	O
dominant	O
chronic	O
keratinization	B-Disease
disorder	I-Disease
,	O
characterized	O
by	O
multiple	O
superficial	O
keratotic	B-Disease
lesions	I-Disease
surrounded	O
by	O
a	O
slightly	O
raised	O
keratotic	O
border	O
.	O

Thus	O
far	O
,	O
although	O
two	O
loci	O
for	O
DSAP	B-Disease
have	O
been	O
identified	O
,	O
the	O
genetic	O
basis	O
and	O
pathogenesis	O
of	O
this	O
disorder	O
have	O
not	O
been	O
elucidated	O
yet	O
.	O

In	O
this	O
study	O
,	O
we	O
performed	O
a	O
genome	O
-	O
wide	O
linkage	O
analysis	O
in	O
three	O
Chinese	O
affected	O
families	O
and	O
localized	O
the	O
gene	O
in	O
an	O
8	O
.	O
0	O
cM	O
interval	O
defined	O
by	O
D12S330	O
and	O
D12S354	O
on	O
chromosome	O
12	O
.	O

Upon	O
screening	O
30	O
candidate	O
genes	O
,	O
we	O
identified	O
a	O
missense	O
mutation	O
,	O
p	O
.	O
Ser63Asn	O
in	O
SSH1	O
in	O
one	O
family	O
,	O
a	O
frameshift	O
mutation	O
,	O
p	O
.	O
Ser19CysfsX24	O
in	O
an	O
alternative	O
variant	O
(	O
isoform	O
f	O
)	O
of	O
SSH1	O
in	O
another	O
family	O
,	O
and	O
a	O
frameshift	O
mutation	O
,	O
p	O
.	O
Pro27ProfsX54	O
in	O
the	O
same	O
alternative	O
variant	O
in	O
one	O
non	O
-	O
familial	O
case	O
with	O
DSAP	B-Disease
.	O

SSH1	O
encodes	O
a	O
phosphatase	O
that	O
plays	O
a	O
pivotal	O
role	O
in	O
actin	O
dynamics	O
.	O

Our	O
data	O
suggested	O
that	O
cytoskeleton	O
disorganization	O
in	O
epidermal	O
cells	O
is	O
likely	O
associated	O
with	O
the	O
pathogenesis	O
of	O
DSAP	B-Disease
.	O


Array	O
-	O
based	O
comparative	O
genomic	O
hybridization	O
analysis	O
reveals	O
recurrent	O
chromosomal	O
alterations	O
and	O
prognostic	O
parameters	O
in	O
primary	B-Disease
cutaneous	I-Disease
large	I-Disease
B	I-Disease
-	I-Disease
cell	I-Disease
lymphoma	I-Disease
.	O

PURPOSE	O
:	O
To	O
evaluate	O
the	O
clinical	O
relevance	O
of	O
genomic	O
aberrations	O
in	O
primary	B-Disease
cutaneous	I-Disease
large	I-Disease
B	I-Disease
-	I-Disease
cell	I-Disease
lymphoma	I-Disease
(	O
PCLBCL	B-Disease
).	O

PATIENTS	O
AND	O
METHODS	O
:	O
Skin	O
biopsy	O
samples	O
of	O
31	O
patients	O
with	O
a	O
PCLBCL	B-Disease
classified	O
as	O
either	O
primary	B-Disease
cutaneous	I-Disease
follicle	I-Disease
center	I-Disease
lymphoma	I-Disease
(	O
PCFCL	B-Disease
;	O
n	O
=	O
19	O
)	O
or	O
PCLBCL	B-Disease
,	O
leg	O
type	O
(	O
n	O
=	O
12	O
),	O
according	O
to	O
the	O
WHO	O
-	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	B-Disease
(	O
EORTC	O
)	O
classification	O
,	O
were	O
investigated	O
using	O
array	O
-	O
based	O
comparative	O
genomic	O
hybridization	O
,	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
),	O
and	O
examination	O
of	O
promoter	O
hypermethylation	O
.	O

RESULTS	O
:	O
The	O
most	O
recurrent	O
alterations	O
in	O
PCFCL	B-Disease
were	O
high	O
-	O
level	O
DNA	O
amplifications	O
at	O
2p16	O
.	O
1	O
(	O
63	O
%)	O
and	O
deletion	O
of	O
chromosome	O
14q32	O
.	O
33	O
(	O
68	O
%).	O

FISH	O
analysis	O
confirmed	O
c	O
-	O
REL	O
amplification	O
in	O
patients	O
with	O
gains	O
at	O
2p16	O
.	O
1	O
.	O

In	O
PCLBCL	B-Disease
,	O
leg	O
type	O
,	O
most	O
prominent	O
aberrations	O
were	O
a	O
high	O
-	O
level	O
DNA	O
amplification	O
of	O
18q21	O
.	O
31	O
-	O
q21	O
.	O
33	O
(	O
67	O
%),	O
including	O
the	O
BCL	O
-	O
2	O
and	O
MALT1	O
genes	O
as	O
confirmed	O
by	O
FISH	O
,	O
and	O
deletions	O
of	O
a	O
small	O
region	O
within	O
9p21	O
.	O
3	O
containing	O
the	O
CDKN2A	O
,	O
CDKN2B	O
,	O
and	O
NSG	O
-	O
x	O
genes	O
.	O

Homozygous	O
deletion	O
of	O
9p21	O
.	O
3	O
was	O
detected	O
in	O
five	O
of	O
12	O
patients	O
with	O
PCLBCL	B-Disease
,	O
leg	O
type	O
,	O
but	O
in	O
zero	O
of	O
19	O
patients	O
with	O
PCFCL	B-Disease
.	O

Complete	O
methylation	O
of	O
the	O
promoter	O
region	O
of	O
the	O
CDKN2A	O
gene	O
was	O
demonstrated	O
in	O
one	O
PCLBCL	B-Disease
,	O
leg	O
type	O
,	O
patient	O
with	O
hemizygous	O
deletion	O
,	O
in	O
one	O
patient	O
without	O
deletion	O
,	O
but	O
in	O
zero	O
of	O
19	O
patients	O
with	O
PCFCL	B-Disease
.	O

Seven	O
of	O
seven	O
PCLBCL	B-Disease
,	O
leg	O
type	O
,	O
patients	O
with	O
deletion	O
of	O
9p21	O
.	O
3	O
and	O
/	O
or	O
complete	O
methylation	O
of	O
CDKN2A	O
died	O
as	O
a	O
result	O
of	O
their	O
lymphoma	B-Disease
.	O

CONCLUSION	O
:	O
Our	O
results	O
demonstrate	O
prominent	O
differences	O
in	O
chromosomal	O
alterations	O
between	O
PCFCL	B-Disease
and	O
PCLBCL	B-Disease
,	O
leg	O
type	O
,	O
that	O
support	O
their	O
classification	O
as	O
separate	O
entities	O
within	O
the	O
WHO	O
-	O
EORTC	O
scheme	O
.	O

Inactivation	O
of	O
CDKN2A	O
by	O
either	O
deletion	O
or	O
methylation	O
of	O
its	O
promoter	O
could	O
be	O
an	O
important	O
prognostic	O
parameter	O
for	O
the	O
group	O
of	O
PCLBCL	B-Disease
,	O
leg	O
type	O
.	O


Osteogenesis	B-Disease
imperfecta	I-Disease
type	I-Disease
III	I-Disease
with	O
intracranial	B-Disease
hemorrhage	I-Disease
and	O
brachydactyly	B-Disease
associated	O
with	O
mutations	O
in	O
exon	O
49	O
of	O
COL1A2	O
.	O

Osteogenesis	B-Disease
imperfecta	I-Disease
(	O
OI	B-Disease
)	O
is	O
a	O
heritable	O
bone	B-Disease
disorder	I-Disease
characterized	O
by	O
fractures	B-Disease
with	O
minimal	O
trauma	B-Disease
.	O

Intracranial	B-Disease
hemorrhage	I-Disease
has	O
been	O
reported	O
in	O
a	O
small	O
number	O
of	O
OI	B-Disease
patients	O
.	O

Here	O
we	O
describe	O
three	O
patients	O
,	O
a	O
boy	O
(	O
aged	O
15	O
years	O
)	O
and	O
two	O
girls	O
(	O
aged	O
17	O
and	O
7	O
years	O
)	O
with	O
OI	B-Disease
type	I-Disease
III	I-Disease
who	O
suffered	O
intracranial	B-Disease
hemorrhage	I-Disease
and	O
in	O
addition	O
had	O
brachydactyly	B-Disease
and	O
nail	B-Disease
hypoplasia	I-Disease
.	O

In	O
all	O
of	O
these	O
patients	O
,	O
OI	B-Disease
was	O
caused	O
by	O
glycine	O
mutations	O
affecting	O
exon	O
49	O
of	O
the	O
COL1A2	O
gene	O
,	O
which	O
codes	O
for	O
the	O
most	O
carboxy	O
-	O
terminal	O
part	O
of	O
the	O
triple	O
-	O
helical	O
domain	O
of	O
the	O
collagen	O
type	O
I	O
alpha	O
2	O
chain	O
.	O

These	O
observations	O
suggest	O
that	O
mutations	O
in	O
this	O
region	O
of	O
the	O
collagen	O
type	O
I	O
alpha	O
2	O
chain	O
carry	O
a	O
high	O
risk	O
of	O
abnormal	B-Disease
limb	I-Disease
development	I-Disease
and	O
intracranial	B-Disease
bleeding	I-Disease
.	O


Bilateral	O
haemorrhagic	B-Disease
infarction	I-Disease
of	I-Disease
the	I-Disease
globus	I-Disease
pallidus	I-Disease
after	O
cocaine	O
and	O
alcohol	O
intoxication	O
.	O

Cocaine	O
is	O
a	O
risk	O
factor	O
for	O
both	O
ischemic	B-Disease
and	I-Disease
haemorrhagic	I-Disease
stroke	I-Disease
.	O

We	O
present	O
the	O
case	O
of	O
a	O
31	O
-	O
year	O
-	O
old	O
man	O
with	O
bilateral	O
ischemia	B-Disease
of	I-Disease
the	I-Disease
globus	I-Disease
pallidus	I-Disease
after	O
excessive	O
alcohol	O
and	O
intranasal	O
cocaine	O
use	O
.	O

Drug	O
-	O
related	O
globus	B-Disease
pallidus	I-Disease
infarctions	I-Disease
are	O
most	O
often	O
associated	O
with	O
heroin	O
.	O

Bilateral	O
basal	B-Disease
ganglia	I-Disease
infarcts	I-Disease
after	O
the	O
use	O
of	O
cocaine	O
,	O
without	O
concurrent	O
heroin	O
use	O
,	O
have	O
never	O
been	O
reported	O
.	O

In	O
our	O
patient	O
,	O
transient	O
cardiac	B-Disease
arrhythmia	I-Disease
or	O
respiratory	B-Disease
dysfunction	I-Disease
related	O
to	O
cocaine	O
and	O
/	O
or	O
ethanol	O
use	O
were	O
the	O
most	O
likely	O
causes	O
of	O
cerebral	B-Disease
hypoperfusion	I-Disease
.	O


The	O
fibrinogen	O
gamma	O
10034C	O
>	O
T	O
polymorphism	O
is	O
not	O
associated	O
with	O
Peripheral	B-Disease
Arterial	I-Disease
Disease	I-Disease
.	O

Conversion	O
of	O
fibrinogen	O
to	O
fibrin	O
plays	O
an	O
essential	O
role	O
in	O
hemostasis	O
and	O
results	O
in	O
stabilization	O
of	O
the	O
fibrin	O
clot	O
.	O

Fibrinogen	O
consists	O
of	O
three	O
pairs	O
of	O
non	O
-	O
identical	O
polypeptide	O
chains	O
,	O
encoded	O
by	O
different	O
genes	O
(	O
fibrinogen	O
alpha	O
[	O
FGA	O
],	O
fibrinogen	O
beta	O
[	O
FGB	O
]	O
and	O
fibrinogen	O
gamma	O
[	O
FGG	O
]).	O

A	O
functional	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
the	O
FGG	O
gene	O
(	O
FGG	O
10034C	O
>	O
T	O
,	O
rs2066865	O
)	O
has	O
been	O
associated	O
with	O
deep	B-Disease
venous	I-Disease
thrombosis	I-Disease
and	O
myocardial	B-Disease
infarction	I-Disease
.	O

Aim	O
of	O
the	O
present	O
study	O
was	O
to	O
analyze	O
the	O
role	O
of	O
this	O
polymorphism	O
in	O
peripheral	B-Disease
arterial	I-Disease
disease	I-Disease
(	O
PAD	B-Disease
).	O

The	O
study	O
was	O
designed	O
as	O
case	O
-	O
control	O
study	O
including	O
891	O
patients	O
with	O
documented	O
PAD	B-Disease
and	O
777	O
control	O
subjects	O
.	O

FGG	O
genotypes	O
were	O
determined	O
by	O
exonuclease	O
(	O
TaqMan	O
)	O
assays	O
.	O

FGG	O
genotype	O
frequencies	O
were	O
not	O
significantly	O
different	O
between	O
PAD	B-Disease
patients	O
(	O
CC	O
:	O
57	O
.	O
3	O
%,	O
CT	O
:	O
36	O
.	O
7	O
%,	O
TT	O
:	O
5	O
.	O
8	O
%)	O
and	O
control	O
subjects	O
(	O
CC	O
:	O
60	O
.	O
9	O
%,	O
CT	O
:	O
33	O
.	O
5	O
%,	O
TT	O
5	O
.	O
6	O
%;	O
p	O
=	O
0	O
.	O
35	O
).	O

In	O
a	O
multivariate	O
logistic	O
regression	O
analysis	O
including	O
age	O
,	O
sex	O
,	O
smoking	O
,	O
diabetes	B-Disease
,	O
arterial	O
hypertension	B-Disease
and	O
hypercholesterolemia	B-Disease
,	O
the	O
FGG	O
10034	O
T	O
variant	O
was	O
not	O
significantly	O
associated	O
with	O
the	O
presence	O
of	O
PAD	B-Disease
(	O
Odds	O
ratio	O
1	O
.	O
7	O
,	O
95	O
%	O
confidence	O
interval	O
0	O
.	O
84	O
-	O
1	O
.	O
37	O
;	O
p	O
=	O
0	O
.	O
60	O
).	O

The	O
FGG	O
10034C	O
>	O
T	O
polymorphism	O
was	O
furthermore	O
not	O
associated	O
with	O
age	O
at	O
onset	O
of	O
PAD	B-Disease
.	O

We	O
conclude	O
that	O
the	O
thrombophilic	O
FGG	O
10034	O
T	O
gene	O
variant	O
does	O
not	O
contribute	O
to	O
the	O
genetic	O
susceptibility	O
to	O
PAD	B-Disease
.	O


Genotype	O
rs8099917	O
near	O
the	O
IL28B	O
gene	O
and	O
amino	O
acid	O
substitution	O
at	O
position	O
70	O
in	O
the	O
core	O
region	O
of	O
the	O
hepatitis	O
C	O
virus	O
are	O
determinants	O
of	O
serum	O
apolipoprotein	O
B	O
-	O
100	O
concentration	O
in	O
chronic	B-Disease
hepatitis	I-Disease
C	I-Disease
.	O

The	O
life	O
cycle	O
of	O
the	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
is	O
closely	O
related	O
to	O
host	O
lipoprotein	O
metabolism	O
.	O

Serum	O
levels	O
of	O
lipid	O
are	O
associated	O
with	O
the	O
response	O
to	O
pegylated	O
interferon	O
plus	O
ribavirin	O
(	O
PEG	O
-	O
IFN	O
/	O
RBV	O
)	O
therapy	O
,	O
while	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
around	O
the	O
human	O
interleukin	O
28B	O
(	O
IL28B	O
)	O
gene	O
locus	O
and	O
amino	O
acid	O
substitutions	O
in	O
the	O
core	O
region	O
of	O
the	O
HCV	O
have	O
been	O
reported	O
to	O
affect	O
the	O
efficacy	O
of	O
PEG	O
-	O
IFN	O
/	O
RBV	O
therapy	O
in	O
chronic	B-Disease
hepatitis	I-Disease
with	O
HCV	B-Disease
genotype	I-Disease
1b	I-Disease
infection	I-Disease
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
elucidate	O
the	O
relationship	O
between	O
serum	O
lipid	O
and	O
factors	O
that	O
are	O
able	O
to	O
predict	O
the	O
efficacy	O
of	O
PEG	O
-	O
IFN	O
/	O
RB	O
therapy	O
,	O
with	O
specific	O
focus	O
on	O
apolipoprotein	O
B	O
-	O
100	O
(	O
apoB	O
-	O
100	O
)	O
in	O
148	O
subjects	O
with	O
chronic	O
HCV	B-Disease
G1b	I-Disease
infection	I-Disease
.	O

Our	O
results	O
demonstrated	O
that	O
both	O
the	O
aa	O
70	O
substitution	O
in	O
the	O
core	O
region	O
of	O
the	O
HCV	O
and	O
the	O
rs8099917	O
SNP	O
located	O
proximal	O
to	O
the	O
IL28B	O
were	O
independent	O
factors	O
in	O
determining	O
serum	O
apoB	O
-	O
100	O
and	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
cholesterol	O
levels	O
.	O

A	O
significant	O
association	O
was	O
noted	O
between	O
higher	O
levels	O
of	O
apoB	O
-	O
100	O
(	O
P	O
=	O
1	O
.	O
1	O
10	O
(-	O
3	O
))	O
and	O
LDL	O
cholesterol	O
(	O
P	O
=	O
0	O
.	O
2	O
)	O
and	O
the	O
subjects	O
having	O
Arg70	O
.	O

A	O
significant	O
association	O
was	O
also	O
observed	O
between	O
subjects	O
carrying	O
the	O
rs8099917	O
TT	O
responder	O
genotype	O
and	O
higher	O
levels	O
of	O
apoB	O
-	O
100	O
(	O
P	O
=	O
6	O
.	O
4	O
10	O
(-	O
3	O
))	O
and	O
LDL	O
cholesterol	O
(	O
P	O
=	O
4	O
.	O
2	O
10	O
(-	O
3	O
)).	O

Our	O
results	O
suggest	O
that	O
apoB	O
-	O
100	O
and	O
LDL	O
cholesterol	O
are	O
markers	O
of	O
impaired	O
cellular	O
lipoprotein	O
pathways	O
and	O
/	O
or	O
host	O
endogenous	O
interferon	O
response	O
to	O
HCV	O
in	O
chronic	O
HCV	B-Disease
infection	I-Disease
.	O

In	O
particular	O
,	O
serum	O
apoB	O
-	O
100	O
concentration	O
might	O
be	O
an	O
informative	O
marker	O
for	O
judging	O
changes	O
in	O
HCV	O
-	O
associated	O
intracellular	O
lipoprotein	O
metabolism	O
in	O
patients	O
carrying	O
the	O
rs8099917	O
responder	O
genotype	O
.	O


Phosphatidylinositol	O
4	O
-	O
kinase	O
IIb	O
negatively	O
regulates	O
invadopodia	O
formation	O
and	O
suppresses	O
an	O
invasive	O
cellular	O
phenotype	O
.	O

The	O
type	O
II	O
phosphatidylinositol	O
4	O
-	O
kinase	O
(	O
PI4KII	O
)	O
enzymes	O
synthesize	O
the	O
lipid	O
phosphatidylinositol	O
4	O
-	O
phosphate	O
(	O
PI	O
(	O
4	O
)	O
P	O
),	O
which	O
has	O
been	O
detected	O
at	O
the	O
Golgi	O
complex	O
and	O
endosomal	O
compartments	O
and	O
recruits	O
clathrin	O
adaptors	O
.	O

Despite	O
common	O
mechanistic	O
similarities	O
between	O
the	O
isoforms	O
,	O
the	O
extent	O
of	O
their	O
redundancy	O
is	O
unclear	O
.	O

We	O
found	O
that	O
depletion	O
of	O
PI4KIIa	O
and	O
PI4KIIb	O
using	O
small	O
interfering	O
RNA	O
led	O
to	O
actin	O
remodeling	O
.	O

Depletion	O
of	O
PI4KIIb	O
also	O
induced	O
the	O
formation	O
of	O
invadopodia	O
containing	O
membrane	O
type	O
I	O
matrix	O
metalloproteinase	O
(	O
MT1	O
-	O
MMP	O
).	O

Depletion	O
of	O
PI4KII	O
isoforms	O
also	O
differentially	O
affected	O
trans	O
-	O
Golgi	O
network	O
(	O
TGN	O
)	O
pools	O
of	O
PI	O
(	O
4	O
)	O
P	O
and	O
post	O
-	O
TGN	O
traffic	O
.	O

PI4KIIb	O
depletion	O
caused	O
increased	O
MT1	O
-	O
MMP	O
trafficking	O
to	O
invasive	O
structures	O
at	O
the	O
plasma	O
membrane	O
and	O
was	O
accompanied	O
by	O
reduced	O
colocalization	O
of	O
MT1	O
-	O
MMP	O
with	O
membranes	O
containing	O
the	O
endosomal	O
markers	O
Rab5	O
and	O
Rab7	O
but	O
increased	O
localization	O
with	O
the	O
exocytic	O
Rab8	O
.	O

Depletion	O
of	O
PI4KIIb	O
was	O
sufficient	O
to	O
confer	O
an	O
aggressive	O
invasive	O
phenotype	O
on	O
minimally	O
invasive	O
HeLa	O
and	O
MCF	O
-	O
7	O
cell	O
lines	O
.	O

Mining	O
oncogenomic	O
databases	O
revealed	O
that	O
loss	O
of	O
the	O
PI4K2B	O
allele	O
and	O
underexpression	O
of	O
PI4KIIb	O
mRNA	O
are	O
associated	O
with	O
human	O
cancers	B-Disease
.	O

This	O
finding	O
supports	O
the	O
cell	O
data	O
and	O
suggests	O
that	O
PI4KIIb	O
may	O
be	O
a	O
clinically	O
significant	O
suppressor	O
of	O
invasion	O
.	O

We	O
propose	O
that	O
PI4KIIb	O
synthesizes	O
a	O
pool	O
of	O
PI	O
(	O
4	O
)	O
P	O
that	O
maintains	O
MT1	O
-	O
MMP	O
traffic	O
in	O
the	O
degradative	O
pathway	O
and	O
suppresses	O
the	O
formation	O
of	O
invadopodia	O
.	O


CenpH	O
regulates	O
meiotic	O
G2	O
/	O
M	O
transition	O
by	O
modulating	O
the	O
APC	O
/	O
CCdh1	O
-	O
cyclin	O
B1	O
pathway	O
in	O
oocytes	O
.	O

Meiotic	O
resumption	O
(	O
G2	O
/	O
M	O
transition	O
)	O
and	O
progression	O
through	O
meiosis	O
I	O
(	O
MI	O
)	O
are	O
two	O
key	O
stages	O
for	O
producing	O
fertilization	O
-	O
competent	O
eggs	O
.	O

Here	O
,	O
we	O
report	O
that	O
CenpH	O
,	O
a	O
component	O
of	O
the	O
kinetochore	O
inner	O
plate	O
,	O
is	O
responsible	O
for	O
G2	O
/	O
M	O
transition	O
in	O
meiotic	O
mouse	O
oocytes	O
.	O

Depletion	O
of	O
CenpH	O
by	O
morpholino	O
injection	O
decreased	O
cyclin	O
B1	O
levels	O
,	O
resulting	O
in	O
attenuation	O
of	O
maturation	O
-	O
promoting	O
factor	O
(	O
MPF	O
)	O
activation	O
,	O
and	O
severely	O
compromised	O
meiotic	O
resumption	O
.	O

CenpH	O
protects	O
cyclin	O
B1	O
from	O
destruction	O
by	O
competing	O
with	O
the	O
action	O
of	O
APC	O
/	O
C	O
(	O
Cdh1	O
)	O
Impaired	O
G2	O
/	O
M	O
transition	O
after	O
CenpH	O
depletion	O
could	O
be	O
rescued	O
by	O
expression	O
of	O
exogenous	O
cyclin	O
B1	O
.	O

Unexpectedly	O
,	O
blocking	O
CenpH	O
did	O
not	O
affect	O
spindle	O
organization	O
and	O
meiotic	O
cell	O
cycle	O
progression	O
after	O
germinal	O
vesicle	O
breakdown	O
.	O

Our	O
findings	O
reveal	O
a	O
novel	O
role	O
of	O
CenpH	O
in	O
regulating	O
meiotic	O
G2	O
/	O
M	O
transition	O
by	O
acting	O
via	O
the	O
APC	O
/	O
C	O
(	O
Cdh1	O
)-	O
cyclin	O
B1	O
pathway	O
.	O


CRYBA3	O
/	O
A1	O
gene	O
mutation	O
associated	O
with	O
suture	O
-	O
sparing	O
autosomal	B-Disease
dominant	I-Disease
congenital	I-Disease
nuclear	I-Disease
cataract	I-Disease
:	O
a	O
novel	O
phenotype	O
.	O

PURPOSE	O
:	O
To	O
identify	O
the	O
genetic	B-Disease
defect	I-Disease
leading	O
to	O
the	O
congenital	B-Disease
nuclear	I-Disease
cataract	I-Disease
affecting	O
a	O
large	O
five	O
-	O
generation	O
Swiss	O
family	O
.	O

METHODS	O
:	O
Family	O
history	O
and	O
clinical	O
data	O
were	O
recorded	O
.	O

The	O
phenotype	O
was	O
documented	O
by	O
both	O
slit	O
lamp	O
and	O
Scheimpflug	O
photography	O
.	O

One	O
cortical	O
lens	O
was	O
evaluated	O
by	O
electron	O
microscopy	O
after	O
cataract	B-Disease
extraction	O
.	O

Lenticular	O
phenotyping	O
and	O
genotyping	O
were	O
performed	O
independently	O
with	O
short	O
tandem	O
repeat	O
polymorphism	O
.	O

Linkage	O
analysis	O
was	O
performed	O
,	O
and	O
candidate	O
genes	O
were	O
PCR	O
amplified	O
and	O
screened	O
for	O
mutations	O
on	O
both	O
strands	O
using	O
direct	O
sequencing	O
.	O

RESULTS	O
:	O
Affected	O
individuals	O
had	O
a	O
congenital	B-Disease
nuclear	I-Disease
lactescent	I-Disease
cataract	I-Disease
in	O
both	O
eyes	O
.	O

Linkage	O
was	O
observed	O
on	O
chromosome	O
17	O
for	O
DNA	O
marker	O
D17S1857	O
(	O
lod	O
score	O
:	O
3	O
.	O
44	O
at	O
theta	O
=	O
0	O
).	O

Direct	O
sequencing	O
of	O
CRYBA3	O
/	O
A1	O
,	O
which	O
maps	O
to	O
the	O
vicinity	O
,	O
revealed	O
an	O
in	O
-	O
frame	O
3	O
-	O
bp	O
deletion	O
in	O
exon	O
4	O
(	O
279delGAG	O
).	O

This	O
mutation	O
involved	O
a	O
deletion	O
of	O
glycine	O
-	O
91	O
,	O
cosegregated	O
in	O
all	O
affected	O
individuals	O
,	O
and	O
was	O
not	O
observed	O
in	O
unaffected	O
individuals	O
or	O
in	O
250	O
normal	O
control	O
subjects	O
from	O
the	O
same	O
ethnic	O
background	O
.	O

Electron	O
microscopy	O
showed	O
that	O
cortical	O
lens	O
fiber	O
morphology	O
was	O
normal	O
.	O

CONCLUSIONS	O
:	O
The	O
DeltaG91	O
mutation	O
in	O
CRYBA3	O
/	O
A1	O
is	O
associated	O
with	O
an	O
autosomal	B-Disease
dominant	I-Disease
congenital	I-Disease
nuclear	I-Disease
lactescent	I-Disease
cataract	I-Disease
.	O

A	O
splice	O
mutation	O
(	O
IVS3	O
+	O
1G	O
/	O
A	O
)	O
in	O
this	O
gene	O
has	O
been	O
reported	O
in	O
a	O
zonular	B-Disease
cataract	I-Disease
with	O
sutural	O
opacities	O
.	O

These	O
results	O
indicate	O
phenotypic	O
heterogeneity	O
related	O
to	O
mutations	O
in	O
this	O
gene	O
.	O


Vitamin	O
D	O
-	O
binding	O
protein	O
gene	O
polymorphism	O
association	O
with	O
IA	O
-	O
2	O
autoantibodies	O
in	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
.	O

BACKGROUND	O
:	O
Vitamin	O
D	O
-	O
binding	O
protein	O
(	O
DBP	O
)	O
is	O
the	O
main	O
systemic	O
transporter	O
of	O
1	O
.	O
25	O
(	O
OH	O
)	O
2D3	O
and	O
is	O
essential	O
for	O
its	O
cellular	O
endocytosis	O
.	O

There	O
are	O
two	O
known	O
polymorphisms	O
in	O
exon	O
11	O
of	O
the	O
DBP	O
gene	O
resulting	O
in	O
amino	O
acid	O
variants	O
:	O
GAT	O
-->	O
GAG	O
substitution	O
replaces	O
aspartic	O
acid	O
by	O
glutamic	O
acid	O
in	O
codon	O
416	O
;	O
and	O
ACG	O
-->	O
AAG	O
substitution	O
in	O
codon	O
420	O
leads	O
to	O
an	O
exchange	O
of	O
threonine	O
for	O
lysine	O
.	O

These	O
DBP	O
variants	O
lead	O
to	O
differences	O
in	O
the	O
affinity	O
for	O
1	O
.	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

Correlations	O
between	O
DBP	O
alleles	O
and	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
have	O
been	O
described	O
in	O
different	O
populations	O
.	O

Therefore	O
,	O
we	O
investigated	O
the	O
polymorphism	O
in	O
codon	O
416	O
of	O
the	O
DBP	O
gene	O
for	O
an	O
association	O
with	O
autoimmune	O
markers	O
of	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
.	O

DESIGN	O
AND	O
METHODS	O
:	O
The	O
present	O
analysis	O
was	O
a	O
case	O
control	O
study	O
.	O

110	O
patients	O
,	O
68	O
controls	O
,	O
and	O
115	O
first	O
-	O
degree	O
relatives	O
were	O
genotyped	O
for	O
the	O
DBP	O
polymorphism	O
in	O
codon	O
416	O
.	O

DNA	O
typing	O
of	O
DBP	O
locus	O
was	O
performed	O
by	O
the	O
PCR	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
method	O
(	O
RFLP	O
).	O

RESULTS	O
:	O
The	O
frequencies	O
of	O
the	O
Asp	O
/	O
Glu	O
and	O
Glu	O
/	O
Glu	O
were	O
significantly	O
increased	O
in	O
diabetic	B-Disease
subjects	O
with	O
detectable	O
IA	O
-	O
2	O
antibodies	O
(	O
P	O
<	O
0	O
.	O
1	O
).	O

On	O
the	O
contrary	O
,	O
the	O
DBP	O
Glu	O
-	O
containing	O
genotype	O
was	O
not	O
accompanied	O
by	O
differences	O
in	O
the	O
prevalence	O
of	O
GAD65	O
antibodies	O
.	O

These	O
finding	O
supports	O
a	O
role	O
of	O
the	O
vitamin	O
D	O
endocrine	O
system	O
in	O
the	O
autoimmune	O
process	O
of	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
.	O


Characterization	O
of	O
Bietti	B-Disease
crystalline	I-Disease
dystrophy	I-Disease
patients	O
with	O
CYP4V2	O
mutations	O
.	O

PURPOSE	O
:	O
Mutations	O
of	O
the	O
CYP4V2	O
gene	O
,	O
a	O
novel	O
family	O
member	O
of	O
the	O
cytochrome	O
P450	O
genes	O
on	O
chromosome	O
4q35	O
,	O
have	O
recently	O
been	O
identified	O
in	O
patients	O
with	O
Bietti	B-Disease
crystalline	I-Disease
dystrophy	I-Disease
(	O
BCD	B-Disease
).	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
spectrum	O
of	O
mutations	O
in	O
this	O
gene	O
in	O
BCD	B-Disease
patients	O
from	O
Singapore	O
,	O
and	O
to	O
characterize	O
their	O
phenotype	O
.	O

METHODS	O
:	O
Nine	O
patients	O
with	O
BCD	B-Disease
from	O
six	O
families	O
were	O
recruited	O
into	O
the	O
study	O
.	O

The	O
11	O
exons	O
of	O
the	O
CYP4V2	O
gene	O
were	O
amplified	O
from	O
genomic	O
DNA	O
of	O
patients	O
by	O
polymerase	O
chain	O
reaction	O
and	O
then	O
sequenced	O
.	O

Detailed	O
characterization	O
of	O
the	O
patients	O
'	O
phenotype	O
was	O
performed	O
with	O
fundal	O
photography	O
,	O
visual	O
field	O
testing	O
,	O
fundal	O
fluorescein	O
angiography	O
,	O
and	O
electroretinography	O
(	O
ERG	O
).	O

RESULTS	O
:	O
Three	O
pathogenic	O
mutations	O
were	O
identified	O
;	O
two	O
mutations	O
,	O
S482X	O
and	O
K386T	O
,	O
were	O
novel	O
and	O
found	O
in	O
three	O
patients	O
.	O

The	O
third	O
mutation	O
,	O
a	O
previously	O
identified	O
15	O
-	O
bp	O
deletion	O
that	O
included	O
the	O
3	O
'	O
splice	O
site	O
for	O
exon	O
7	O
,	O
was	O
found	O
in	O
all	O
nine	O
patients	O
,	O
with	O
six	O
patients	O
carrying	O
the	O
deletion	O
in	O
the	O
homozygous	O
state	O
.	O

Haplotype	O
analysis	O
in	O
patients	O
and	O
controls	O
indicated	O
a	O
founder	O
effect	O
for	O
this	O
deletion	O
mutation	O
in	O
exon	O
7	O
.	O

Clinical	O
heterogeneity	O
was	O
present	O
in	O
the	O
patients	O
.	O

Compound	O
heterozygotes	O
for	O
the	O
deletion	O
in	O
exon	O
7	O
seemed	O
to	O
have	O
more	O
severe	O
disease	O
compared	O
to	O
patients	O
homozygous	O
for	O
the	O
deletion	O
.	O

There	O
was	O
good	O
correlation	O
between	O
clinical	O
stage	O
of	O
disease	O
and	O
ERG	O
changes	O
,	O
but	O
age	O
did	O
not	O
correlate	O
with	O
disease	O
severity	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
identified	O
novel	O
mutations	O
in	O
the	O
CYP4V2	O
gene	O
as	O
a	O
cause	O
of	O
BCD	B-Disease
.	O

A	O
high	O
carrier	O
frequency	O
for	O
the	O
15	O
-	O
bp	O
deletion	O
in	O
exon	O
7	O
may	O
exist	O
in	O
the	O
Singapore	O
population	O
.	O

Phenotype	O
characterization	O
showed	O
clinical	O
heterogeneity	O
,	O
and	O
age	O
did	O
not	O
correlate	O
with	O
disease	O
severity	O
.	O


An	O
extremely	O
rare	O
case	O
of	O
delusional	B-Disease
parasitosis	I-Disease
in	O
a	O
chronic	B-Disease
hepatitis	I-Disease
C	I-Disease
patient	O
during	O
pegylated	O
interferon	O
alpha	O
-	O
2b	O
and	O
ribavirin	O
treatment	O
.	O

During	O
treatment	O
of	O
chronic	B-Disease
hepatitis	I-Disease
C	I-Disease
patients	O
with	O
interferon	O
and	O
ribavirin	O
,	O
a	O
lot	O
of	O
side	O
effects	O
are	O
described	O
.	O

Twenty	O
-	O
three	O
percent	O
to	O
44	O
%	O
of	O
patients	O
develop	O
depression	B-Disease
.	O

A	O
minority	O
of	O
patients	O
evolve	O
to	O
psychosis	B-Disease
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
no	O
cases	O
of	O
psychogenic	B-Disease
parasitosis	I-Disease
occurring	O
during	O
interferon	O
therapy	O
have	O
been	O
described	O
in	O
the	O
literature	O
.	O

We	O
present	O
a	O
49	O
-	O
year	O
-	O
old	O
woman	O
who	O
developed	O
a	O
delusional	B-Disease
parasitosis	I-Disease
during	O
treatment	O
with	O
pegylated	O
interferon	O
alpha	O
-	O
2b	O
weekly	O
and	O
ribavirin	O
.	O

She	O
complained	O
of	O
seeing	O
parasites	O
and	O
the	O
larvae	O
of	O
fleas	O
in	O
her	O
stools	O
.	O

This	O
could	O
not	O
be	O
confirmed	O
by	O
any	O
technical	O
examination	O
.	O

All	O
the	O
complaints	O
disappeared	O
after	O
stopping	O
pegylated	O
interferon	O
alpha	O
-	O
2b	O
and	O
reappeared	O
after	O
restarting	O
it	O
.	O

She	O
had	O
a	O
complete	O
sustained	O
viral	O
response	O
.	O


Protein	O
-	O
Trap	O
Insertional	O
Mutagenesis	O
Uncovers	O
New	O
Genes	O
Involved	O
in	O
Zebrafish	O
Skin	O
Development	O
,	O
Including	O
a	O
Neuregulin	O
2a	O
-	O
Based	O
ErbB	O
Signaling	O
Pathway	O
Required	O
during	O
Median	O
Fin	O
Fold	O
Morphogenesis	O
.	O

Skin	B-Disease
disorders	I-Disease
are	O
widespread	O
,	O
but	O
available	O
treatments	O
are	O
limited	O
.	O

A	O
more	O
comprehensive	O
understanding	O
of	O
skin	O
development	O
mechanisms	O
will	O
drive	O
identification	O
of	O
new	O
treatment	O
targets	O
and	O
modalities	O
.	O

Here	O
we	O
report	O
the	O
Zebrafish	O
Integument	O
Project	O
(	O
ZIP	O
),	O
an	O
expression	O
-	O
driven	O
platform	O
for	O
identifying	O
new	O
skin	O
genes	O
and	O
phenotypes	O
in	O
the	O
vertebrate	O
model	O
Danio	O
rerio	O
(	O
zebrafish	O
).	O

In	O
vivo	O
selection	O
for	O
skin	O
-	O
specific	O
expression	O
of	O
gene	O
-	O
break	O
transposon	O
(	O
GBT	O
)	O
mutant	O
lines	O
identified	O
eleven	O
new	O
,	O
revertible	O
GBT	O
alleles	O
of	O
genes	O
involved	O
in	O
skin	O
development	O
.	O

Eight	O
genes	O
--	O
fras1	O
,	O
grip1	O
,	O
hmcn1	O
,	O
msxc	O
,	O
col4a4	O
,	O
ahnak	O
,	O
capn12	O
,	O
and	O
nrg2a	O
--	O
had	O
been	O
described	O
in	O
an	O
integumentary	O
context	O
to	O
varying	O
degrees	O
,	O
while	O
arhgef25b	O
,	O
fkbp10b	O
,	O
and	O
megf6a	O
emerged	O
as	O
novel	O
skin	O
genes	O
.	O

Embryos	O
homozygous	O
for	O
a	O
GBT	O
insertion	O
within	O
neuregulin	O
2a	O
(	O
nrg2a	O
)	O
revealed	O
a	O
novel	O
requirement	O
for	O
a	O
Neuregulin	O
2a	O
(	O
Nrg2a	O
)-	O
ErbB2	O
/	O
3	O
-	O
AKT	O
signaling	O
pathway	O
governing	O
the	O
apicobasal	O
organization	O
of	O
a	O
subset	O
of	O
epidermal	O
cells	O
during	O
median	O
fin	O
fold	O
(	O
MFF	O
)	O
morphogenesis	O
.	O

In	O
nrg2a	O
mutant	O
larvae	O
,	O
the	O
basal	O
keratinocytes	O
within	O
the	O
apical	O
MFF	O
,	O
known	O
as	O
ridge	O
cells	O
,	O
displayed	O
reduced	O
pAKT	O
levels	O
as	O
well	O
as	O
reduced	O
apical	O
domains	O
and	O
exaggerated	O
basolateral	O
domains	O
.	O

Those	O
defects	O
compromised	O
proper	O
ridge	O
cell	O
elongation	O
into	O
a	O
flattened	O
epithelial	O
morphology	O
,	O
resulting	O
in	O
thickened	O
MFF	O
edges	O
.	O

Pharmacological	O
inhibition	O
verified	O
that	O
Nrg2a	O
signals	O
through	O
the	O
ErbB	O
receptor	O
tyrosine	O
kinase	O
network	O
.	O

Moreover	O
,	O
knockdown	O
of	O
the	O
epithelial	O
polarity	O
regulator	O
and	O
tumor	B-Disease
suppressor	O
lgl2	O
ameliorated	O
the	O
nrg2a	O
mutant	O
phenotype	O
.	O

Identifying	O
Lgl2	O
as	O
an	O
antagonist	O
of	O
Nrg2a	O
-	O
ErbB	O
signaling	O
revealed	O
a	O
significantly	O
earlier	O
role	O
for	O
Lgl2	O
during	O
epidermal	O
morphogenesis	O
than	O
has	O
been	O
described	O
to	O
date	O
.	O

Furthermore	O
,	O
our	O
findings	O
demonstrated	O
that	O
successive	O
,	O
coordinated	O
ridge	O
cell	O
shape	O
changes	O
drive	O
apical	O
MFF	O
development	O
,	O
making	O
MFF	O
ridge	O
cells	O
a	O
valuable	O
model	O
for	O
investigating	O
how	O
the	O
coordinated	O
regulation	O
of	O
cell	O
polarity	O
and	O
cell	O
shape	O
changes	O
serves	O
as	O
a	O
crucial	O
mechanism	O
of	O
epithelial	O
morphogenesis	O
.	O


Mutation	O
analysis	O
of	O
CHRNA1	O
,	O
CHRNB1	O
,	O
CHRND	O
,	O
and	O
RAPSN	O
genes	O
in	O
multiple	B-Disease
pterygium	I-Disease
syndrome	I-Disease
/	O
fetal	B-Disease
akinesia	I-Disease
patients	O
.	O

Multiple	B-Disease
pterygium	I-Disease
syndromes	I-Disease
(	O
MPS	B-Disease
)	O
comprise	O
a	O
group	O
of	O
multiple	O
congenital	B-Disease
anomaly	I-Disease
disorders	I-Disease
characterized	O
by	O
webbing	O
(	O
pterygia	O
)	O
of	O
the	O
neck	O
,	O
elbows	O
,	O
and	O
/	O
or	O
knees	O
and	O
joint	B-Disease
contractures	I-Disease
(	O
arthrogryposis	B-Disease
).	O

MPS	B-Disease
are	O
phenotypically	O
and	O
genetically	O
heterogeneous	O
but	O
are	O
traditionally	O
divided	O
into	O
prenatally	O
lethal	O
and	O
nonlethal	O
(	O
Escobar	O
)	O
types	O
.	O

Previously	O
,	O
we	O
and	O
others	O
reported	O
that	O
recessive	O
mutations	O
in	O
the	O
embryonal	O
acetylcholine	O
receptor	O
g	O
subunit	O
(	O
CHRNG	O
)	O
can	O
cause	O
both	O
lethal	O
and	O
nonlethal	O
MPS	B-Disease
,	O
thus	O
demonstrating	O
that	O
pterygia	O
resulted	O
from	O
fetal	B-Disease
akinesia	I-Disease
.	O

We	O
hypothesized	O
that	O
mutations	O
in	O
acetylcholine	O
receptor	O
-	O
related	O
genes	O
might	O
also	O
result	O
in	O
a	O
MPS	B-Disease
/	O
fetal	B-Disease
akinesia	I-Disease
phenotype	O
and	O
so	O
we	O
analyzed	O
15	O
cases	O
of	O
lethal	O
MPS	B-Disease
/	O
fetal	B-Disease
akinesia	I-Disease
without	O
CHRNG	O
mutations	O
for	O
mutations	O
in	O
the	O
CHRNA1	O
,	O
CHRNB1	O
,	O
CHRND	O
,	O
and	O
rapsyn	O
(	O
RAPSN	O
)	O
genes	O
.	O

No	O
CHRNA1	O
,	O
CHRNB1	O
,	O
or	O
CHRND	O
mutations	O
were	O
detected	O
,	O
but	O
a	O
homozygous	O
RAPSN	O
frameshift	O
mutation	O
,	O
c	O
.	O
1177	O
-	O
1178delAA	O
,	O
was	O
identified	O
in	O
a	O
family	O
with	O
three	O
children	O
affected	O
with	O
lethal	O
fetal	B-Disease
akinesia	I-Disease
sequence	I-Disease
.	O

Previously	O
,	O
RAPSN	O
mutations	O
have	O
been	O
reported	O
in	O
congenital	B-Disease
myasthenia	I-Disease
.	O

Functional	O
studies	O
were	O
consistent	O
with	O
the	O
hypothesis	O
that	O
whereas	O
incomplete	O
loss	O
of	O
rapsyn	O
function	O
may	O
cause	O
congenital	B-Disease
myasthenia	I-Disease
,	O
more	O
severe	O
loss	O
of	O
function	O
can	O
result	O
in	O
a	O
lethal	O
fetal	B-Disease
akinesia	I-Disease
phenotype	O
.	O


Pure	O
monosomy	O
and	O
pure	O
trisomy	O
of	O
13q21	O
.	O
2	O
-	O
31	O
.	O
1	O
consequent	O
to	O
a	O
familial	O
insertional	O
translocation	O
:	O
exclusion	O
of	O
PCDH9	O
as	O
the	O
responsible	O
gene	O
for	O
autosomal	B-Disease
dominant	I-Disease
auditory	I-Disease
neuropathy	I-Disease
(	O
AUNA1	B-Disease
).	O

Insertional	O
translocations	O
(	O
IT	O
)	O
are	O
rare	O
structural	O
rearrangements	O
.	O

Offspring	O
of	O
IT	O
balanced	O
carriers	O
are	O
at	O
high	O
risk	O
to	O
have	O
either	O
pure	O
partial	O
trisomy	O
or	O
monosomy	O
for	O
the	O
inserted	O
segment	O
as	O
manifested	O
by	O
pure	O
phenotypes	O
.	O

We	O
describe	O
an	O
IT	O
between	O
chromosomes	O
3	O
and	O
13	O
segregating	O
in	O
a	O
three	O
-	O
generation	O
pedigree	O
.	O

Short	O
tandem	O
repeat	O
(	O
STR	O
)	O
segregation	O
analysis	O
and	O
array	O
-	O
comparative	O
genomic	O
hybridization	O
were	O
used	O
to	O
define	O
the	O
IT	O
as	O
a	O
25	O
.	O
1	O
Mb	O
segment	O
spanning	O
13q21	O
.	O
2	O
-	O
q31	O
.	O
1	O
.	O

The	O
phenotype	O
of	O
pure	O
monosomy	O
included	O
deafness	B-Disease
,	O
duodenal	B-Disease
stenosis	I-Disease
,	O
developmental	B-Disease
and	I-Disease
growth	I-Disease
delay	I-Disease
,	O
vertebral	B-Disease
anomalies	I-Disease
,	O
and	O
facial	B-Disease
dysmorphisms	I-Disease
;	O
the	O
trisomy	O
was	O
manifested	O
by	O
only	O
minor	O
dysmorphisms	B-Disease
.	O

As	O
the	O
AUNA1	B-Disease
deafness	I-Disease
locus	O
on	O
13q14	O
-	O
21	O
overlaps	O
the	O
IT	O
in	O
the	O
PCDH9	O
(	O
protocadherin	O
-	O
9	O
)	O
gene	O
region	O
,	O
PCDH9	O
was	O
investigated	O
as	O
a	O
candidate	O
gene	O
for	O
deafness	B-Disease
in	O
both	O
families	O
.	O

Genotyping	O
of	O
STRs	O
and	O
single	O
nucleotide	O
polymorphisms	O
defined	O
the	O
AUNA1	B-Disease
breakpoint	O
as	O
35	O
kb	O
5	O
'	O
to	O
PCDH9	O
,	O
with	O
a	O
2	O
.	O
4	O
Mb	O
area	O
of	O
overlap	O
with	O
the	O
IT	O
.	O

DNA	O
sequencing	O
of	O
coding	O
regions	O
in	O
the	O
AUNA1	B-Disease
family	O
and	O
in	O
the	O
retained	O
homologue	O
chromosome	O
in	O
the	O
monosomic	O
patient	O
revealed	O
no	O
mutations	O
.	O

We	O
conclude	O
that	O
AUNA1	B-Disease
deafness	I-Disease
does	O
not	O
share	O
a	O
common	O
etiology	O
with	O
deafness	B-Disease
associated	O
with	O
monosomy	O
13q21	O
.	O
2	O
-	O
q31	O
.	O
3	O
;	O
deafness	B-Disease
may	O
result	O
from	O
monosomy	O
of	O
PCHD9	O
or	O
another	O
gene	O
in	O
the	O
IT	O
,	O
as	O
has	O
been	O
demonstrated	O
in	O
contiguous	O
gene	O
deletion	O
syndromes	O
.	O

Precise	O
characterization	O
of	O
the	O
breakpoints	O
of	O
the	O
translocated	O
region	O
is	O
useful	O
to	O
identify	O
which	O
genes	O
may	O
be	O
contributing	O
to	O
the	O
phenotype	O
,	O
either	O
through	O
haploinsufficiency	O
or	O
extra	O
dosage	O
effects	O
,	O
in	O
order	O
to	O
define	O
genotype	O
-	O
phenotype	O
correlations	O
.	O


A	O
Taiwanese	O
boy	O
with	O
congenital	B-Disease
generalized	I-Disease
lipodystrophy	I-Disease
caused	O
by	O
homozygous	O
Ile262fs	O
mutation	O
in	O
the	O
BSCL2	O
gene	O
.	O

Congenital	B-Disease
generalized	I-Disease
lipodystrophy	I-Disease
(	O
CGL	B-Disease
)	O
is	O
a	O
rare	O
autosomal	B-Disease
recessive	I-Disease
disease	I-Disease
that	O
is	O
characterized	O
by	O
a	O
near	O
-	O
complete	O
absence	O
of	O
adipose	O
tissue	O
from	O
birth	O
or	O
early	O
infancy	O
.	O

Mutations	O
in	O
the	O
BSCL2	O
gene	O
are	O
known	O
to	O
result	O
in	O
CGL2	B-Disease
,	O
a	O
more	O
severe	O
phenotype	O
than	O
CGL1	B-Disease
,	O
with	O
earlier	O
onset	O
,	O
more	O
extensive	O
fat	O
loss	O
and	O
biochemical	O
changes	O
,	O
more	O
severe	O
intellectual	B-Disease
impairment	I-Disease
,	O
and	O
more	O
severe	O
cardiomyopathy	B-Disease
.	O

We	O
report	O
a	O
3	O
-	O
month	O
-	O
old	O
Taiwanese	O
boy	O
with	O
initial	O
presentation	O
of	O
a	O
lack	O
of	O
subcutaneous	O
fat	O
,	O
prominent	O
musculature	O
,	O
generalized	O
eruptive	B-Disease
xanthomas	I-Disease
,	O
and	O
extreme	O
hypertriglyceridemia	B-Disease
.	O

Absence	O
of	O
mechanical	O
adipose	O
tissue	O
in	O
the	O
orbits	O
and	O
scalp	O
was	O
revealed	O
by	O
head	O
magnetic	O
resonance	O
imaging	O
.	O

Hepatomegaly	B-Disease
was	O
noticed	O
,	O
and	O
histological	O
examination	O
of	O
a	O
liver	O
biopsy	O
specimen	O
suggested	O
severe	O
hepatic	B-Disease
steatosis	I-Disease
and	O
periportal	O
necrosis	B-Disease
.	O

However	O
,	O
echocardiography	O
indicated	O
no	O
sign	O
of	O
cardiomyopathy	B-Disease
and	O
he	O
showed	O
no	O
distinct	O
intellectual	B-Disease
impairment	I-Disease
that	O
interfered	O
with	O
daily	O
life	O
.	O

About	O
1	O
year	O
later	O
,	O
abdominal	O
computed	O
tomography	O
revealed	O
enlargement	B-Disease
of	I-Disease
kidneys	I-Disease
.	O

He	O
had	O
a	O
homozygous	O
insertion	O
of	O
a	O
nucleotide	O
,	O
783insG	O
(	O
Ile262fs	O
mutation	O
),	O
in	O
exon	O
7	O
of	O
the	O
BSCL2	O
gene	O
.	O

We	O
reviewed	O
the	O
genotype	O
of	O
CGL	B-Disease
cases	O
from	O
Japan	O
,	O
India	O
,	O
China	O
and	O
Taiwan	O
,	O
and	O
found	O
that	O
BSCL2	O
is	O
a	O
major	O
causative	O
gene	O
for	O
CGL	B-Disease
in	O
Asian	O
.	O


Concordance	O
between	O
PIK3CA	O
mutations	O
in	O
endoscopic	O
biopsy	O
and	O
surgically	O
resected	O
specimens	O
of	O
esophageal	B-Disease
squamous	I-Disease
cell	I-Disease
carcinoma	I-Disease
.	O

BACKGROUND	O
:	O
PIK3CA	O
mutations	O
are	O
expected	O
to	O
be	O
potential	O
therapeutic	O
targets	O
for	O
esophageal	B-Disease
squamous	I-Disease
cell	I-Disease
carcinoma	I-Disease
(	O
ESCC	B-Disease
).	O

We	O
aimed	O
to	O
clarify	O
the	O
concordance	O
between	O
PIK3CA	O
mutations	O
detected	O
in	O
endoscopic	O
biopsy	O
specimens	O
and	O
corresponding	O
surgically	O
resected	O
specimens	O
.	O

METHODS	O
:	O
We	O
examined	O
five	O
hotspot	O
mutations	O
in	O
the	O
PIK3CA	O
gene	O
(	O
E542K	O
,	O
E545K	O
,	O
E546K	O
,	O
H1047R	O
,	O
and	O
H1047L	O
)	O
in	O
formalin	O
-	O
fixed	O
and	O
paraffin	O
-	O
embedded	O
tissue	O
sections	O
of	O
paired	O
endoscopic	O
biopsy	O
and	O
surgically	O
resected	O
specimens	O
from	O
181	O
patients	O
undergoing	O
curative	O
resection	O
for	O
ESCC	B-Disease
between	O
2000	O
and	O
2011	O
using	O
a	O
Luminex	O
technology	O
-	O
based	O
multiplex	O
gene	O
mutation	O
detection	O
kit	O
.	O

RESULTS	O
:	O
Mutation	O
analyses	O
were	O
successfully	O
performed	O
for	O
both	O
endoscopic	O
biopsy	O
and	O
surgically	O
resected	O
specimens	O
in	O
all	O
the	O
cases	O
.	O

A	O
PIK3CA	O
mutation	O
was	O
detected	O
in	O
either	O
type	O
of	O
specimen	O
in	O
13	O
cases	O
(	O
7	O
.	O
2	O
%,	O
95	O
%	O
confidence	O
interval	O
:	O
3	O
.	O
9	O
-	O
12	O
.	O
0	O
).	O

The	O
overall	O
concordance	O
rate	O
,	O
positive	O
predictive	O
value	O
,	O
and	O
negative	O
predictive	O
value	O
were	O
98	O
.	O
3	O
%	O
(	O
178	O
/	O
181	O
),	O
90	O
.	O
9	O
%	O
(	O
10	O
/	O
11	O
),	O
and	O
98	O
.	O
8	O
%	O
(	O
168	O
/	O
170	O
),	O
respectively	O
.	O

Among	O
patients	O
with	O
a	O
PIK3CA	O
mutation	O
detected	O
in	O
both	O
types	O
of	O
specimens	O
,	O
the	O
concordance	O
between	O
PIK3CA	O
mutation	O
genotypes	O
was	O
100	O
%.	O

There	O
were	O
three	O
cases	O
with	O
a	O
discordant	O
mutation	O
status	O
between	O
the	O
types	O
of	O
specimens	O
(	O
PIK3CA	O
mutation	O
in	O
surgically	O
resected	O
specimen	O
and	O
wild	O
-	O
type	O
in	O
biopsy	O
specimen	O
in	O
two	O
cases	O
,	O
and	O
the	O
opposite	O
pattern	O
in	O
one	O
case	O
),	O
suggesting	O
possible	O
intratumoral	O
heterogeneity	O
in	O
the	O
PIK3CA	O
mutation	O
status	O
.	O

CONCLUSIONS	O
:	O
The	O
PIK3CA	O
mutation	O
status	O
was	O
highly	O
concordant	O
between	O
endoscopic	O
biopsy	O
and	O
surgically	O
resected	O
specimens	O
from	O
the	O
same	O
patient	O
,	O
suggesting	O
that	O
endoscopic	O
biopsy	O
specimens	O
can	O
be	O
clinically	O
used	O
to	O
detect	O
PIK3CA	O
mutations	O
in	O
patients	O
with	O
ESCC	B-Disease
.	O


Polymorphisms	O
of	O
the	O
DNA	O
mismatch	O
repair	O
gene	O
HMSH2	O
in	O
breast	B-Disease
cancer	I-Disease
occurence	O
and	O
progression	O
.	O

The	O
response	O
of	O
the	O
cell	O
to	O
DNA	O
damage	O
and	O
its	O
ability	O
to	O
maintain	O
genomic	O
stability	O
by	O
DNA	O
repair	O
are	O
crucial	O
in	O
preventing	O
cancer	B-Disease
initiation	I-Disease
and	O
progression	O
.	O

Therefore	O
,	O
polymorphism	O
of	O
DNA	O
repair	O
genes	O
may	O
affect	O
the	O
process	O
of	O
carcinogenesis	B-Disease
.	O

The	O
importance	O
of	O
genetic	O
variability	O
of	O
the	O
components	O
of	O
mismatch	O
repair	O
(	O
MMR	O
)	O
genes	O
is	O
well	O
documented	O
in	O
colorectal	B-Disease
cancer	I-Disease
,	O
but	O
little	O
is	O
known	O
about	O
its	O
role	O
in	O
breast	B-Disease
cancer	I-Disease
.	O

hMSH2	O
is	O
one	O
of	O
the	O
crucial	O
proteins	O
of	O
MMR	O
.	O

We	O
performed	O
a	O
case	O
-	O
control	O
study	O
to	O
test	O
the	O
association	O
between	O
two	O
polymorphisms	O
in	O
the	O
hMSH2	O
gene	O
:	O
an	O
A	O
-->	O
G	O
transition	O
at	O
127	O
position	O
producing	O
an	O
Asn	O
-->	O
Ser	O
substitution	O
at	O
codon	O
127	O
(	O
the	O
Asn127Ser	O
polymorphism	O
)	O
and	O
a	O
G	O
-->	O
A	O
transition	O
at	O
1032	O
position	O
resulting	O
in	O
a	O
Gly	O
-->	O
Asp	O
change	O
at	O
codon	O
322	O
(	O
the	O
Gly322Asp	O
polymorphism	O
)	O
and	O
breast	B-Disease
cancer	I-Disease
risk	O
and	O
cancer	B-Disease
progression	O
.	O

Genotypes	O
were	O
determined	O
in	O
DNA	O
from	O
peripheral	O
blood	O
lymphocytes	O
of	O
150	O
breast	B-Disease
cancer	I-Disease
patients	O
and	O
150	O
age	O
-	O
matched	O
women	O
(	O
controls	O
)	O
by	O
restriction	O
fragment	O
length	O
polymorphism	O
and	O
allele	O
-	O
specific	O
PCR	O
.	O

We	O
did	O
not	O
observe	O
any	O
correlation	O
between	O
studied	O
polymorphisms	O
and	O
breast	B-Disease
cancer	I-Disease
progression	O
evaluated	O
by	O
node	O
-	O
metastasis	O
,	O
tumor	B-Disease
size	O
and	O
Bloom	O
-	O
Richardson	O
grading	O
.	O

A	O
strong	O
association	O
between	O
breast	B-Disease
cancer	I-Disease
occurrence	O
and	O
the	O
Gly	O
/	O
Gly	O
phenotype	O
of	O
the	O
Gly322Asp	O
polymorphism	O
(	O
odds	O
ratio	O
8	O
.	O
39	O
;	O
95	O
%	O
confidence	O
interval	O
1	O
.	O
44	O
-	O
48	O
.	O
8	O
)	O
was	O
found	O
.	O

Therefore	O
,	O
MMR	O
may	O
play	O
a	O
role	O
in	O
the	O
breast	B-Disease
carcinogenesis	I-Disease
and	O
the	O
Gly322Asp	O
polymorphism	O
of	O
the	O
hMSH2	O
gene	O
may	O
be	O
considered	O
as	O
a	O
potential	O
marker	O
in	O
breast	B-Disease
cancer	I-Disease
.	O


Atorvastatin	O
prevented	O
and	O
reversed	O
dexamethasone	O
-	O
induced	O
hypertension	B-Disease
in	O
the	O
rat	O
.	O

To	O
assess	O
the	O
antioxidant	O
effects	O
of	O
atorvastatin	O
(	O
atorva	O
)	O
on	O
dexamethasone	O
(	O
dex	O
)-	O
induced	O
hypertension	B-Disease
,	O
60	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
treated	O
with	O
atorva	O
30	O
mg	O
/	O
kg	O
/	O
day	O
or	O
tap	O
water	O
for	O
15	O
days	O
.	O

Dex	O
increased	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
from	O
109	O
+/-	O
1	O
.	O
8	O
to	O
135	O
+/-	O
0	O
.	O
6	O
mmHg	O
and	O
plasma	O
superoxide	O
(	O
5711	O
+/-	O
284	O
.	O
9	O
saline	O
,	O
7931	O
+/-	O
392	O
.	O
8	O
U	O
/	O
ml	O
dex	O
,	O
P	O
<	O
0	O
.	O
1	O
).	O

In	O
this	O
prevention	O
study	O
,	O
SBP	O
in	O
the	O
atorva	O
+	O
dex	O
group	O
was	O
increased	O
from	O
115	O
+/-	O
0	O
.	O
4	O
to	O
124	O
+/-	O
1	O
.	O
5	O
mmHg	O
,	O
but	O
this	O
was	O
significantly	O
lower	O
than	O
in	O
the	O
dex	O
-	O
only	O
group	O
(	O
P	O
'	O
<	O
0	O
.	O
5	O
).	O

Atorva	O
reversed	O
dex	O
-	O
induced	O
hypertension	B-Disease
(	O
129	O
+/-	O
0	O
.	O
6	O
mmHg	O
,	O
vs	O
.	O

135	O
+/-	O
0	O
.	O
6	O
mmHg	O
P	O
'	O
<	O
0	O
.	O
5	O
)	O
and	O
decreased	O
plasma	O
superoxide	O
(	O
7931	O
+/-	O
392	O
.	O
8	O
dex	O
,	O
1187	O
+/-	O
441	O
.	O
2	O
atorva	O
+	O
dex	O
,	O
P	O
<	O
0	O
.	O
1	O
).	O

Plasma	O
nitrate	O
/	O
nitrite	O
(	O
NOx	O
)	O
was	O
decreased	O
in	O
dex	O
-	O
treated	O
rats	O
compared	O
to	O
saline	O
-	O
treated	O
rats	O
(	O
11	O
.	O
2	O
+/-	O
1	O
.	O
8	O
microm	O
,	O
15	O
.	O
3	O
+/-	O
1	O
.	O
17	O
microm	O
,	O
respectively	O
,	O
P	O
<	O
0	O
.	O
5	O
).	O

Atorva	O
affected	O
neither	O
plasma	O
NOx	O
nor	O
thymus	O
weight	O
.	O

Thus	O
,	O
atorvastatin	O
prevented	O
and	O
reversed	O
dexamethasone	O
-	O
induced	O
hypertension	B-Disease
in	O
the	O
rat	O
.	O


Gene	O
polymorphisms	O
implicated	O
in	O
influencing	O
susceptibility	O
to	O
venous	B-Disease
and	I-Disease
arterial	I-Disease
thromboembolism	I-Disease
:	O
frequency	O
distribution	O
in	O
a	O
healthy	O
German	O
population	O
.	O

Evolvement	O
and	O
progression	O
of	O
cardiovascular	B-Disease
diseases	I-Disease
affecting	O
the	O
venous	O
and	O
arterial	O
system	O
are	O
influenced	O
by	O
a	O
multitude	O
of	O
environmental	O
and	O
hereditary	O
factors	O
.	O

Many	O
of	O
these	O
hereditary	O
factors	O
consist	O
of	O
defined	O
gene	O
polymorphisms	O
,	O
such	O
as	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
or	O
insertion	O
-	O
deletion	O
polymorphisms	O
,	O
which	O
directly	O
or	O
indirectly	O
affect	O
the	O
hemostatic	O
system	O
.	O

The	O
frequencies	O
of	O
individual	O
hemostatic	O
gene	O
polymorphisms	O
in	O
different	O
normal	O
populations	O
are	O
well	O
defined	O
.	O

However	O
,	O
descriptions	O
of	O
patterns	O
of	O
genetic	O
variability	O
of	O
a	O
larger	O
extent	O
of	O
different	O
factors	O
of	O
hereditary	B-Disease
hypercoagulability	I-Disease
in	O
single	O
populations	O
are	O
scarce	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
i	O
)	O
to	O
give	O
a	O
detailed	O
description	O
of	O
the	O
frequencies	O
of	O
factors	O
of	O
hereditary	B-Disease
thrombophilia	I-Disease
and	O
their	O
combinations	O
in	O
a	O
German	O
population	O
(	O
n	O
=	O
282	O
)	O
and	O
ii	O
)	O
to	O
compare	O
their	O
distributions	O
with	O
those	O
reported	O
for	O
other	O
regions	O
.	O

Variants	O
of	O
coagulation	O
factors	O
[	O
factor	O
V	O
1691G	O
>	O
A	O
(	O
factor	O
V	O
Leiden	O
),	O
factor	O
V	O
4070A	O
>	O
G	O
(	O
factor	O
V	O
HR2	O
haplotype	O
),	O
factor	O
VII	O
Arg353Gln	O
,	O
factor	O
XIII	O
Val34Leu	O
,	O
beta	O
-	O
fibrinogen	O
-	O
455G	O
>	O
A	O
,	O
prothrombin	O
20210G	O
>	O
A	O
],	O
coagulation	O
inhibitors	O
[	O
tissue	O
factor	O
pathway	O
inhibitor	O
536C	O
>	O
T	O
,	O
thrombomodulin	O
127G	O
>	O
A	O
],	O
fibrinolytic	O
factors	O
[	O
angiotensin	O
converting	O
enzyme	O
intron	O
16	O
insertion	O
/	O
deletion	O
,	O
factor	O
VII	O
-	O
activating	O
protease	O
1601G	O
>	O
A	O
(	O
FSAP	O
Marburg	O
I	O
),	O
plasminogen	O
activator	O
inhibitor	O
1	O
-	O
675	O
insertion	O
/	O
deletion	O
(	O
5G	O
/	O
4G	O
),	O
tissue	O
plasminogen	O
activator	O
intron	O
h	O
deletion	O
/	O
insertion	O
],	O
and	O
other	O
factors	O
implicated	O
in	O
influencing	O
susceptibility	O
to	O
thromboembolic	B-Disease
diseases	I-Disease
[	O
apolipoprotein	O
E2	O
/	O
E3	O
/	O
E4	O
,	O
glycoprotein	O
Ia	O
807C	O
>	O
T	O
,	O
methylenetetrahydrofolate	O
reductase	O
677C	O
>	O
T	O
]	O
were	O
included	O
.	O

The	O
distribution	O
of	O
glycoprotein	O
Ia	O
807C	O
>	O
T	O
deviated	O
significantly	O
from	O
the	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
,	O
and	O
a	O
comparison	O
with	O
previously	O
published	O
data	O
indicates	O
marked	O
region	O
and	O
ethnicity	O
dependent	O
differences	O
in	O
the	O
genotype	O
distributions	O
of	O
some	O
other	O
factors	O
.	O


Necrotising	B-Disease
fasciitis	I-Disease
after	O
bortezomib	O
and	O
dexamethasone	O
-	O
containing	O
regimen	O
in	O
an	O
elderly	O
patient	O
of	O
Waldenstrom	B-Disease
macroglobulinaemia	I-Disease
.	O

Bortezomib	O
and	O
high	O
-	O
dose	O
dexamethasone	O
-	O
containing	O
regimens	O
are	O
considered	O
to	O
be	O
generally	O
tolerable	O
with	O
few	O
severe	O
bacterial	B-Disease
infections	I-Disease
in	O
patients	O
with	O
B	O
-	O
cell	O
malignancies	B-Disease
.	O

However	O
,	O
information	O
is	O
limited	O
concerning	O
the	O
safety	O
of	O
the	O
regimen	O
in	O
elderly	O
patients	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
76	O
-	O
year	O
-	O
old	O
man	O
with	O
Waldenstrom	B-Disease
macroglobulinaemia	I-Disease
who	O
suffered	O
necrotising	B-Disease
fasciitis	I-Disease
without	O
neutropenia	B-Disease
after	O
the	O
combination	O
treatment	O
with	O
bortezomib	O
,	O
high	O
-	O
dose	O
dexamethasone	O
and	O
rituximab	O
.	O

Despite	O
immediate	O
intravenous	O
antimicrobial	O
therapy	O
,	O
he	O
succumbed	O
23	O
h	O
after	O
the	O
onset	O
.	O

Physicians	O
should	O
recognise	O
the	O
possibility	O
of	O
fatal	O
bacterial	B-Disease
infections	I-Disease
related	O
to	O
bortezomib	O
plus	O
high	O
-	O
dose	O
dexamethasone	O
in	O
elderly	O
patients	O
,	O
and	O
we	O
believe	O
this	O
case	O
warrants	O
further	O
investigation	O
.	O


rTMS	O
of	O
supplementary	O
motor	O
area	O
modulates	O
therapy	O
-	O
induced	O
dyskinesias	B-Disease
in	O
Parkinson	B-Disease
disease	I-Disease
.	O

The	O
neural	O
mechanisms	O
and	O
circuitry	O
involved	O
in	O
levodopa	O
-	O
induced	O
dyskinesia	B-Disease
are	O
unclear	O
.	O

Using	O
repetitive	O
transcranial	O
magnetic	O
stimulation	O
(	O
rTMS	O
)	O
over	O
the	O
supplementary	O
motor	O
area	O
(	O
SMA	O
)	O
in	O
a	O
group	O
of	O
patients	O
with	O
advanced	O
Parkinson	B-Disease
disease	I-Disease
,	O
the	O
authors	O
investigated	O
whether	O
modulation	O
of	O
SMA	O
excitability	O
may	O
result	O
in	O
a	O
modification	O
of	O
a	O
dyskinetic	B-Disease
state	O
induced	O
by	O
continuous	O
apomorphine	O
infusion	O
.	O

rTMS	O
at	O
1	O
Hz	O
was	O
observed	O
to	O
markedly	O
reduce	O
drug	B-Disease
-	I-Disease
induced	I-Disease
dyskinesias	I-Disease
,	O
whereas	O
5	O
-	O
Hz	O
rTMS	O
induced	O
a	O
slight	O
but	O
not	O
significant	O
increase	O
.	O


Angiotensin	O
converting	O
enzyme	O
gene	O
polymorphism	O
in	O
Turkish	O
asthmatic	B-Disease
patients	O
.	O

Asthma	B-Disease
is	O
a	O
chronic	O
inflammatory	B-Disease
disease	I-Disease
of	O
the	O
airways	O
.	O

Several	O
candidate	O
genes	O
have	O
been	O
identified	O
with	O
a	O
potential	O
role	O
in	O
the	O
pathogenesis	O
of	O
asthma	B-Disease
,	O
including	O
the	O
angiotensin	O
converting	O
enzyme	O
(	O
ACE	O
)	O
gene	O
.	O

We	O
aimed	O
to	O
investigate	O
the	O
frequency	O
of	O
an	O
ACE	O
gene	O
polymorphism	O
in	O
Turkish	O
asthmatic	B-Disease
patients	O
and	O
to	O
determine	O
its	O
impact	O
on	O
clinical	O
parameters	O
and	O
disease	O
severity	O
.	O

Ninety	O
-	O
seven	O
asthmatic	B-Disease
patients	O
(	O
M	O
/	O
F	O
25	O
/	O
72	O
,	O
mean	O
age	O
39	O
+/-	O
13	O
years	O
)	O
and	O
96	O
healthy	O
subjects	O
(	O
M	O
/	O
F	O
26	O
/	O
70	O
,	O
mean	O
age	O
38	O
+/-	O
12	O
years	O
)	O
were	O
included	O
.	O

At	O
baseline	O
,	O
all	O
participants	O
completed	O
a	O
questionnaire	O
on	O
demographics	O
,	O
symptoms	O
,	O
triggering	O
factors	O
,	O
severity	O
of	O
asthma	B-Disease
,	O
and	O
the	O
presence	O
of	O
atopism	B-Disease
.	O

Blood	O
samples	O
were	O
obtained	O
from	O
all	O
patients	O
and	O
genomic	O
DNA	O
was	O
isolated	O
.	O

The	O
frequency	O
of	O
the	O
ACE	O
genotypes	O
(	O
I	O
=	O
insertion	O
and	O
D	O
=	O
deletion	O
)	O
among	O
asthmatics	B-Disease
and	O
controls	O
were	O
compared	O
:	O
asthmatics	B-Disease
showed	O
a	O
40	O
.	O
2	O
%	O
prevalence	O
of	O
the	O
DD	O
genotype	O
(	O
n	O
=	O
39	O
),	O
ID	O
was	O
45	O
.	O
4	O
%	O
(	O
n	O
=	O
44	O
),	O
and	O
II	O
was	O
14	O
.	O
4	O
%	O
(	O
n	O
=	O
14	O
.	O
4	O
).	O

In	O
the	O
control	O
subjects	O
,	O
the	O
frequency	O
of	O
DD	O
was	O
18	O
.	O
8	O
%	O
(	O
n	O
=	O
18	O
),	O
ID	O
was	O
50	O
%	O
(	O
n	O
=	O
48	O
)	O
and	O
II	O
was	O
31	O
.	O
3	O
%	O
(	O
n	O
=	O
30	O
).	O

The	O
DD	O
ACE	O
genotype	O
was	O
significantly	O
more	O
frequent	O
in	O
asthmatics	B-Disease
compared	O
with	O
controls	O
(	O
p	O
<	O
0	O
.	O
1	O
).	O

Asthmatics	B-Disease
with	O
the	O
ID	O
ACE	O
genotype	O
showed	O
a	O
higher	O
frequency	O
of	O
drug	B-Disease
allergies	I-Disease
,	O
although	O
this	O
was	O
not	O
statistically	O
significant	O
(	O
p	O
=	O
0	O
.	O
8	O
).	O

Asthmatics	B-Disease
with	O
the	O
DD	O
genotype	O
appeared	O
to	O
have	O
a	O
higher	O
incidence	O
of	O
asthmatic	B-Disease
episode	O
exacerbations	O
due	O
to	O
viral	B-Disease
infections	I-Disease
,	O
but	O
again	O
this	O
was	O
not	O
statistically	O
significant	O
(	O
p	O
=	O
0	O
.	O
8	O
).	O

Patients	O
with	O
mild	O
or	O
moderate	O
-	O
severe	O
asthma	B-Disease
had	O
similar	O
frequencies	O
of	O
these	O
mutations	O
.	O

We	O
found	O
a	O
higher	O
frequency	O
of	O
the	O
ACE	O
DD	O
gene	O
mutation	O
in	O
Turkish	O
asthmatic	B-Disease
patients	O
compared	O
with	O
non	O
-	O
asthmatics	B-Disease
,	O
suggesting	O
that	O
this	O
ACE	O
gene	O
polymorphism	O
may	O
be	O
a	O
risk	O
factor	O
for	O
asthma	B-Disease
but	O
does	O
not	O
increase	O
the	O
severity	O
of	O
the	O
disease	O
.	O


The	O
impact	O
of	O
PPARa	O
activation	O
on	O
whole	O
genome	O
gene	O
expression	O
in	O
human	O
precision	O
cut	O
liver	O
slices	O
.	O

BACKGROUND	O
:	O
Studies	O
in	O
mice	O
have	O
shown	O
that	O
PPARa	O
is	O
an	O
important	O
regulator	O
of	O
lipid	O
metabolism	O
in	O
liver	O
and	O
key	O
transcription	O
factor	O
involved	O
in	O
the	O
adaptive	O
response	O
to	O
fasting	O
.	O

However	O
,	O
much	O
less	O
is	O
known	O
about	O
the	O
role	O
of	O
PPARa	O
in	O
human	O
liver	O
.	O

METHODS	O
:	O
Here	O
we	O
set	O
out	O
to	O
study	O
the	O
function	O
of	O
PPARa	O
in	O
human	O
liver	O
via	O
analysis	O
of	O
whole	O
genome	O
gene	O
regulation	O
in	O
human	O
liver	O
slices	O
treated	O
with	O
the	O
PPARa	O
agonist	O
Wy14643	O
.	O

RESULTS	O
:	O
Quantitative	O
PCR	O
indicated	O
that	O
PPARa	O
is	O
well	O
expressed	O
in	O
human	O
liver	O
and	O
human	O
liver	O
slices	O
and	O
that	O
the	O
classical	O
PPARa	O
targets	O
PLIN2	O
,	O
VLDLR	O
,	O
ANGPTL4	O
,	O
CPT1A	O
and	O
PDK4	O
are	O
robustly	O
induced	O
by	O
PPARa	O
activation	O
.	O

Transcriptomics	O
analysis	O
indicated	O
that	O
617	O
genes	O
were	O
upregulated	O
and	O
665	O
genes	O
were	O
downregulated	O
by	O
PPARa	O
activation	O
(	O
q	O
value	O
<	O
0	O
.	O
5	O
).	O

Many	O
genes	O
induced	O
by	O
PPARa	O
activation	O
were	O
involved	O
in	O
lipid	O
metabolism	O
(	O
ACSL5	O
,	O
AGPAT9	O
,	O
FADS1	O
,	O
SLC27A4	O
),	O
xenobiotic	O
metabolism	O
(	O
POR	O
,	O
ABCC2	O
,	O
CYP3A5	O
)	O
or	O
the	O
unfolded	O
protein	O
response	O
,	O
whereas	O
most	O
of	O
the	O
downregulated	O
genes	O
were	O
involved	O
in	O
immune	O
-	O
related	O
pathways	O
.	O

Among	O
the	O
most	O
highly	O
repressed	O
genes	O
upon	O
PPARa	O
activation	O
were	O
several	O
chemokines	O
(	O
e	O
.	O
g	O
.	O

CXCL9	O
-	O
11	O
,	O
CCL8	O
,	O
CX3CL1	O
,	O
CXCL6	O
),	O
interferon	O
g	O
-	O
induced	O
genes	O
(	O
e	O
.	O
g	O
.	O

IFITM1	O
,	O
IFIT1	O
,	O
IFIT2	O
,	O
IFIT3	O
)	O
and	O
numerous	O
other	O
immune	O
-	O
related	O
genes	O
(	O
e	O
.	O
g	O
.	O

TLR3	O
,	O
NOS2	O
,	O
and	O
LCN2	O
).	O

Comparative	O
analysis	O
of	O
gene	O
regulation	O
by	O
Wy14643	O
between	O
human	O
liver	O
slices	O
and	O
primary	O
human	O
hepatocytes	O
showed	O
that	O
down	O
-	O
regulation	O
of	O
gene	O
expression	O
by	O
PPARa	O
is	O
much	O
better	O
captured	O
by	O
liver	O
slices	O
as	O
compared	O
to	O
primary	O
hepatocytes	O
.	O

In	O
particular	O
,	O
PPARa	O
activation	O
markedly	O
suppressed	O
immunity	O
/	O
inflammation	B-Disease
-	O
related	O
genes	O
in	O
human	O
liver	O
slices	O
but	O
not	O
in	O
primary	O
hepatocytes	O
.	O

Finally	O
,	O
several	O
putative	O
new	O
target	O
genes	O
of	O
PPARa	O
were	O
identified	O
that	O
were	O
commonly	O
induced	O
by	O
PPARa	O
activation	O
in	O
the	O
two	O
human	O
liver	O
model	O
systems	O
,	O
including	O
TSKU	O
,	O
RHOF	O
,	O
CA12	O
and	O
VSIG10L	O
.	O

CONCLUSION	O
:	O
Our	O
paper	O
demonstrates	O
the	O
suitability	O
and	O
superiority	O
of	O
human	O
liver	O
slices	O
over	O
primary	O
hepatocytes	O
for	O
studying	O
the	O
functional	O
role	O
of	O
PPARa	O
in	O
human	O
liver	O
.	O

Our	O
data	O
underscore	O
the	O
major	O
role	O
of	O
PPARa	O
in	O
regulation	O
of	O
hepatic	O
lipid	O
and	O
xenobiotic	O
metabolism	O
in	O
human	O
liver	O
and	O
reveal	O
a	O
marked	O
immuno	O
-	O
suppressive	O
/	O
anti	O
-	O
inflammatory	B-Disease
effect	O
of	O
PPARa	O
in	O
human	O
liver	O
slices	O
that	O
may	O
be	O
therapeutically	O
relevant	O
for	O
non	B-Disease
-	I-Disease
alcoholic	I-Disease
fatty	I-Disease
liver	I-Disease
disease	I-Disease
.	O


Oncogenic	O
activity	O
of	O
amplified	O
miniature	O
chromosome	O
maintenance	O
8	O
in	O
human	O
malignancies	B-Disease
.	O

Miniature	O
chromosome	O
maintenance	O
(	O
MCM	O
)	O
proteins	O
play	O
critical	O
roles	O
in	O
DNA	O
replication	O
licensing	O
,	O
initiation	O
and	O
elongation	O
.	O

MCM8	O
,	O
one	O
of	O
the	O
MCM	O
proteins	O
playing	O
a	O
critical	O
role	O
in	O
DNA	O
repairing	O
and	O
recombination	O
,	O
was	O
found	O
to	O
have	O
overexpression	O
and	O
increased	O
DNA	O
copy	O
number	O
in	O
a	O
variety	O
of	O
human	O
malignancies	B-Disease
.	O

The	O
gain	O
of	O
MCM8	O
is	O
associated	O
with	O
aggressive	O
clinical	O
features	O
of	O
several	O
human	O
cancers	B-Disease
.	O

Increased	O
expression	O
of	O
MCM8	O
in	O
prostate	B-Disease
cancer	I-Disease
is	O
associated	O
with	O
cancer	B-Disease
recurrence	O
.	O

Forced	O
expression	O
of	O
MCM8	O
in	O
RWPE1	O
cells	O
,	O
the	O
immortalized	O
but	O
non	O
-	O
transformed	O
prostate	O
epithelial	O
cell	O
line	O
,	O
exhibited	O
fast	O
cell	O
growth	O
and	O
transformation	O
,	O
while	O
knock	O
down	O
of	O
MCM8	O
in	O
PC3	O
,	O
DU145	O
and	O
LNCaP	O
cells	O
induced	O
cell	O
growth	O
arrest	O
,	O
and	O
decreased	O
tumour	B-Disease
volumes	O
and	O
mortality	O
of	O
severe	O
combined	O
immunodeficiency	B-Disease
mice	O
xenografted	O
with	O
PC3	O
and	O
DU145	O
cells	O
.	O

MCM8	O
bound	O
cyclin	O
D1	O
and	O
activated	O
Rb	O
protein	O
phosphorylation	O
by	O
cyclin	O
-	O
dependent	O
kinase	O
4	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
cyclin	O
D1	O
/	O
MCM8	O
interaction	O
is	O
required	O
for	O
Rb	O
phosphorylation	O
and	O
S	O
-	O
phase	O
entry	O
in	O
cancer	B-Disease
cells	O
.	O

As	O
a	O
result	O
,	O
our	O
study	O
showed	O
that	O
copy	O
number	O
increase	O
and	O
overexpression	O
of	O
MCM8	O
may	O
play	O
critical	O
roles	O
in	O
human	O
cancer	B-Disease
development	O
.	O


Enhanced	O
isoproterenol	O
-	O
induced	O
cardiac	B-Disease
hypertrophy	I-Disease
in	O
transgenic	O
rats	O
with	O
low	O
brain	O
angiotensinogen	O
.	O

We	O
have	O
previously	O
shown	O
that	O
a	O
permanent	O
deficiency	O
in	O
the	O
brain	O
renin	O
-	O
angiotensin	O
system	O
(	O
RAS	O
)	O
may	O
increase	O
the	O
sensitivity	O
of	O
the	O
baroreflex	O
control	O
of	O
heart	O
rate	O
.	O

In	O
this	O
study	O
we	O
aimed	O
at	O
studying	O
the	O
involvement	O
of	O
the	O
brain	O
RAS	O
in	O
the	O
cardiac	O
reactivity	O
to	O
the	O
beta	O
-	O
adrenoceptor	O
(	O
beta	O
-	O
AR	O
)	O
agonist	O
isoproterenol	O
(	O
Iso	O
).	O

Transgenic	O
rats	O
with	O
low	O
brain	O
angiotensinogen	O
(	O
TGR	O
)	O
were	O
used	O
.	O

In	O
isolated	O
hearts	O
,	O
Iso	O
induced	O
a	O
significantly	O
greater	O
increase	O
in	O
left	O
ventricular	O
(	O
LV	O
)	O
pressure	O
and	O
maximal	O
contraction	O
(+	O
dP	O
/	O
dt	O
(	O
max	O
))	O
in	O
the	O
TGR	O
than	O
in	O
the	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
rats	O
.	O

LV	B-Disease
hypertrophy	I-Disease
induced	O
by	O
Iso	O
treatment	O
was	O
significantly	O
higher	O
in	O
TGR	O
than	O
in	O
SD	O
rats	O
(	O
in	O
g	O
LV	O
wt	O
/	O
100	O
g	O
body	O
wt	O
,	O
0	O
.	O
28	O
+/-	O
0	O
.	O
4	O
vs	O
.	O

0	O
.	O
24	O
+/-	O
0	O
.	O
4	O
,	O
respectively	O
).	O

The	O
greater	O
LV	B-Disease
hypertrophy	I-Disease
in	O
TGR	O
rats	O
was	O
associated	O
with	O
more	O
pronounced	O
downregulation	O
of	O
beta	O
-	O
AR	O
and	O
upregulation	O
of	O
LV	O
beta	O
-	O
AR	O
kinase	O
-	O
1	O
mRNA	O
levels	O
compared	O
with	O
those	O
in	O
SD	O
rats	O
.	O

The	O
decrease	O
in	O
the	O
heart	O
rate	O
(	O
HR	O
)	O
induced	O
by	O
the	O
beta	O
-	O
AR	O
antagonist	O
metoprolol	O
in	O
conscious	O
rats	O
was	O
significantly	O
attenuated	O
in	O
TGR	O
compared	O
with	O
SD	O
rats	O
(-	O
9	O
.	O
9	O
+/-	O
1	O
.	O
7	O
%	O
vs	O
.	O

-	O
18	O
.	O
1	O
+/-	O
1	O
.	O
5	O
%),	O
whereas	O
the	O
effect	O
of	O
parasympathetic	O
blockade	O
by	O
atropine	O
on	O
HR	O
was	O
similar	O
in	O
both	O
strains	O
.	O

These	O
results	O
indicate	O
that	O
TGR	O
are	O
more	O
sensitive	O
to	O
beta	O
-	O
AR	O
agonist	O
-	O
induced	O
cardiac	O
inotropic	O
response	O
and	O
hypertrophy	B-Disease
,	O
possibly	O
due	O
to	O
chronically	O
low	O
sympathetic	O
outflow	O
directed	O
to	O
the	O
heart	O
.	O


Intronic	O
deletions	O
in	O
the	O
SLC34A3	O
gene	O
cause	O
hereditary	B-Disease
hypophosphatemic	I-Disease
rickets	I-Disease
with	I-Disease
hypercalciuria	I-Disease
.	O

CONTEXT	O
:	O
Hereditary	B-Disease
hypophosphatemic	I-Disease
rickets	I-Disease
with	I-Disease
hypercalciuria	I-Disease
(	O
HHRH	B-Disease
)	O
is	O
a	O
rare	O
metabolic	B-Disease
disorder	I-Disease
,	O
characterized	O
by	O
hypophosphatemia	B-Disease
and	O
rickets	B-Disease
/	O
osteomalacia	B-Disease
with	O
increased	O
serum	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D	O
[	O
1	O
,	O
25	O
-(	O
OH	O
)(	O
2	O
)	O
D	O
]	O
resulting	O
in	O
hypercalciuria	B-Disease
.	O

OBJECTIVE	O
:	O
Our	O
objective	O
was	O
to	O
determine	O
whether	O
mutations	O
in	O
the	O
SLC34A3	O
gene	O
,	O
which	O
encodes	O
sodium	O
-	O
phosphate	O
cotransporter	O
type	O
IIc	O
,	O
are	O
responsible	O
for	O
the	O
occurrence	O
of	O
HHRH	B-Disease
.	O

DESIGN	O
AND	O
SETTING	O
:	O
Mutation	O
analysis	O
of	O
exons	O
and	O
adjacent	O
introns	O
in	O
the	O
SLC34A3	O
gene	O
was	O
conducted	O
at	O
an	O
academic	O
research	O
laboratory	O
and	O
medical	O
center	O
.	O

PATIENTS	O
OR	O
OTHER	O
PARTICIPANTS	O
:	O
Members	O
of	O
two	O
unrelated	O
families	O
with	O
HHRH	B-Disease
participated	O
in	O
the	O
study	O
.	O

RESULTS	O
:	O
Two	O
affected	O
siblings	O
in	O
one	O
family	O
were	O
homozygous	O
for	O
a	O
101	O
-	O
bp	O
deletion	O
in	O
intron	O
9	O
.	O

Haplotype	O
analysis	O
of	O
the	O
SLC34A3	O
locus	O
in	O
the	O
family	O
showed	O
that	O
the	O
two	O
deletions	O
are	O
on	O
different	O
haplotypes	O
.	O

An	O
unrelated	O
individual	O
with	O
HHRH	B-Disease
was	O
a	O
compound	O
heterozygote	O
for	O
an	O
85	O
-	O
bp	O
deletion	O
in	O
intron	O
10	O
and	O
a	O
G	O
-	O
to	O
-	O
A	O
substitution	O
at	O
the	O
last	O
nucleotide	O
in	O
exon	O
7	O
.	O

The	O
intron	O
9	O
deletion	O
(	O
and	O
likely	O
the	O
other	O
two	O
mutations	O
)	O
identified	O
in	O
this	O
study	O
causes	O
aberrant	O
RNA	O
splicing	O
.	O

Sequence	O
analysis	O
of	O
the	O
deleted	O
regions	O
revealed	O
the	O
presence	O
of	O
direct	O
repeats	O
of	O
homologous	O
sequences	O
.	O

CONCLUSION	O
:	O
HHRH	B-Disease
is	O
caused	O
by	O
biallelic	O
mutations	O
in	O
the	O
SLC34A3	O
gene	O
.	O

Haplotype	O
analysis	O
suggests	O
that	O
the	O
two	O
intron	O
9	O
deletions	O
arose	O
independently	O
.	O

The	O
identification	O
of	O
three	O
independent	O
deletions	O
in	O
introns	O
9	O
and	O
10	O
suggests	O
that	O
the	O
SLC34A3	O
gene	O
may	O
be	O
susceptible	O
to	O
unequal	O
crossing	O
over	O
because	O
of	O
sequence	O
misalignment	O
during	O
meiosis	O
.	O


Vitamin	O
D	O
receptor	O
expression	O
is	O
associated	O
with	O
PIK3CA	O
and	O
KRAS	O
mutations	O
in	O
colorectal	B-Disease
cancer	I-Disease
.	O

Vitamin	O
D	O
is	O
associated	O
with	O
decreased	O
risks	O
of	O
various	O
cancers	B-Disease
,	O
including	O
colon	B-Disease
cancer	I-Disease
.	O

The	O
vitamin	O
D	O
receptor	O
(	O
VDR	O
)	O
is	O
a	O
transcription	O
factor	O
,	O
which	O
plays	O
an	O
important	O
role	O
in	O
cellular	O
differentiation	O
and	O
inhibition	O
of	O
proliferation	O
.	O

A	O
link	O
between	O
VDR	O
and	O
the	O
RAS	O
-	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
or	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PI3K	O
)-	O
AKT	O
pathway	O
has	O
been	O
suggested	O
.	O

However	O
,	O
the	O
prognostic	O
role	O
of	O
VDR	O
expression	O
or	O
its	O
relationship	O
with	O
PIK3CA	O
or	O
KRAS	O
mutation	O
remains	O
uncertain	O
.	O

Among	O
619	O
colorectal	B-Disease
cancers	I-Disease
in	O
two	O
prospective	O
cohort	O
studies	O
,	O
233	O
(	O
38	O
%)	O
tumors	B-Disease
showed	O
VDR	O
overexpression	O
by	O
immunohistochemistry	O
.	O

We	O
analyzed	O
for	O
PIK3CA	O
and	O
KRAS	O
mutations	O
and	O
LINE	O
-	O
1	O
methylation	O
by	O
Pyrosequencing	O
,	O
microsatellite	O
instability	O
(	O
MSI	O
),	O
and	O
DNA	O
methylation	O
(	O
epigenetic	O
changes	O
)	O
in	O
eight	O
CpG	O
island	O
methylator	O
phenotype	O
(	O
CIMP	O
)-	O
specific	O
promoters	O
[	O
CACNA1G	O
,	O
CDKN2A	O
(	O
p16	O
),	O
CRABP1	O
,	O
IGF2	O
,	O
MLH1	O
,	O
NEUROG1	O
,	O
RUNX3	O
,	O
and	O
SOCS1	O
]	O
by	O
MethyLight	O
(	O
real	O
-	O
time	O
PCR	O
).	O

VDR	O
overexpression	O
was	O
significantly	O
associated	O
with	O
KRAS	O
mutation	O
(	O
odds	O
ratio	O
,	O
1	O
.	O
55	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
11	O
-	O
2	O
.	O
16	O
)	O
and	O
PIK3CA	O
mutation	O
(	O
odds	O
ratio	O
,	O
2	O
.	O
17	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
36	O
-	O
3	O
.	O
47	O
),	O
both	O
of	O
which	O
persisted	O
in	O
multivariate	O
logistic	O
regression	O
analysis	O
.	O

VDR	O
was	O
not	O
independently	O
associated	O
with	O
body	O
mass	O
index	O
,	O
family	O
history	O
of	O
colorectal	B-Disease
cancer	I-Disease
,	O
tumor	B-Disease
location	O
(	O
colon	O
versus	O
rectum	O
),	O
stage	O
,	O
tumor	B-Disease
grade	O
,	O
signet	O
ring	O
cells	O
,	O
CIMP	O
,	O
MSI	O
,	O
LINE	O
-	O
1	O
hypomethylation	O
,	O
BRAF	O
,	O
p53	O
,	O
p21	O
,	O
beta	O
-	O
catenin	O
,	O
or	O
cyclooxygenase	O
-	O
2	O
.	O

VDR	O
expression	O
was	O
not	O
significantly	O
related	O
with	O
patient	O
survival	O
,	O
prognosis	O
,	O
or	O
clinical	O
outcome	O
.	O

In	O
conclusion	O
,	O
VDR	O
overexpression	O
in	O
colorectal	B-Disease
cancer	I-Disease
is	O
independently	O
associated	O
with	O
PIK3CA	O
and	O
KRAS	O
mutations	O
.	O

Our	O
data	O
support	O
potential	O
interactions	O
between	O
the	O
VDR	O
,	O
RAS	O
-	O
MAPK	O
and	O
PI3K	O
-	O
AKT	O
pathways	O
,	O
and	O
possible	O
influence	O
by	O
KRAS	O
or	O
PIK3CA	O
mutation	O
on	O
therapy	O
or	O
chemoprevention	O
targeting	O
VDR	O
.	O


Cultured	O
mycelium	O
Cordyceps	O
sinensis	O
protects	O
liver	O
sinusoidal	O
endothelial	O
cells	O
in	O
acute	O
liver	B-Disease
injured	I-Disease
mice	O
.	O

Cultured	O
mycelium	O
Cordyceps	O
sinensis	O
(	O
CMCS	O
)	O
was	O
widely	O
used	O
for	O
a	O
variety	O
of	O
diseases	O
including	O
liver	B-Disease
injury	I-Disease
,	O
the	O
current	O
study	O
aims	O
to	O
investigate	O
the	O
protective	O
effects	O
of	O
CMCS	O
on	O
liver	O
sinusoidal	O
endothelial	O
cells	O
(	O
LSECs	O
)	O
in	O
acute	O
injury	B-Disease
liver	I-Disease
and	O
related	O
action	O
mechanisms	O
.	O

The	O
mice	O
were	O
injected	O
intraperitoneally	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
and	O
D	O
-	O
galactosamine	O
(	O
D	O
-	O
GalN	O
).	O

39	O
male	O
BABL	O
/	O
c	O
mice	O
were	O
randomly	O
divided	O
into	O
four	O
groups	O
:	O
normal	O
control	O
,	O
model	O
control	O
,	O
CMCS	O
treatment	O
and	O
1	O
,	O
10	O
-	O
phenanthroline	O
treatment	O
groups	O
.	O

The	O
Serum	O
liver	O
function	O
parameters	O
including	O
alanine	O
aminotransferase	O
(	O
ALT	O
)	O
and	O
aspartate	O
aminotransferase	O
(	O
AST	O
)	O
levels	O
were	O
assayed	O
with	O
the	O
commercial	O
kit	O
.	O

The	O
inflammation	B-Disease
and	O
scaffold	O
structure	O
in	O
liver	O
were	O
stained	O
with	O
hematoxylin	O
and	O
eosin	O
and	O
silver	O
staining	O
respectively	O
.	O

The	O
LSECs	O
and	O
sub	O
-	O
endothelial	O
basement	O
membrane	O
were	O
observed	O
with	O
the	O
scanning	O
and	O
transmission	O
electronic	O
microscope	O
.	O

The	O
protein	O
expressions	O
of	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
(	O
ICAM	O
-	O
1	O
)	O
and	O
vascular	O
cell	O
adhesion	O
molecule	O
-	O
1	O
(	O
VCAM	O
-	O
1	O
)	O
in	O
liver	O
were	O
analyzed	O
with	O
Western	O
blotting	O
.	O

Expression	O
of	O
von	O
Willebrand	O
factor	O
(	O
vWF	O
)	O
was	O
investigated	O
with	O
immunofluorescence	O
staining	O
.	O

The	O
lipid	O
peroxidation	O
indicators	O
including	O
antisuperoxideanion	O
(	O
ASAFR	O
),	O
hydroxyl	O
free	O
radical	O
(.	O
OH	O
),	O
superoxide	O
dismutase	O
(	O
SOD	O
),	O
malondialdehyde	O
and	O
glutathione	O
S	O
-	O
transferase	O
(	O
GST	O
)	O
were	O
determined	O
with	O
kits	O
,	O
and	O
matrix	O
metalloproteinase	O
-	O
2	O
and	O
9	O
(	O
MMP	O
-	O
2	O
/	O
9	O
)	O
activities	O
in	O
liver	O
were	O
analyzed	O
with	O
gelatin	O
zymography	O
and	O
in	O
situ	O
fluorescent	O
zymography	O
respectively	O
.	O

The	O
model	O
mice	O
had	O
much	O
higher	O
serum	O
levels	O
of	O
ALT	O
and	O
AST	O
than	O
the	O
normal	O
mice	O
.	O

Compared	O
to	O
that	O
in	O
the	O
normal	O
control	O
,	O
more	O
severe	O
liver	B-Disease
inflammation	I-Disease
and	O
hepatocyte	O
apoptosis	O
,	O
worse	O
hepatic	O
lipid	O
peroxidation	O
demonstrated	O
by	O
the	O
increased	O
ASAFR	O
,	O
.	O
OH	O
and	O
MDA	O
,	O
but	O
decreased	O
SOD	O
and	O
GST	O
,	O
increased	O
MMP	O
-	O
2	O
/	O
9	O
activities	O
and	O
VCAM	O
-	O
1	O
,	O
ICAM	O
-	O
1	O
and	O
vWF	O
expressions	O
,	O
which	O
revealed	O
obvious	O
LSEC	B-Disease
injury	I-Disease
and	O
scaffold	O
structure	O
broken	O
,	O
were	O
shown	O
in	O
the	O
model	O
control	O
.	O

Compared	O
with	O
the	O
model	O
group	O
,	O
CMCS	O
and	O
1	O
,	O
10	O
-	O
phenanthroline	O
significantly	O
improved	O
serum	O
ALT	O
/	O
AST	O
,	O
attenuated	O
hepatic	B-Disease
inflammation	I-Disease
and	O
improved	O
peroxidative	O
injury	B-Disease
in	I-Disease
liver	I-Disease
,	O
decreased	O
MMP	O
-	O
2	O
/	O
9	O
activities	O
in	O
liver	O
tissue	O
,	O
improved	O
integration	O
of	O
scaffold	O
structure	O
,	O
and	O
decreased	O
protein	O
expression	O
of	O
VCAM	O
-	O
1	O
and	O
ICAM	O
-	O
1	O
.	O

CMCS	O
could	O
protect	O
LSECs	B-Disease
from	I-Disease
injury	I-Disease
and	O
maintain	O
the	O
microvasculature	O
integration	O
in	O
acute	O
injured	B-Disease
liver	I-Disease
of	O
mice	O
induced	O
by	O
LPS	O
/	O
D	O
-	O
GalN	O
.	O

Its	O
action	O
mechanism	O
was	O
associated	O
with	O
the	O
down	O
-	O
regulation	O
of	O
MMP	O
-	O
2	O
/	O
9	O
activities	O
and	O
inhibition	O
of	O
peroxidation	O
in	O
injured	B-Disease
liver	I-Disease
.	O


A	O
Type	B-Disease
2	I-Disease
Diabetes	I-Disease
-	O
Associated	O
Functional	O
Regulatory	O
Variant	O
in	O
a	O
Pancreatic	O
Islet	O
Enhancer	O
at	O
the	O
ADCY5	O
Locus	O
.	O

Molecular	O
mechanisms	O
remain	O
unknown	O
for	O
most	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
genome	O
-	O
wide	O
association	O
study	O
identified	O
loci	O
.	O

Variants	O
associated	O
with	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
and	O
fasting	O
glucose	O
levels	O
reside	O
in	O
introns	O
of	O
ADCY5	O
,	O
a	O
gene	O
that	O
encodes	O
adenylate	O
cyclase	O
5	O
.	O

Adenylate	O
cyclase	O
5	O
catalyzes	O
the	O
production	O
of	O
cyclic	O
AMP	O
,	O
which	O
is	O
a	O
second	O
messenger	O
molecule	O
involved	O
in	O
cell	O
signaling	O
and	O
pancreatic	O
b	O
-	O
cell	O
insulin	O
secretion	O
.	O

We	O
demonstrated	O
that	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
risk	O
alleles	O
are	O
associated	O
with	O
decreased	O
ADCY5	O
expression	O
in	O
human	O
islets	O
and	O
examined	O
candidate	O
variants	O
for	O
regulatory	O
function	O
.	O

rs11708067	O
overlaps	O
a	O
predicted	O
enhancer	O
region	O
in	O
pancreatic	O
islets	O
.	O

The	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
risk	O
rs11708067	O
-	O
A	O
allele	O
showed	O
fewer	O
H3K27ac	O
ChIP	O
-	O
seq	O
reads	O
in	O
human	O
islets	O
,	O
lower	O
transcriptional	O
activity	O
in	O
reporter	O
assays	O
in	O
rodent	O
b	O
-	O
cells	O
(	O
rat	O
832	O
/	O
13	O
and	O
mouse	O
MIN6	O
),	O
and	O
increased	O
nuclear	O
protein	O
binding	O
compared	O
with	O
the	O
rs11708067	O
-	O
G	O
allele	O
.	O

Homozygous	O
deletion	O
of	O
the	O
orthologous	O
enhancer	O
region	O
in	O
832	O
/	O
13	O
cells	O
resulted	O
in	O
a	O
64	O
%	O
reduction	O
in	O
expression	O
level	O
of	O
Adcy5	O
,	O
but	O
not	O
adjacent	O
gene	O
Sec22a	O
,	O
and	O
a	O
39	O
%	O
reduction	O
in	O
insulin	O
secretion	O
.	O

Together	O
,	O
these	O
data	O
suggest	O
that	O
rs11708067	O
-	O
A	O
risk	O
allele	O
contributes	O
to	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
by	O
disrupting	O
an	O
islet	O
enhancer	O
,	O
which	O
results	O
in	O
reduced	O
ADCY5	O
expression	O
and	O
impaired	B-Disease
insulin	I-Disease
secretion	I-Disease
.	O


Homozygously	O
deleted	O
gene	O
DACH1	O
regulates	O
tumor	B-Disease
-	O
initiating	O
activity	O
of	O
glioma	B-Disease
cells	O
.	O

Loss	O
or	O
reduction	O
in	O
function	O
of	O
tumor	B-Disease
suppressor	O
genes	O
contributes	O
to	O
tumorigenesis	B-Disease
.	O

Here	O
,	O
by	O
allelic	O
DNA	O
copy	O
number	O
analysis	O
using	O
single	O
-	O
nucleotide	O
polymorphism	O
genotyping	O
array	O
and	O
mass	O
spectrometry	O
,	O
we	O
report	O
homozygous	O
deletion	O
in	O
glioblastoma	B-Disease
multiformes	O
at	O
chromosome	O
13q21	O
,	O
where	O
DACH1	O
gene	O
is	O
located	O
.	O

We	O
found	O
decreased	O
cell	O
proliferation	O
of	O
a	O
series	O
of	O
glioma	B-Disease
cell	O
lines	O
by	O
forced	O
expression	O
of	O
DACH1	O
.	O

We	O
then	O
generated	O
U87TR	O
-	O
Da	O
glioma	B-Disease
cells	O
,	O
where	O
DACH1	O
expression	O
could	O
be	O
activated	O
by	O
exposure	O
of	O
the	O
cells	O
to	O
doxycycline	O
.	O

Both	O
ex	O
vivo	O
cellular	O
proliferation	O
and	O
in	O
vivo	O
growth	O
of	O
s	O
.	O
c	O
.	O

transplanted	O
tumors	B-Disease
in	O
mice	O
are	O
reduced	O
in	O
U87TR	O
-	O
Da	O
cells	O
with	O
DACH1	O
expression	O
(	O
U87	O
-	O
DACH1	O
-	O
high	O
),	O
compared	O
with	O
DACH1	O
-	O
nonexpressing	O
U87TR	O
-	O
Da	O
cells	O
(	O
U87	O
-	O
DACH1	O
-	O
low	O
).	O

U87	O
-	O
DACH1	O
-	O
low	O
cells	O
form	O
spheroids	O
with	O
CD133	O
and	O
Nestin	O
expression	O
in	O
serum	O
-	O
free	O
medium	O
but	O
U87	O
-	O
DACH1	O
-	O
high	O
cells	O
do	O
not	O
.	O

Compared	O
with	O
spheroid	O
-	O
forming	O
U87	O
-	O
DACH1	O
-	O
low	O
cells	O
,	O
adherent	O
U87	O
-	O
DACH1	O
-	O
high	O
cells	O
display	O
lower	O
tumorigenicity	O
,	O
indicating	O
DACH1	O
decreases	O
the	O
number	O
of	O
tumor	B-Disease
-	O
initiating	O
cells	O
.	O

Gene	O
expression	O
analysis	O
and	O
chromatin	O
immunoprecipitation	O
assay	O
reveal	O
that	O
fibroblast	O
growth	O
factor	O
2	O
(	O
FGF2	O
/	O
bFGF	O
)	O
is	O
transcriptionally	O
repressed	O
by	O
DACH1	O
,	O
especially	O
in	O
cells	O
cultured	O
in	O
serum	O
-	O
free	O
medium	O
.	O

Exogenous	O
bFGF	O
rescues	O
spheroid	O
-	O
forming	O
activity	O
and	O
tumorigenicity	O
of	O
the	O
U87	O
-	O
DACH1	O
-	O
high	O
cells	O
,	O
suggesting	O
that	O
loss	O
of	O
DACH1	O
increases	O
the	O
number	O
of	O
tumor	B-Disease
-	O
initiating	O
cells	O
through	O
transcriptional	O
activation	O
of	O
bFGF	O
.	O

These	O
results	O
illustrate	O
that	O
DACH1	O
is	O
a	O
distinctive	O
tumor	B-Disease
suppressor	O
,	O
which	O
does	O
not	O
only	O
suppress	O
growth	O
of	O
tumor	B-Disease
cells	O
but	O
also	O
regulates	O
bFGF	O
-	O
mediated	O
tumor	B-Disease
-	O
initiating	O
activity	O
of	O
glioma	B-Disease
cells	O
.	O


Definition	O
and	O
management	O
of	O
anemia	B-Disease
in	O
patients	O
infected	B-Disease
with	I-Disease
hepatitis	I-Disease
C	I-Disease
virus	I-Disease
.	O

Chronic	B-Disease
infection	I-Disease
with	I-Disease
hepatitis	I-Disease
C	I-Disease
virus	I-Disease
(	O
HCV	O
)	O
can	O
progress	O
to	O
cirrhosis	B-Disease
,	O
hepatocellular	B-Disease
carcinoma	I-Disease
,	O
and	O
end	B-Disease
-	I-Disease
stage	I-Disease
liver	I-Disease
disease	I-Disease
.	O

The	O
current	O
best	O
treatment	O
for	O
HCV	B-Disease
infection	I-Disease
is	O
combination	O
therapy	O
with	O
pegylated	O
interferon	O
and	O
ribavirin	O
.	O

Although	O
this	O
regimen	O
produces	O
sustained	O
virologic	O
responses	O
(	O
SVRs	O
)	O
in	O
approximately	O
50	O
%	O
of	O
patients	O
,	O
it	O
can	O
be	O
associated	O
with	O
a	O
potentially	O
dose	O
-	O
limiting	O
hemolytic	B-Disease
anemia	I-Disease
.	O

Hemoglobin	O
concentrations	O
decrease	O
mainly	O
as	O
a	O
result	O
of	O
ribavirin	O
-	O
induced	O
hemolysis	B-Disease
,	O
and	O
this	O
anemia	B-Disease
can	O
be	O
problematic	O
in	O
patients	O
with	O
HCV	B-Disease
infection	I-Disease
,	O
especially	O
those	O
who	O
have	O
comorbid	O
renal	B-Disease
or	I-Disease
cardiovascular	I-Disease
disorders	I-Disease
.	O

In	O
general	O
,	O
anemia	B-Disease
can	O
increase	O
the	O
risk	O
of	O
morbidity	O
and	O
mortality	O
,	O
and	O
may	O
have	O
negative	O
effects	O
on	O
cerebral	O
function	O
and	O
quality	O
of	O
life	O
.	O

Although	O
ribavirin	O
-	O
associated	O
anemia	B-Disease
can	O
be	O
reversed	O
by	O
dose	O
reduction	O
or	O
discontinuation	O
,	O
this	O
approach	O
compromises	O
outcomes	O
by	O
significantly	O
decreasing	O
SVR	O
rates	O
.	O

Recombinant	O
human	O
erythropoietin	O
has	O
been	O
used	O
to	O
manage	O
ribavirin	O
-	O
associated	O
anemia	B-Disease
but	O
has	O
other	O
potential	O
disadvantages	O
.	O

Viramidine	O
,	O
a	O
liver	O
-	O
targeting	O
prodrug	O
of	O
ribavirin	O
,	O
has	O
the	O
potential	O
to	O
maintain	O
the	O
virologic	O
efficacy	O
of	O
ribavirin	O
while	O
decreasing	O
the	O
risk	O
of	O
hemolytic	B-Disease
anemia	I-Disease
in	O
patients	O
with	O
chronic	B-Disease
hepatitis	I-Disease
C	I-Disease
.	O


Association	O
between	O
an	O
endoglin	O
gene	O
polymorphism	O
and	O
systemic	B-Disease
sclerosis	I-Disease
-	O
related	O
pulmonary	B-Disease
arterial	I-Disease
hypertension	I-Disease
.	O

Systemic	B-Disease
sclerosis	I-Disease
(	O
SSc	B-Disease
)	O
is	O
a	O
connective	O
tissue	O
disorder	O
characterized	O
by	O
early	O
generalized	O
microangiopathy	B-Disease
with	O
disturbed	O
angiogenesis	O
.	O

Endoglin	O
gene	O
(	O
ENG	O
)	O
encodes	O
a	O
transmembrane	O
glycoprotein	O
which	O
acts	O
as	O
an	O
accessory	O
receptor	O
for	O
the	O
transforming	O
growth	O
factor	O
-	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
superfamily	O
,	O
and	O
is	O
crucial	O
for	O
maintaining	O
vascular	O
integrity	O
.	O

A	O
6	O
-	O
base	O
insertion	O
in	O
intron	O
7	O
(	O
6bINS	O
)	O
of	O
ENG	O
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
microvascular	O
disturbance	O
.	O

OBJECTIVES	O
:	O
Our	O
objective	O
was	O
to	O
investigate	O
the	O
relationship	O
between	O
6bINS	O
and	O
the	O
vascular	B-Disease
complication	I-Disease
pulmonary	I-Disease
arterial	I-Disease
hypertension	I-Disease
(	O
PAH	B-Disease
)	O
in	O
SSc	B-Disease
in	O
a	O
French	O
Caucasian	O
population	O
.	O

METHODS	O
:	O
Two	O
hundred	O
eighty	O
SSc	B-Disease
cases	O
containing	O
29	O
/	O
280	O
having	O
PAH	B-Disease
diagnosed	O
by	O
catheterism	O
were	O
compared	O
with	O
140	O
patients	O
with	O
osteoarthritis	B-Disease
.	O

Genotyping	O
was	O
performed	O
by	O
polymerase	O
-	O
chain	O
-	O
reaction	O
-	O
based	O
fluorescence	O
and	O
direct	O
sequencing	O
of	O
genomic	O
DNA	O
.	O

RESULTS	O
:	O
The	O
polymorphism	O
was	O
in	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
.	O

We	O
observed	O
a	O
significant	O
lower	O
frequency	O
of	O
6bINS	O
allele	O
in	O
SSc	B-Disease
patients	O
with	O
associated	O
PAH	B-Disease
compared	O
with	O
controls	O
[	O
10	O
.	O
3	O
vs	O
23	O
.	O
9	O
%,	O
P	O
=	O
0	O
.	O
1	O
;	O
odds	O
ratio	O
(	O
OR	O
)	O
0	O
.	O
37	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
0	O
.	O
15	O
-	O
0	O
.	O
89	O
],	O
and	O
a	O
trend	O
in	O
comparison	O
with	O
SSc	B-Disease
patients	O
without	O
PAH	B-Disease
(	O
10	O
.	O
3	O
vs	O
20	O
.	O
3	O
%,	O
P	O
=	O
0	O
.	O
5	O
;	O
OR	O
:	O
0	O
.	O
45	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
19	O
-	O
1	O
.	O
8	O
).	O

Genotypes	O
carrying	O
allele	O
6bINS	O
were	O
also	O
less	O
frequent	O
in	O
SSc	B-Disease
patients	O
with	O
PAH	B-Disease
than	O
in	O
controls	O
(	O
20	O
.	O
7	O
vs	O
42	O
.	O
9	O
%,	O
P	O
=	O
0	O
.	O
2	O
).	O

CONCLUSIONS	O
:	O
Thus	O
the	O
frequency	O
of	O
6bINS	O
differs	O
between	O
SSc	B-Disease
patients	O
with	O
or	O
without	O
PAH	B-Disease
,	O
suggesting	O
the	O
implication	O
of	O
ENG	O
in	O
this	O
devastating	O
vascular	B-Disease
complication	I-Disease
of	O
SSc	B-Disease
.	O


Assessment	O
of	O
a	O
new	O
non	O
-	O
invasive	O
index	O
of	O
cardiac	O
performance	O
for	O
detection	O
of	O
dobutamine	O
-	O
induced	O
myocardial	B-Disease
ischemia	I-Disease
.	O

BACKGROUND	O
:	O
Electrocardiography	O
has	O
a	O
very	O
low	O
sensitivity	O
in	O
detecting	O
dobutamine	O
-	O
induced	O
myocardial	B-Disease
ischemia	I-Disease
.	O

OBJECTIVES	O
:	O
To	O
assess	O
the	O
added	O
diagnostic	O
value	O
of	O
a	O
new	O
cardiac	O
performance	O
index	O
(	O
dP	O
/	O
dtejc	O
)	O
measurement	O
,	O
based	O
on	O
brachial	O
artery	O
flow	O
changes	O
,	O
as	O
compared	O
to	O
standard	O
12	O
-	O
lead	O
ECG	O
,	O
for	O
detecting	O
dobutamine	O
-	O
induced	O
myocardial	B-Disease
ischemia	I-Disease
,	O
using	O
Tc99m	O
-	O
Sestamibi	O
single	O
-	O
photon	O
emission	O
computed	O
tomography	O
as	O
the	O
gold	O
standard	O
of	O
comparison	O
to	O
assess	O
the	O
presence	O
or	O
absence	O
of	O
ischemia	B-Disease
.	O

METHODS	O
:	O
The	O
study	O
group	O
comprised	O
40	O
patients	O
undergoing	O
Sestamibi	O
-	O
SPECT	O
/	O
dobutamine	O
stress	O
test	O
.	O

Simultaneous	O
measurements	O
of	O
ECG	O
and	O
brachial	O
artery	O
dP	O
/	O
dtejc	O
were	O
performed	O
at	O
each	O
dobutamine	O
level	O
.	O

In	O
19	O
of	O
the	O
40	O
patients	O
perfusion	O
defects	O
compatible	O
with	O
ischemia	B-Disease
were	O
detected	O
on	O
SPECT	O
.	O

The	O
increase	O
in	O
dP	O
/	O
dtejc	O
during	O
infusion	O
of	O
dobutamine	O
in	O
this	O
group	O
was	O
severely	O
impaired	O
as	O
compared	O
to	O
the	O
non	O
-	O
ischemic	O
group	O
.	O

dP	O
/	O
dtejc	O
outcome	O
was	O
combined	O
with	O
the	O
ECG	O
results	O
,	O
giving	O
an	O
ECG	O
-	O
enhanced	O
value	O
,	O
and	O
compared	O
to	O
ECG	O
alone	O
.	O

RESULTS	O
:	O
The	O
sensitivity	O
improved	O
dramatically	O
from	O
16	O
%	O
to	O
79	O
%,	O
positive	O
predictive	O
value	O
increased	O
from	O
60	O
%	O
to	O
68	O
%	O
and	O
negative	O
predictive	O
value	O
from	O
54	O
%	O
to	O
78	O
%,	O
and	O
specificity	O
decreased	O
from	O
90	O
%	O
to	O
67	O
%.	O

CONCLUSIONS	O
:	O
If	O
ECG	O
alone	O
is	O
used	O
for	O
specificity	O
,	O
the	O
combination	O
with	O
dP	O
/	O
dtejc	O
improved	O
the	O
sensitivity	O
of	O
the	O
test	O
and	O
could	O
be	O
a	O
cost	O
-	O
savings	O
alternative	O
to	O
cardiac	O
imaging	O
or	O
perfusion	O
studies	O
to	O
detect	O
myocardial	B-Disease
ischemia	I-Disease
,	O
especially	O
in	O
patients	O
unable	O
to	O
exercise	O
.	O


Effects	O
of	O
common	O
germline	O
genetic	O
variation	O
in	O
cell	O
cycle	O
control	O
genes	O
on	O
breast	B-Disease
cancer	I-Disease
survival	O
:	O
results	O
from	O
a	O
population	O
-	O
based	O
cohort	O
.	O

INTRODUCTION	O
:	O
Somatic	O
alterations	O
have	O
been	O
shown	O
to	O
correlate	O
with	O
breast	B-Disease
cancer	I-Disease
prognosis	O
and	O
survival	O
,	O
but	O
less	O
is	O
known	O
about	O
the	O
effects	O
of	O
common	O
inherited	O
genetic	O
variation	O
.	O

Of	O
particular	O
interest	O
are	O
genes	O
involved	O
in	O
cell	O
cycle	O
pathways	O
,	O
which	O
regulate	O
cell	O
division	O
.	O

METHODS	O
:	O
We	O
examined	O
associations	O
between	O
common	O
germline	O
genetic	O
variation	O
in	O
13	O
genes	O
involved	O
in	O
cell	O
cycle	O
control	O
(	O
CCND1	O
,	O
CCND2	O
,	O
CCND3	O
,	O
CCNE1	O
,	O
CDK2	O
[	O
p33	O
],	O
CDK4	O
,	O
CDK6	O
,	O
CDKN1A	O
[	O
p21	O
,	O
Cip1	O
],	O
CDKN1B	O
[	O
p27	O
,	O
Kip1	O
],	O
CDKN2A	O
[	O
p16	O
],	O
CDKN2B	O
[	O
p15	O
],	O
CDKN2C	O
[	O
p18	O
],	O
and	O
CDKN2D	O
[	O
p19	O
])	O
and	O
survival	O
among	O
women	O
diagnosed	O
with	O
invasive	B-Disease
breast	I-Disease
cancer	I-Disease
participating	O
in	O
the	O
SEARCH	O
(	O
Studies	O
of	O
Epidemiology	O
and	O
Risk	O
factors	O
in	O
Cancer	O
Heredity	O
)	O
breast	B-Disease
cancer	I-Disease
study	O
.	O

DNA	O
from	O
up	O
to	O
4	O
,	O
470	O
women	O
was	O
genotyped	O
for	O
85	O
polymorphisms	O
that	O
tag	O
the	O
known	O
common	O
polymorphisms	O
(	O
minor	O
allele	O
frequency	O
>	O
0	O
.	O
5	O
)	O
in	O
the	O
genes	O
.	O

The	O
genotypes	O
of	O
each	O
polymorphism	O
were	O
tested	O
for	O
association	O
with	O
survival	O
using	O
Cox	O
regression	O
analysis	O
.	O

RESULTS	O
:	O
The	O
rare	O
allele	O
of	O
the	O
tagging	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
rs2479717	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
death	B-Disease
(	O
hazard	O
ratio	O
=	O
1	O
.	O
26	O
per	O
rare	O
allele	O
carried	O
,	O
95	O
%	O
confidence	O
interval	O
:	O
1	O
.	O
12	O
to	O
1	O
.	O
42	O
;	O
P	O
=	O
0	O
.	O
1	O
),	O
which	O
was	O
not	O
attenuated	O
after	O
adjusting	O
for	O
tumour	B-Disease
stage	O
,	O
grade	O
,	O
and	O
treatment	O
.	O

This	O
SNP	O
is	O
part	O
of	O
a	O
large	O
linkage	O
disequilibrium	O
block	O
,	O
which	O
contains	O
CCND3	O
,	O
BYSL	O
,	O
TRFP	O
,	O
USP49	O
,	O
C6ofr49	O
,	O
FRS3	O
,	O
and	O
PGC	O
.	O

We	O
evaluated	O
the	O
association	O
of	O
survival	O
and	O
somatic	O
expression	O
of	O
these	O
genes	O
in	O
breast	B-Disease
tumours	I-Disease
using	O
expression	O
microarray	O
data	O
from	O
seven	O
published	O
datasets	O
.	O

Elevated	O
expression	O
of	O
the	O
C6orf49	O
transcript	O
was	O
associated	O
with	O
breast	B-Disease
cancer	I-Disease
survival	O
,	O
adding	O
biological	O
interest	O
to	O
the	O
finding	O
.	O

CONCLUSION	O
:	O
It	O
is	O
possible	O
that	O
CCND3	O
rs2479717	O
,	O
or	O
another	O
variant	O
it	O
tags	O
,	O
is	O
associated	O
with	O
prognosis	O
after	O
a	O
diagnosis	O
of	O
breast	B-Disease
cancer	I-Disease
.	O

Further	O
study	O
is	O
required	O
to	O
validate	O
this	O
finding	O
.	O


Upregulation	O
of	O
centrosomal	O
protein	O
55	O
is	O
associated	O
with	O
unfavorable	O
prognosis	O
and	O
tumor	B-Disease
invasion	O
in	O
epithelial	B-Disease
ovarian	I-Disease
carcinoma	I-Disease
.	O

Centrosomal	O
protein	O
55	O
(	O
CEP55	O
)	O
is	O
a	O
cell	O
cycle	O
regulator	O
implicated	O
in	O
development	O
of	O
certain	O
cancers	B-Disease
.	O

However	O
,	O
characteristics	O
of	O
CEP55	O
expression	O
and	O
its	O
clinical	O
/	O
prognostic	O
significance	O
are	O
unclear	O
in	O
human	O
epithelial	B-Disease
ovarian	I-Disease
carcinoma	I-Disease
(	O
EOC	B-Disease
).	O

Therefore	O
,	O
we	O
investigated	O
the	O
expression	O
and	O
clinicopathological	O
significance	O
of	O
CEP55	O
in	O
patients	O
with	O
EOC	B-Disease
and	O
its	O
role	O
in	O
regulating	O
invasion	O
and	O
metastasis	B-Disease
of	I-Disease
ovarian	I-Disease
cell	O
lines	O
.	O

CEP55	O
mRNA	O
and	O
protein	O
expression	O
levels	O
were	O
detected	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
(	O
qRT	O
-	O
PCR	O
),	O
Western	O
blotting	O
,	O
and	O
immunohistochemistry	O
(	O
IHC	O
).	O

Potential	O
associations	O
of	O
CEP55	O
expression	O
scores	O
with	O
clinical	O
parameters	O
and	O
patient	O
survival	O
were	O
evaluated	O
.	O

CEP55	O
function	O
was	O
investigated	O
further	O
using	O
RNA	O
interference	O
,	O
wound	O
healing	O
assay	O
,	O
transwell	O
assay	O
,	O
immunofluorescence	O
analysis	O
,	O
qRT	O
-	O
PCR	O
,	O
and	O
Western	O
blotting	O
.	O

CEP55	O
was	O
significantly	O
upregulated	O
in	O
ovarian	B-Disease
cancer	I-Disease
cell	O
lines	O
and	O
lesions	O
compared	O
with	O
normal	O
cells	O
and	O
adjacent	O
noncancerous	O
ovarian	O
tissues	O
.	O

In	O
the	O
213	O
EOC	B-Disease
samples	O
,	O
CEP55	O
protein	O
levels	O
were	O
positively	O
correlated	O
with	O
clinical	O
stage	O
(	O
P	O
<	O
0	O
.	O
1	O
),	O
lymph	B-Disease
node	I-Disease
metastasis	I-Disease
(	O
P	O
<	O
0	O
.	O
1	O
),	O
intraperitoneal	B-Disease
metastasis	I-Disease
(	O
P	O
<	O
0	O
.	O
1	O
),	O
tumor	B-Disease
recurrence	O
(	O
P	O
<	O
0	O
.	O
1	O
),	O
differentiation	O
grade	O
(	O
P	O
<	O
0	O
.	O
1	O
),	O
residual	O
tumor	B-Disease
size	O
(	O
P	O
<	O
0	O
.	O
1	O
),	O
ascites	B-Disease
see	O
tumor	B-Disease
cells	O
(	O
P	O
=	O
0	O
.	O
20	O
),	O
and	O
serum	O
CA153	O
level	O
(	O
P	O
<	O
0	O
.	O
1	O
).	O

Moreover	O
,	O
patients	O
with	O
aberrant	O
CEP55	O
protein	O
expression	O
showed	O
tendencies	O
to	O
receive	O
neoadjuvant	O
chemotherapy	O
(	O
P	O
<	O
0	O
.	O
1	O
)	O
and	O
cytoreductive	O
surgery	O
(	O
P	O
=	O
0	O
.	O
20	O
).	O

By	O
contrast	O
,	O
no	O
significant	O
correlation	O
was	O
detected	O
between	O
the	O
protein	O
levels	O
and	O
patient	O
age	O
,	O
histological	O
type	O
,	O
or	O
serum	O
CA125	O
,	O
CA199	O
,	O
CA724	O
,	O
NSE	O
,	O
CEA	O
,	O
and	O
b	O
-	O
HCG	O
levels	O
.	O

Patients	O
with	O
high	O
CEP55	O
protein	O
expression	O
had	O
shorter	O
overall	O
survival	O
and	O
disease	O
-	O
free	O
survival	O
compared	O
with	O
those	O
with	O
low	O
CEP55	O
expression	O
.	O

Multivariate	O
analysis	O
implicated	O
CEP55	O
as	O
an	O
independent	O
prognostic	O
indicator	O
for	O
EOC	B-Disease
patients	O
.	O

Additionally	O
,	O
downregulation	O
of	O
CEP55	O
in	O
ovarian	B-Disease
cancer	I-Disease
cells	O
remarkably	O
inhibited	O
cellular	O
motility	O
and	O
invasion	O
.	O

Aberrant	O
CEP55	O
expression	O
may	O
predict	O
unfavorable	O
clinical	O
outcomes	O
in	O
EOC	B-Disease
patients	O
and	O
play	O
an	O
important	O
role	O
in	O
regulating	O
invasion	O
in	O
ovarian	B-Disease
cancer	I-Disease
cells	O
.	O

Thus	O
,	O
CEP55	O
may	O
serve	O
as	O
a	O
prognostic	O
marker	O
and	O
therapeutic	O
target	O
for	O
EOC	B-Disease
.	O


Male	O
11b	O
-	O
HSD1	O
Knockout	O
Mice	O
Fed	O
Trans	O
-	O
Fats	O
and	O
Fructose	O
Are	O
Not	O
Protected	O
From	O
Metabolic	B-Disease
Syndrome	I-Disease
or	O
Nonalcoholic	B-Disease
Fatty	I-Disease
Liver	I-Disease
Disease	I-Disease
.	O

Nonalcoholic	B-Disease
fatty	I-Disease
liver	I-Disease
disease	I-Disease
(	O
NAFLD	B-Disease
)	O
defines	O
a	O
spectrum	O
of	O
conditions	O
from	O
simple	O
steatosis	B-Disease
to	O
nonalcoholic	B-Disease
steatohepatitis	I-Disease
(	O
NASH	B-Disease
)	O
and	O
cirrhosis	B-Disease
and	O
is	O
regarded	O
as	O
the	O
hepatic	O
manifestation	O
of	O
the	O
metabolic	B-Disease
syndrome	I-Disease
.	O

Glucocorticoids	O
can	O
promote	O
steatosis	B-Disease
by	O
stimulating	O
lipolysis	O
within	O
adipose	O
tissue	O
,	O
free	O
fatty	O
acid	O
delivery	O
to	O
liver	O
and	O
hepatic	O
de	O
novo	O
lipogenesis	O
.	O

Glucocorticoids	O
can	O
be	O
reactivated	O
in	O
liver	O
through	O
11b	O
-	O
hydroxysteroid	O
dehydrogenase	O
type	O
1	O
(	O
11b	O
-	O
HSD1	O
)	O
enzyme	O
activity	O
.	O

Inhibition	O
of	O
11b	O
-	O
HSD1	O
has	O
been	O
suggested	O
as	O
a	O
potential	O
treatment	O
for	O
NAFLD	B-Disease
.	O

To	O
test	O
this	O
,	O
male	O
mice	O
with	O
global	O
(	O
11b	O
-	O
HSD1	O
knockout	O
[	O
KO	O
])	O
and	O
liver	O
-	O
specific	O
(	O
LKO	O
)	O
11b	O
-	O
HSD1	O
loss	O
of	O
function	O
were	O
fed	O
the	O
American	O
Lifestyle	O
Induced	O
Obesity	O
Syndrome	O
(	O
ALIOS	O
)	O
diet	O
,	O
known	O
to	O
recapitulate	O
the	O
spectrum	O
of	O
NAFLD	B-Disease
,	O
and	O
metabolic	O
and	O
liver	O
phenotypes	O
assessed	O
.	O

Body	O
weight	O
,	O
muscle	O
and	O
adipose	O
tissue	O
masses	O
,	O
and	O
parameters	O
of	O
glucose	O
homeostasis	O
showed	O
that	O
11b	O
-	O
HSD1KO	O
and	O
LKO	O
mice	O
were	O
not	O
protected	O
from	O
systemic	O
metabolic	B-Disease
disease	I-Disease
.	O

Evaluation	O
of	O
hepatic	O
histology	O
,	O
triglyceride	O
content	O
,	O
and	O
blinded	O
NAFLD	B-Disease
activity	O
score	O
assessment	O
indicated	O
that	O
levels	O
of	O
steatosis	B-Disease
were	O
similar	O
between	O
11b	O
-	O
HSD1KO	O
,	O
LKO	O
,	O
and	O
control	O
mice	O
.	O

Unexpectedly	O
,	O
histological	O
analysis	O
revealed	O
significantly	O
increased	O
levels	O
of	O
immune	O
foci	O
present	O
in	O
livers	O
of	O
11b	O
-	O
HSD1KO	O
but	O
not	O
LKO	O
or	O
control	O
mice	O
,	O
suggestive	O
of	O
a	O
transition	O
to	O
NASH	B-Disease
.	O

This	O
was	O
endorsed	O
by	O
elevated	O
hepatic	O
expression	O
of	O
key	O
immune	O
cell	O
and	O
inflammatory	B-Disease
markers	O
.	O

These	O
data	O
indicate	O
that	O
11b	O
-	O
HSD1	O
-	O
deficient	O
mice	O
are	O
not	O
protected	O
from	O
metabolic	B-Disease
disease	I-Disease
or	O
hepatosteatosis	B-Disease
in	O
the	O
face	O
of	O
a	O
NAFLD	B-Disease
-	O
inducing	O
diet	O
.	O

However	O
,	O
global	O
deficiency	O
of	O
11b	O
-	O
HSD1	O
did	O
increase	O
markers	O
of	O
hepatic	B-Disease
inflammation	I-Disease
and	O
suggests	O
a	O
critical	O
role	O
for	O
11b	O
-	O
HSD1	O
in	O
restraining	O
the	O
transition	O
to	O
NASH	B-Disease
.	O


Single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
of	O
the	O
FMR1	O
gene	O
in	O
autistic	B-Disease
and	O
mentally	B-Disease
retarded	I-Disease
children	O
in	O
Japan	O
.	O

Fragile	B-Disease
X	I-Disease
syndrome	I-Disease
is	O
one	O
of	O
the	O
most	O
common	O
causes	O
of	O
mental	B-Disease
retardation	I-Disease
in	O
males	O
,	O
and	O
patients	O
with	O
fragile	B-Disease
X	I-Disease
syndrome	I-Disease
occasionally	O
develop	O
autism	B-Disease
.	O

It	O
is	O
usually	O
caused	O
by	O
an	O
expansion	O
of	O
the	O
trinucleotide	O
repeat	O
in	O
the	O
5	O
'-	O
untranslated	O
region	O
of	O
the	O
FMR1	O
gene	O
,	O
but	O
in	O
a	O
small	O
number	O
of	O
patients	O
deletions	O
and	O
point	O
mutations	O
have	O
been	O
identified	O
.	O

We	O
screened	O
all	O
17	O
exons	O
of	O
the	O
FMR1	O
gene	O
for	O
mutations	O
in	O
90	O
autistic	B-Disease
or	O
mentally	B-Disease
retarded	I-Disease
children	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)-	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
.	O

No	O
mutations	O
were	O
found	O
in	O
76	O
male	O
patients	O
.	O

However	O
,	O
one	O
female	O
patient	O
was	O
heterozygous	O
for	O
a	O
normal	O
allele	O
and	O
a	O
mutant	O
allele	O
with	O
an	O
A	O
to	O
C	O
substitution	O
at	O
nucleotide	O
879	O
in	O
exon	O
9	O
.	O

This	O
mutation	O
was	O
not	O
found	O
in	O
50	O
controls	O
.	O

Reverse	O
transcription	O
-	O
PCR	O
revealed	O
that	O
a	O
large	O
proportion	O
of	O
the	O
mutant	O
transcripts	O
were	O
spliced	O
aberrantly	O
,	O
causing	O
premature	O
termination	O
of	O
the	O
protein	O
synthesis	O
.	O

Although	O
uncommon	O
,	O
point	O
mutations	O
in	O
the	O
FMR1	O
gene	O
may	O
be	O
a	O
cause	O
of	O
autism	B-Disease
and	O
mental	B-Disease
retardation	I-Disease
in	O
Japanese	O
patients	O
.	O


Pheochromocytoma	B-Disease
unmasked	O
by	O
amisulpride	O
and	O
tiapride	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
the	O
unmasking	O
of	O
pheochromocytoma	B-Disease
in	O
a	O
patient	O
treated	O
with	O
amisulpride	O
and	O
tiapride	O
.	O

CASE	O
SUMMARY	O
:	O
A	O
42	O
-	O
year	O
-	O
old	O
white	O
man	O
developed	O
acute	O
hypertension	B-Disease
with	O
severe	O
headache	B-Disease
and	O
vomiting	B-Disease
2	O
hours	O
after	O
the	O
first	O
doses	O
of	O
amisulpride	O
100	O
mg	O
and	O
tiapride	O
100	O
mg	O
.	O

Both	O
drugs	O
were	O
immediately	O
discontinued	O
,	O
and	O
the	O
patient	O
recovered	O
after	O
subsequent	O
nicardipine	O
and	O
verapamil	O
treatment	O
.	O

Abdominal	O
ultrasound	O
showed	O
an	O
adrenal	O
mass	O
,	O
and	O
postoperative	O
histologic	O
examination	O
confirmed	O
the	O
diagnosis	O
of	O
pheochromocytoma	B-Disease
.	O

DISCUSSION	O
:	O
Drug	O
-	O
induced	O
symptoms	O
of	O
pheochromocytoma	B-Disease
are	O
often	O
associated	O
with	O
the	O
use	O
of	O
substituted	O
benzamide	O
drugs	O
,	O
but	O
the	O
underlying	O
mechanism	O
is	O
unknown	O
.	O

In	O
our	O
case	O
,	O
use	O
of	O
the	O
Naranjo	O
probability	O
scale	O
indicated	O
a	O
possible	O
relationship	O
between	O
the	O
hypertensive	B-Disease
crisis	O
and	O
amisulpride	O
and	O
tiapride	O
therapy	O
.	O

CONCLUSIONS	O
:	O
As	O
of	O
March	O
24	O
,	O
2005	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
amisulpride	O
-	O
and	O
tiapride	O
-	O
induced	O
hypertensive	B-Disease
crisis	O
in	O
a	O
patient	O
with	O
pheochromocytoma	B-Disease
.	O

Physicians	O
and	O
other	O
healthcare	O
professionals	O
should	O
be	O
aware	O
of	O
this	O
potential	O
adverse	O
effect	O
of	O
tiapride	O
and	O
amisulpride	O
.	O


Phenylephrine	O
but	O
not	O
ephedrine	O
reduces	O
frontal	O
lobe	O
oxygenation	O
following	O
anesthesia	O
-	O
induced	O
hypotension	B-Disease
.	O

BACKGROUND	O
:	O
Vasopressor	O
agents	O
are	O
used	O
to	O
correct	O
anesthesia	O
-	O
induced	O
hypotension	B-Disease
.	O

We	O
describe	O
the	O
effect	O
of	O
phenylephrine	O
and	O
ephedrine	O
on	O
frontal	O
lobe	O
oxygenation	O
(	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
))	O
following	O
anesthesia	O
-	O
induced	O
hypotension	B-Disease
.	O

METHODS	O
:	O
Following	O
induction	O
of	O
anesthesia	O
by	O
fentanyl	O
(	O
0	O
.	O
15	O
mg	O
kg	O
(-	O
1	O
))	O
and	O
propofol	O
(	O
2	O
.	O
0	O
mg	O
kg	O
(-	O
1	O
)),	O
13	O
patients	O
received	O
phenylephrine	O
(	O
0	O
.	O
1	O
mg	O
iv	O
)	O
and	O
12	O
patients	O
received	O
ephedrine	O
(	O
10	O
mg	O
iv	O
)	O
to	O
restore	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
).	O

Heart	O
rate	O
(	O
HR	O
),	O
MAP	O
,	O
stroke	B-Disease
volume	O
(	O
SV	O
),	O
cardiac	O
output	O
(	O
CO	O
),	O
and	O
frontal	O
lobe	O
oxygenation	O
(	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
))	O
were	O
registered	O
.	O

RESULTS	O
:	O
Induction	O
of	O
anesthesia	O
was	O
followed	O
by	O
a	O
decrease	O
in	O
MAP	O
,	O
HR	O
,	O
SV	O
,	O
and	O
CO	O
concomitant	O
with	O
an	O
elevation	O
in	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
).	O

After	O
administration	O
of	O
phenylephrine	O
,	O
MAP	O
increased	O
(	O
51	O
+/-	O
12	O
to	O
81	O
+/-	O
13	O
mmHg	O
;	O
P	O
<	O
0	O
.	O
1	O
;	O
mean	O
+/-	O
SD	O
).	O

However	O
,	O
a	O
14	O
%	O
(	O
from	O
70	O
+/-	O
8	O
%	O
to	O
60	O
+/-	O
7	O
%)	O
reduction	O
in	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
(	O
P	O
<	O
0	O
.	O
5	O
)	O
followed	O
with	O
no	O
change	O
in	O
CO	O
(	O
3	O
.	O
7	O
+/-	O
1	O
.	O
1	O
to	O
3	O
.	O
4	O
+/-	O
0	O
.	O
9	O
l	O
min	O
(-	O
1	O
)).	O

The	O
administration	O
of	O
ephedrine	O
led	O
to	O
a	O
similar	O
increase	O
in	O
MAP	O
(	O
53	O
+/-	O
9	O
to	O
79	O
+/-	O
8	O
mmHg	O
;	O
P	O
<	O
0	O
.	O
1	O
),	O
restored	O
CO	O
(	O
3	O
.	O
2	O
+/-	O
1	O
.	O
2	O
to	O
5	O
.	O
0	O
+/-	O
1	O
.	O
3	O
l	O
min	O
(-	O
1	O
)),	O
and	O
preserved	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
).	O

CONCLUSIONS	O
:	O
The	O
utilization	O
of	O
phenylephrine	O
to	O
correct	O
hypotension	B-Disease
induced	O
by	O
anesthesia	O
has	O
a	O
negative	O
impact	O
on	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
while	O
ephedrine	O
maintains	O
frontal	O
lobe	O
oxygenation	O
potentially	O
related	O
to	O
an	O
increase	O
in	O
CO	O
.	O


Somatic	O
and	O
gonadal	O
mosaicism	O
in	O
X	B-Disease
-	I-Disease
linked	I-Disease
retinitis	I-Disease
pigmentosa	I-Disease
.	O

The	O
g	O
.	O
ORF15	O
+	O
652	O
-	O
653delAG	O
mutation	O
in	O
the	O
RPGR	O
gene	O
is	O
the	O
most	O
frequent	O
mutation	O
in	O
X	B-Disease
-	I-Disease
linked	I-Disease
retinitis	I-Disease
pigmentosa	I-Disease
(	O
XLRP	B-Disease
).	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
possibility	O
of	O
mosaicism	O
in	O
an	O
XLRP	B-Disease
family	O
.	O

Eight	O
subjects	O
in	O
the	O
RP	B-Disease
family	O
were	O
recruited	O
.	O

Blood	O
samples	O
were	O
collected	O
for	O
DNA	O
extraction	O
.	O

Haplotype	O
analysis	O
and	O
mutational	O
screening	O
on	O
the	O
RPGR	O
gene	O
were	O
performed	O
.	O

Additionally	O
,	O
samples	O
of	O
hair	O
follicles	O
and	O
buccal	O
cells	O
from	O
the	O
mother	O
of	O
the	O
proband	O
were	O
acquired	O
for	O
DNA	O
extraction	O
and	O
molecular	O
analysis	O
.	O

Phenotype	O
was	O
characterized	O
with	O
routine	O
ophthalmic	O
examination	O
,	O
Goldmann	O
perimetry	O
,	O
electroretinography	O
,	O
and	O
color	O
fundus	O
photography	O
.	O

A	O
g	O
.	O
ORF15	O
+	O
652	O
-	O
653delAG	O
mutation	O
was	O
identified	O
in	O
second	O
-	O
and	O
third	O
-	O
generation	O
patients	O
/	O
carriers	O
.	O

A	O
first	O
-	O
generation	O
female	O
,	O
who	O
was	O
considered	O
to	O
be	O
an	O
obligate	O
carrier	O
,	O
demonstrated	O
a	O
normal	O
phenotype	O
as	O
well	O
as	O
a	O
normal	O
genotype	O
in	O
lymphocytic	O
DNA	O
,	O
indicating	O
the	O
gonadal	O
mosaicism	O
;	O
however	O
,	O
a	O
heterozygous	O
AG	O
-	O
deletion	O
at	O
nucleotide	O
652	O
and	O
653	O
was	O
identified	O
in	O
the	O
genomic	O
DNA	O
of	O
hair	O
follicles	O
,	O
hair	O
shaft	O
,	O
and	O
buccal	O
cells	O
,	O
indicating	O
that	O
the	O
mutation	O
is	O
somatic	O
.	O

In	O
conclusion	O
,	O
we	O
reported	O
on	O
a	O
family	O
in	O
which	O
an	O
asymptomatic	O
woman	O
with	O
somatic	O
-	O
gonadal	O
mosaicism	O
for	O
a	O
RPGR	O
gene	O
mutation	O
transmitted	O
the	O
mutation	O
to	O
an	O
asymptomatic	O
daughter	O
and	O
to	O
a	O
son	O
with	O
XLRP	B-Disease
.	O

Gonadal	O
mosaicism	O
may	O
be	O
responsible	O
for	O
a	O
proportion	O
of	O
multiplex	O
or	O
simplex	O
RP	B-Disease
families	O
,	O
in	O
which	O
more	O
than	O
50	O
%	O
of	O
all	O
cases	O
of	O
RP	B-Disease
are	O
found	O
.	O

(	O
c	O
)	O
2007	O
Wiley	O
-	O
Liss	O
,	O
Inc	O
.	O


Complete	B-Disease
atrioventricular	I-Disease
block	I-Disease
secondary	O
to	O
lithium	O
therapy	O
.	O

Sinus	B-Disease
node	I-Disease
dysfunction	I-Disease
has	O
been	O
reported	O
most	O
frequently	O
among	O
the	O
adverse	B-Disease
cardiovascular	I-Disease
effects	I-Disease
of	O
lithium	O
.	O

In	O
the	O
present	O
case	O
,	O
complete	B-Disease
atrioventricular	I-Disease
(	I-Disease
AV	I-Disease
)	I-Disease
block	I-Disease
with	O
syncopal	B-Disease
attacks	I-Disease
developed	O
secondary	O
to	O
lithium	O
therapy	O
,	O
necessitating	O
permanent	O
pacemaker	O
implantation	O
.	O

Serum	O
lithium	O
levels	O
remained	O
under	O
or	O
within	O
the	O
therapeutic	O
range	O
during	O
the	O
syncopal	B-Disease
attacks	I-Disease
.	O

Lithium	O
should	O
be	O
used	O
with	O
extreme	O
caution	O
,	O
especially	O
in	O
patients	O
with	O
mild	O
disturbance	O
of	O
AV	O
conduction	O
.	O


Organophosphate	O
-	O
induced	O
convulsions	B-Disease
and	O
prevention	O
of	O
neuropathological	B-Disease
damages	I-Disease
.	O

Such	O
organophosphorus	O
(	O
OP	O
)	O
compounds	O
as	O
diisopropylfluorophosphate	O
(	O
DFP	O
),	O
sarin	O
and	O
soman	O
are	O
potent	O
inhibitors	O
of	O
acetylcholinesterases	O
(	O
AChEs	O
)	O
and	O
butyrylcholinesterases	O
(	O
BChEs	O
).	O

The	O
acute	O
toxicity	B-Disease
of	O
OPs	O
is	O
the	O
result	O
of	O
their	O
irreversible	O
binding	O
with	O
AChEs	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
),	O
which	O
elevates	O
acetylcholine	O
(	O
ACh	O
)	O
levels	O
.	O

The	O
protective	O
action	O
of	O
subcutaneously	O
(	O
SC	O
)	O
administered	O
antidotes	O
or	O
their	O
combinations	O
in	O
DFP	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
intoxication	O
was	O
studied	O
in	O
9	O
-	O
10	O
-	O
weeks	O
-	O
old	O
Han	O
-	O
Wistar	O
male	O
rats	O
.	O

The	O
rats	O
received	O
AChE	O
reactivator	O
pralidoxime	O
-	O
2	O
-	O
chloride	O
(	O
2PAM	O
)	O
(	O
30	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
),	O
anticonvulsant	O
diazepam	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
),	O
A	O
(	O
1	O
)-	O
adenosine	O
receptor	O
agonist	O
N	O
(	O
6	O
)-	O
cyclopentyl	O
adenosine	O
(	O
CPA	O
)	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
),	O
NMDA	O
-	O
receptor	O
antagonist	O
dizocilpine	O
maleate	O
(+-	O
MK801	O
hydrogen	O
maleate	O
)	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
or	O
their	O
combinations	O
with	O
cholinolytic	O
drug	O
atropine	O
sulfate	O
(	O
50	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
immediately	O
or	O
30	O
min	O
after	O
the	O
single	O
SC	O
injection	O
of	O
DFP	O
.	O

The	O
control	O
rats	O
received	O
atropine	O
sulfate	O
,	O
but	O
also	O
saline	O
and	O
olive	O
oil	O
instead	O
of	O
other	O
antidotes	O
and	O
DFP	O
,	O
respectively	O
.	O

All	O
rats	O
were	O
terminated	O
either	O
24	O
h	O
or	O
3	O
weeks	O
after	O
the	O
DFP	O
injection	O
.	O

The	O
rats	O
treated	O
with	O
DFP	O
-	O
atropine	O
showed	O
severe	O
typical	O
OP	O
-	O
induced	O
toxicity	B-Disease
signs	O
.	O

When	O
CPA	O
,	O
diazepam	O
or	O
2PAM	O
was	O
given	O
immediately	O
after	O
DFP	O
-	O
atropine	O
,	O
these	O
treatments	O
prevented	O
,	O
delayed	O
or	O
shortened	O
the	O
occurrence	O
of	O
serious	O
signs	O
of	O
poisoning	B-Disease
.	O

Atropine	O
-	O
MK801	O
did	O
not	O
offer	O
any	O
additional	O
protection	O
against	O
DFP	O
toxicity	B-Disease
.	O

In	O
conclusion	O
,	O
CPA	O
,	O
diazepam	O
and	O
2PAM	O
in	O
combination	O
with	O
atropine	O
prevented	O
the	O
occurrence	O
of	O
serious	O
signs	O
of	O
poisoning	B-Disease
and	O
thus	O
reduced	O
the	O
toxicity	B-Disease
of	O
DFP	O
in	O
rat	O
.	O


The	O
activation	O
of	O
spinal	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
receptors	O
may	O
contribute	O
to	O
degeneration	O
of	O
spinal	O
motor	O
neurons	O
induced	O
by	O
neuraxial	O
morphine	O
after	O
a	O
noninjurious	O
interval	O
of	O
spinal	B-Disease
cord	I-Disease
ischemia	I-Disease
.	O

We	O
investigated	O
the	O
relationship	O
between	O
the	O
degeneration	O
of	O
spinal	O
motor	O
neurons	O
and	O
activation	O
of	O
N	O
-	O
methyl	O
-	O
d	O
-	O
aspartate	O
(	O
NMDA	O
)	O
receptors	O
after	O
neuraxial	O
morphine	O
following	O
a	O
noninjurious	O
interval	O
of	O
aortic	B-Disease
occlusion	I-Disease
in	O
rats	O
.	O

Spinal	B-Disease
cord	I-Disease
ischemia	I-Disease
was	O
induced	O
by	O
aortic	B-Disease
occlusion	I-Disease
for	O
6	O
min	O
with	O
a	O
balloon	O
catheter	O
.	O

In	O
a	O
microdialysis	O
study	O
,	O
10	O
muL	O
of	O
saline	O
(	O
group	O
C	O
;	O
n	O
=	O
8	O
)	O
or	O
30	O
mug	O
of	O
morphine	O
(	O
group	O
M	O
;	O
n	O
=	O
8	O
)	O
was	O
injected	O
intrathecally	O
(	O
IT	O
)	O
0	O
.	O
5	O
h	O
after	O
reflow	O
,	O
and	O
30	O
mug	O
of	O
morphine	O
(	O
group	O
SM	O
;	O
n	O
=	O
8	O
)	O
or	O
10	O
muL	O
of	O
saline	O
(	O
group	O
SC	O
;	O
n	O
=	O
8	O
)	O
was	O
injected	O
IT	O
0	O
.	O
5	O
h	O
after	O
sham	O
operation	O
.	O

Microdialysis	O
samples	O
were	O
collected	O
preischemia	O
,	O
before	O
IT	O
injection	O
,	O
and	O
at	O
2	O
,	O
4	O
,	O
8	O
,	O
24	O
,	O
and	O
48	O
h	O
of	O
reperfusion	O
(	O
after	O
IT	O
injection	O
).	O

Second	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
IT	O
MK	O
-	O
801	O
(	O
30	O
mug	O
)	O
on	O
the	O
histopathologic	O
changes	O
in	O
the	O
spinal	O
cord	O
after	O
morphine	O
-	O
induced	O
spastic	B-Disease
paraparesis	I-Disease
.	O

After	O
IT	O
morphine	O
,	O
the	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
glutamate	O
concentration	O
was	O
increased	O
in	O
group	O
M	O
relative	O
to	O
both	O
baseline	O
and	O
group	O
C	O
(	O
P	O
<	O
0	O
.	O
5	O
).	O

This	O
increase	O
persisted	O
for	O
8	O
hrs	O
.	O

IT	O
MK	O
-	O
801	O
significantly	O
reduced	O
the	O
number	O
of	O
dark	O
-	O
stained	O
alpha	O
-	O
motoneurons	O
after	O
morphine	O
-	O
induced	O
spastic	B-Disease
paraparesis	I-Disease
compared	O
with	O
the	O
saline	O
group	O
.	O

These	O
data	O
indicate	O
that	O
IT	O
morphine	O
induces	O
spastic	B-Disease
paraparesis	I-Disease
with	O
a	O
concomitant	O
increase	O
in	O
CSF	O
glutamate	O
,	O
which	O
is	O
involved	O
in	O
NMDA	O
receptor	O
activation	O
.	O

We	O
suggest	O
that	O
opioids	O
may	O
be	O
neurotoxic	B-Disease
in	O
the	O
setting	O
of	O
spinal	B-Disease
cord	I-Disease
ischemia	I-Disease
via	O
NMDA	O
receptor	O
activation	O
.	O


Growth	O
-	O
associated	O
protein	O
43	O
expression	O
in	O
hippocampal	O
molecular	O
layer	O
of	O
chronic	O
epileptic	B-Disease
rats	O
treated	O
with	O
cycloheximide	O
.	O

PURPOSE	O
:	O
GAP43	O
has	O
been	O
thought	O
to	O
be	O
linked	O
with	O
mossy	O
fiber	O
sprouting	O
(	O
MFS	O
)	O
in	O
various	O
experimental	O
models	O
of	O
epilepsy	B-Disease
.	O

To	O
investigate	O
how	O
GAP43	O
expression	O
(	O
GAP43	O
-	O
ir	O
)	O
correlates	O
with	O
MFS	O
,	O
we	O
assessed	O
the	O
intensity	O
(	O
densitometry	O
)	O
and	O
extension	O
(	O
width	O
)	O
of	O
GAP43	O
-	O
ir	O
in	O
the	O
inner	O
molecular	O
layer	O
of	O
the	O
dentate	O
gyrus	O
(	O
IML	O
)	O
of	O
rats	O
subject	O
to	O
status	B-Disease
epilepticus	I-Disease
induced	O
by	O
pilocarpine	O
(	O
Pilo	O
),	O
previously	O
injected	O
or	O
not	O
with	O
cycloheximide	O
(	O
CHX	O
),	O
which	O
has	O
been	O
shown	O
to	O
inhibit	O
MFS	O
.	O

METHODS	O
:	O
CHX	O
was	O
injected	O
before	O
the	O
Pilo	O
injection	O
in	O
adult	O
Wistar	O
rats	O
.	O

The	O
Pilo	O
group	O
was	O
injected	O
with	O
the	O
same	O
drugs	O
,	O
except	O
for	O
CHX	O
.	O

Animals	O
were	O
killed	O
between	O
30	O
and	O
60	O
days	O
later	O
,	O
and	O
brain	O
sections	O
were	O
processed	O
for	O
GAP43	O
immunohistochemistry	O
.	O

RESULTS	O
:	O
Densitometry	O
showed	O
no	O
significant	O
difference	O
regarding	O
GAP43	O
-	O
ir	O
in	O
the	O
IML	O
between	O
Pilo	O
,	O
CHX	O
+	O
Pilo	O
,	O
and	O
control	O
groups	O
.	O

However	O
,	O
the	O
results	O
of	O
the	O
width	O
of	O
the	O
GAP43	O
-	O
ir	O
band	O
in	O
the	O
IML	O
showed	O
that	O
CHX	O
+	O
Pilo	O
and	O
control	O
animals	O
had	O
a	O
significantly	O
larger	O
band	O
(	O
p	O
=	O
0	O
.	O
3	O
)	O
as	O
compared	O
with	O
that	O
in	O
the	O
Pilo	O
group	O
.	O

CONCLUSIONS	O
:	O
Our	O
current	O
finding	O
that	O
animals	O
in	O
the	O
CHX	O
+	O
Pilo	O
group	O
have	O
a	O
GAP43	O
-	O
ir	O
band	O
in	O
the	O
IML	O
,	O
similar	O
to	O
that	O
of	O
controls	O
,	O
reinforces	O
prior	O
data	O
on	O
the	O
blockade	O
of	O
MFS	O
in	O
these	O
animals	O
.	O

The	O
change	O
in	O
GAP43	O
-	O
ir	O
present	O
in	O
Pilo	O
-	O
treated	O
animals	O
was	O
a	O
thinning	O
of	O
the	O
band	O
to	O
a	O
very	O
narrow	O
layer	O
just	O
above	O
the	O
granule	O
cell	O
layer	O
that	O
is	O
likely	O
to	O
be	O
associated	O
with	O
the	O
loss	O
of	O
hilar	O
cell	O
projections	O
that	O
express	O
GAP	O
-	O
43	O
.	O


Daidzein	O
activates	O
choline	O
acetyltransferase	O
from	O
MC	O
-	O
IXC	O
cells	O
and	O
improves	O
drug	O
-	O
induced	O
amnesia	B-Disease
.	O

The	O
choline	O
acetyltransferase	O
(	O
ChAT	O
)	O
activator	O
,	O
which	O
enhances	O
cholinergic	O
transmission	O
via	O
an	O
augmentation	O
of	O
the	O
enzymatic	O
production	O
of	O
acetylcholine	O
(	O
ACh	O
),	O
is	O
an	O
important	O
factor	O
in	O
the	O
treatment	O
of	O
Alzheimer	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
(	O
AD	B-Disease
).	O

Methanolic	O
extracts	O
from	O
Pueraria	O
thunbergiana	O
exhibited	O
an	O
activation	O
effect	O
(	O
46	O
%)	O
on	O
ChAT	O
in	O
vitro	O
.	O

Via	O
the	O
sequential	O
isolation	O
of	O
Pueraria	O
thunbergiana	O
,	O
the	O
active	O
component	O
was	O
ultimately	O
identified	O
as	O
daidzein	O
(	O
4	O
',	O
7	O
-	O
dihydroxy	O
-	O
isoflavone	O
).	O

In	O
order	O
to	O
investigate	O
the	O
effects	O
of	O
daidzein	O
from	O
Pueraria	O
thunbergiana	O
on	O
scopolamine	O
-	O
induced	O
impairments	B-Disease
of	I-Disease
learning	I-Disease
and	I-Disease
memory	I-Disease
,	O
we	O
conducted	O
a	O
series	O
of	O
in	O
vivo	O
tests	O
.	O

Administration	O
of	O
daidzein	O
(	O
4	O
.	O
5	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
to	O
mice	O
was	O
shown	O
significantly	O
to	O
reverse	O
scopolamine	O
-	O
induced	O
amnesia	B-Disease
,	O
according	O
to	O
the	O
results	O
of	O
a	O
Y	O
-	O
maze	O
test	O
.	O

Injections	O
of	O
scopolamine	O
into	O
mice	O
resulted	O
in	O
impaired	O
performance	O
on	O
Y	O
-	O
maze	O
tests	O
(	O
a	O
37	O
%	O
decreases	O
in	O
alternation	O
behavior	O
).	O

By	O
way	O
of	O
contrast	O
,	O
mice	O
treated	O
with	O
daidzein	O
prior	O
to	O
the	O
scopolamine	O
injections	O
were	O
noticeably	O
protected	O
from	O
this	O
performance	O
impairment	O
(	O
an	O
approximately	O
12	O
%-	O
21	O
%	O
decrease	O
in	O
alternation	O
behavior	O
).	O

These	O
results	O
indicate	O
that	O
daidzein	O
might	O
play	O
a	O
role	O
in	O
acetylcholine	O
biosynthesis	O
as	O
a	O
ChAT	O
activator	O
,	O
and	O
that	O
it	O
also	O
ameliorates	O
scopolamine	O
-	O
induced	O
amnesia	B-Disease
.	O


Effect	O
of	O
alpha	O
-	O
tocopherol	O
and	O
deferoxamine	O
on	O
methamphetamine	O
-	O
induced	O
neurotoxicity	B-Disease
.	O

Methamphetamine	O
(	O
MA	O
)-	O
induced	O
dopaminergic	O
neurotoxicity	B-Disease
is	O
believed	O
to	O
be	O
associated	O
with	O
the	O
increased	O
formation	O
of	O
free	O
radicals	O
.	O

This	O
study	O
examined	O
the	O
effect	O
of	O
alpha	O
-	O
tocopherol	O
(	O
alpha	O
-	O
TC	O
),	O
a	O
scavenger	O
of	O
reactive	O
oxygen	O
species	O
,	O
and	O
deferoxamine	O
(	O
DFO	O
),	O
an	O
iron	O
chelator	O
,	O
on	O
the	O
MA	O
-	O
induced	O
neurotoxicity	B-Disease
.	O

Male	O
rats	O
were	O
treated	O
with	O
MA	O
(	O
10	O
mg	O
/	O
kg	O
,	O
every	O
2	O
h	O
for	O
four	O
injections	O
).	O

The	O
rat	O
received	O
either	O
alpha	O
-	O
TC	O
(	O
20	O
mg	O
/	O
kg	O
)	O
intraperitoneally	O
for	O
3	O
days	O
and	O
30	O
min	O
prior	O
to	O
MA	O
administration	O
or	O
DFO	O
(	O
50	O
mg	O
/	O
kg	O
)	O
subcutaneously	O
30	O
min	O
before	O
MA	O
administration	O
.	O

The	O
concentrations	O
of	O
dopamine	O
(	O
DA	O
),	O
serotonin	O
and	O
their	O
metabolites	O
decreased	O
significantly	O
after	O
MA	O
administration	O
,	O
which	O
was	O
inhibited	O
by	O
the	O
alpha	O
-	O
TC	O
and	O
DFO	O
pretreatment	O
.	O

alpha	O
-	O
TC	O
and	O
DFO	O
attenuated	O
the	O
MA	O
-	O
induced	O
hyperthermia	B-Disease
as	O
well	O
as	O
the	O
alterations	O
in	O
the	O
locomotor	O
activity	O
.	O

The	O
level	O
of	O
lipid	O
peroxidation	O
was	O
higher	O
and	O
the	O
reduced	O
glutathione	O
concentration	O
was	O
lower	O
in	O
the	O
MA	O
-	O
treated	O
rats	O
.	O

These	O
changes	O
were	O
significantly	O
attenuated	O
by	O
alpha	O
-	O
TC	O
and	O
DFO	O
.	O

This	O
suggests	O
that	O
alpha	O
-	O
TC	O
and	O
DFO	O
ameliorate	O
the	O
MA	O
-	O
induced	O
neuronal	B-Disease
damage	I-Disease
by	O
decreasing	O
the	O
level	O
of	O
oxidative	O
stress	O
.	O


Cardiac	O
Angiography	O
in	O
Renally	O
Impaired	O
Patients	O
(	O
CARE	O
)	O
study	O
:	O
a	O
randomized	O
double	O
-	O
blind	O
trial	O
of	O
contrast	O
-	O
induced	O
nephropathy	B-Disease
in	O
patients	O
with	O
chronic	B-Disease
kidney	I-Disease
disease	I-Disease
.	O

BACKGROUND	O
:	O
No	O
direct	O
comparisons	O
exist	O
of	O
the	O
renal	O
tolerability	O
of	O
the	O
low	O
-	O
osmolality	O
contrast	O
medium	O
iopamidol	O
with	O
that	O
of	O
the	O
iso	O
-	O
osmolality	O
contrast	O
medium	O
iodixanol	O
in	O
high	O
-	O
risk	O
patients	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
The	O
present	O
study	O
is	O
a	O
multicenter	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
comparison	O
of	O
iopamidol	O
and	O
iodixanol	O
in	O
patients	O
with	O
chronic	B-Disease
kidney	I-Disease
disease	I-Disease
(	O
estimated	O
glomerular	O
filtration	O
rate	O
,	O
20	O
to	O
59	O
mL	O
/	O
min	O
)	O
who	O
underwent	O
cardiac	O
angiography	O
or	O
percutaneous	O
coronary	O
interventions	O
.	O

Serum	O
creatinine	O
(	O
SCr	O
)	O
levels	O
and	O
estimated	O
glomerular	O
filtration	O
rate	O
were	O
assessed	O
at	O
baseline	O
and	O
2	O
to	O
5	O
days	O
after	O
receiving	O
medications	O
.	O

The	O
primary	O
outcome	O
was	O
a	O
postdose	O
SCr	O
increase	O
>	O
or	O
=	O
0	O
.	O
5	O
mg	O
/	O
dL	O
(	O
44	O
.	O
2	O
micromol	O
/	O
L	O
)	O
over	O
baseline	O
.	O

Secondary	O
outcomes	O
were	O
a	O
postdose	O
SCr	O
increase	O
>	O
or	O
=	O
25	O
%,	O
a	O
postdose	O
estimated	O
glomerular	O
filtration	O
rate	O
decrease	O
of	O
>	O
or	O
=	O
25	O
%,	O
and	O
the	O
mean	O
peak	O
change	O
in	O
SCr	O
.	O

In	O
414	O
patients	O
,	O
contrast	O
volume	O
,	O
presence	O
of	O
diabetes	B-Disease
mellitus	I-Disease
,	O
use	O
of	O
N	O
-	O
acetylcysteine	O
,	O
mean	O
baseline	O
SCr	O
,	O
and	O
estimated	O
glomerular	O
filtration	O
rate	O
were	O
comparable	O
in	O
the	O
2	O
groups	O
.	O

SCr	O
increases	O
>	O
or	O
=	O
0	O
.	O
5	O
mg	O
/	O
dL	O
occurred	O
in	O
4	O
.	O
4	O
%	O
(	O
9	O
of	O
204	O
patients	O
)	O
after	O
iopamidol	O
and	O
6	O
.	O
7	O
%	O
(	O
14	O
of	O
210	O
patients	O
)	O
after	O
iodixanol	O
(	O
P	O
=	O
0	O
.	O
39	O
),	O
whereas	O
rates	O
of	O
SCr	O
increases	O
>	O
or	O
=	O
25	O
%	O
were	O
9	O
.	O
8	O
%	O
and	O
12	O
.	O
4	O
%,	O
respectively	O
(	O
P	O
=	O
0	O
.	O
44	O
).	O

In	O
patients	O
with	O
diabetes	B-Disease
,	O
SCr	O
increases	O
>	O
or	O
=	O
0	O
.	O
5	O
mg	O
/	O
dL	O
were	O
5	O
.	O
1	O
%	O
(	O
4	O
of	O
78	O
patients	O
)	O
with	O
iopamidol	O
and	O
13	O
.	O
0	O
%	O
(	O
12	O
of	O
92	O
patients	O
)	O
with	O
iodixanol	O
(	O
P	O
=	O
0	O
.	O
11	O
),	O
whereas	O
SCr	O
increases	O
>	O
or	O
=	O
25	O
%	O
were	O
10	O
.	O
3	O
%	O
and	O
15	O
.	O
2	O
%,	O
respectively	O
(	O
P	O
=	O
0	O
.	O
37	O
).	O

Mean	O
post	O
-	O
SCr	O
increases	O
were	O
significantly	O
less	O
with	O
iopamidol	O
(	O
all	O
patients	O
:	O
0	O
.	O
7	O
versus	O
0	O
.	O
12	O
mg	O
/	O
dL	O
,	O
6	O
.	O
2	O
versus	O
10	O
.	O
6	O
micromol	O
/	O
L	O
,	O
P	O
=	O
0	O
.	O
3	O
;	O
patients	O
with	O
diabetes	B-Disease
:	O
0	O
.	O
7	O
versus	O
0	O
.	O
16	O
mg	O
/	O
dL	O
,	O
6	O
.	O
2	O
versus	O
14	O
.	O
1	O
micromol	O
/	O
L	O
,	O
P	O
=	O
0	O
.	O
1	O
).	O

CONCLUSIONS	O
:	O
The	O
rate	O
of	O
contrast	O
-	O
induced	O
nephropathy	B-Disease
,	O
defined	O
by	O
multiple	O
end	O
points	O
,	O
is	O
not	O
statistically	O
different	O
after	O
the	O
intraarterial	O
administration	O
of	O
iopamidol	O
or	O
iodixanol	O
to	O
high	O
-	O
risk	O
patients	O
,	O
with	O
or	O
without	O
diabetes	B-Disease
mellitus	I-Disease
.	O

Any	O
TRUE	O
difference	O
between	O
the	O
agents	O
is	O
small	O
and	O
not	O
likely	O
to	O
be	O
clinically	O
significant	O
.	O


Estrogen	O
prevents	O
cholesteryl	O
ester	O
accumulation	O
in	O
macrophages	O
induced	O
by	O
the	O
HIV	O
protease	O
inhibitor	O
ritonavir	O
.	O

Individuals	O
with	O
HIV	O
can	O
now	O
live	O
long	O
lives	O
with	O
drug	O
therapy	O
that	O
often	O
includes	O
protease	O
inhibitors	O
such	O
as	O
ritonavir	O
.	O

Many	O
patients	O
,	O
however	O
,	O
develop	O
negative	O
long	O
-	O
term	O
side	O
effects	O
such	O
as	O
premature	B-Disease
atherosclerosis	I-Disease
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
ritonavir	O
treatment	O
increases	O
atherosclerotic	B-Disease
lesion	I-Disease
formation	O
in	O
male	O
mice	O
to	O
a	O
greater	O
extent	O
than	O
in	O
female	O
mice	O
.	O

Furthermore	O
,	O
peripheral	O
blood	O
monocytes	O
isolated	O
from	O
ritonavir	O
-	O
treated	O
females	O
had	O
less	O
cholesteryl	O
ester	O
accumulation	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
investigated	O
the	O
molecular	O
mechanisms	O
by	O
which	O
female	O
hormones	O
influence	O
cholesterol	O
metabolism	O
in	O
macrophages	O
in	O
response	O
to	O
the	O
HIV	O
protease	O
inhibitor	O
ritonavir	O
.	O

We	O
have	O
utilized	O
the	O
human	O
monocyte	O
cell	O
line	O
,	O
THP	O
-	O
1	O
as	O
a	O
model	O
to	O
address	O
this	O
question	O
.	O

Briefly	O
,	O
cells	O
were	O
differentiated	O
for	O
72	O
h	O
with	O
100	O
nM	O
PMA	O
to	O
obtain	O
a	O
macrophage	O
-	O
like	O
phenotype	O
in	O
the	O
presence	O
or	O
absence	O
of	O
1	O
nM	O
17beta	O
-	O
estradiol	O
(	O
E2	O
),	O
100	O
nM	O
progesterone	O
or	O
vehicle	O
(	O
0	O
.	O
1	O
%	O
ethanol	O
).	O

Cells	O
were	O
then	O
treated	O
with	O
30	O
ng	O
/	O
ml	O
ritonavir	O
or	O
vehicle	O
in	O
the	O
presence	O
of	O
aggregated	O
LDL	O
for	O
24	O
h	O
.	O
Cell	O
extracts	O
were	O
harvested	O
,	O
and	O
lipid	O
or	O
total	O
RNA	O
was	O
isolated	O
.	O

E2	O
decreased	O
the	O
accumulation	O
of	O
cholesteryl	O
esters	O
in	O
macrophages	O
following	O
ritonavir	O
treatment	O
.	O

Ritonavir	O
increased	O
the	O
expression	O
of	O
the	O
scavenger	O
receptor	O
,	O
CD36	O
mRNA	O
,	O
responsible	O
for	O
the	O
uptake	O
of	O
LDL	O
.	O

Additionally	O
,	O
ritonavir	O
treatment	O
selectively	O
increased	O
the	O
relative	O
levels	O
of	O
PPARgamma	O
mRNA	O
,	O
a	O
transcription	O
factor	O
responsible	O
for	O
the	O
regulation	O
of	O
CD36	O
mRNA	O
expression	O
.	O

Treatment	O
with	O
E2	O
,	O
however	O
,	O
failed	O
to	O
prevent	O
these	O
increases	O
at	O
the	O
mRNA	O
level	O
.	O

E2	O
did	O
,	O
however	O
,	O
significantly	O
suppress	O
CD36	O
protein	O
levels	O
as	O
measured	O
by	O
fluorescent	O
immunocytochemistry	O
.	O

This	O
data	O
suggests	O
that	O
E2	O
modifies	O
the	O
expression	O
of	O
CD36	O
at	O
the	O
level	O
of	O
protein	O
expression	O
in	O
monocyte	O
-	O
derived	O
macrophages	O
resulting	O
in	O
reduced	O
cholesteryl	O
ester	O
accumulation	O
following	O
ritonavir	O
treatment	O
.	O


Clinical	O
comparison	O
of	O
cardiorespiratory	O
effects	O
during	O
unilateral	O
and	O
conventional	O
spinal	O
anaesthesia	O
.	O

BACKGROUND	O
:	O
Spinal	O
anaesthesia	O
is	O
widely	O
employed	O
in	O
clinical	O
practice	O
but	O
has	O
the	O
main	O
drawback	O
of	O
post	O
-	O
spinal	O
block	O
hypotension	B-Disease
.	O

Efforts	O
must	O
therefore	O
continue	O
to	O
be	O
made	O
to	O
obviate	O
this	O
setback	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
cardiovascular	O
and	O
respiratory	O
changes	O
during	O
unilateral	O
and	O
conventional	O
spinal	O
anaesthesia	O
.	O

METHODS	O
:	O
With	O
ethical	O
approval	O
,	O
we	O
studied	O
74	O
American	O
Society	O
of	O
Anesthesiologists	O
(	O
ASA	O
),	O
physical	O
status	O
class	O
1	O
and	O
2	O
patients	O
scheduled	O
for	O
elective	O
unilateral	O
lower	O
limb	O
surgery	O
.	O

Patients	O
were	O
randomly	O
allocated	O
into	O
one	O
of	O
two	O
groups	O
:	O
lateral	O
and	O
conventional	O
spinal	O
anaesthesia	O
groups	O
.	O

In	O
the	O
lateral	O
position	O
with	O
operative	O
side	O
down	O
,	O
patients	O
recived	O
10	O
mg	O
(	O
2mls	O
)	O
of	O
0	O
.	O
5	O
%	O
hyperbaric	O
bupivacaine	O
through	O
a	O
25	O
-	O
gauge	O
spinal	O
needle	O
.	O

Patients	O
in	O
the	O
unilateral	O
group	O
were	O
maintained	O
in	O
the	O
lateral	O
position	O
for	O
15	O
minutes	O
following	O
spinal	O
injection	O
while	O
those	O
in	O
the	O
conventional	O
group	O
were	O
turned	O
supine	O
immediately	O
after	O
injection	O
.	O

Blood	O
pressure	O
,	O
heart	O
rate	O
,	O
respiratory	O
rate	O
and	O
oxygen	O
saturation	O
were	O
monitored	O
over	O
1	O
hour	O
.	O

RESULTS	O
:	O
Three	O
patients	O
(	O
8	O
.	O
1	O
%)	O
in	O
the	O
unilateral	O
group	O
and	O
5	O
(	O
13	O
.	O
5	O
%)	O
in	O
the	O
conventional	O
group	O
developed	O
hypotension	B-Disease
,	O
P	O
=	O
0	O
.	O
71	O
.	O

Four	O
(	O
10	O
.	O
8	O
%)	O
patients	O
in	O
the	O
conventional	O
group	O
and	O
1	O
(	O
2	O
.	O
7	O
%)	O
in	O
the	O
unilateral	O
group	O
,	O
P	O
=	O
0	O
.	O
17	O
required	O
epinephrine	O
infusion	O
to	O
treat	O
hypotension	B-Disease
.	O

Patients	O
in	O
the	O
conventional	O
group	O
had	O
statistically	O
significant	O
greater	O
fall	O
in	O
the	O
systolic	O
blood	O
pressures	O
at	O
15	O
,	O
30	O
and	O
45	O
minutes	O
when	O
compared	O
to	O
the	O
baseline	O
(	O
P	O
=	O
0	O
.	O
3	O
,	O
0	O
.	O
1	O
and	O
0	O
.	O
4	O
).	O

The	O
mean	O
respiratory	O
rate	O
and	O
oxygen	O
saturations	O
in	O
the	O
two	O
groups	O
were	O
similar	O
.	O

CONCLUSION	O
:	O
Compared	O
to	O
conventional	O
spinal	O
anaesthesia	O
,	O
unilateral	O
spinal	O
anaesthesia	O
was	O
associated	O
with	O
fewer	O
cardiovascular	O
perturbations	O
.	O

Also	O
,	O
the	O
type	O
of	O
spinal	O
block	O
instituted	O
affected	O
neither	O
the	O
respiratory	O
rate	O
nor	O
the	O
arterial	O
oxygen	O
saturation	O
.	O


Acute	O
effects	O
of	O
N	O
-(	O
2	O
-	O
propylpentanoyl	O
)	O
urea	O
on	O
hippocampal	O
amino	O
acid	O
neurotransmitters	O
in	O
pilocarpine	O
-	O
induced	O
seizure	B-Disease
in	O
rats	O
.	O

The	O
present	O
study	O
aimed	O
to	O
investigate	O
the	O
anticonvulsant	O
activity	O
as	O
well	O
as	O
the	O
effects	O
on	O
the	O
level	O
of	O
hippocampal	O
amino	O
acid	O
neurotransmitters	O
(	O
glutamate	O
,	O
aspartate	O
,	O
glycine	O
and	O
GABA	O
)	O
of	O
N	O
-(	O
2	O
-	O
propylpentanoyl	O
)	O
urea	O
(	O
VPU	O
)	O
in	O
comparison	O
to	O
its	O
parent	O
compound	O
,	O
valproic	O
acid	O
(	O
VPA	O
).	O

VPU	O
was	O
more	O
potent	O
than	O
VPA	O
,	O
exhibiting	O
the	O
median	O
effective	O
dose	O
(	O
ED	O
(	O
50	O
))	O
of	O
49	O
mg	O
/	O
kg	O
in	O
protecting	O
rats	O
against	O
pilocarpine	O
-	O
induced	O
seizure	B-Disease
whereas	O
the	O
corresponding	O
value	O
for	O
VPA	O
was	O
322	O
mg	O
/	O
kg	O
.	O

In	O
vivo	O
microdialysis	O
demonstrated	O
that	O
an	O
intraperitoneal	O
administration	O
of	O
pilocarpine	O
induced	O
a	O
pronounced	O
increment	O
of	O
hippocampal	O
glutamate	O
and	O
aspartate	O
whereas	O
no	O
significant	O
change	O
was	O
observed	O
on	O
the	O
level	O
of	O
glycine	O
and	O
GABA	O
.	O

Pretreatment	O
with	O
either	O
VPU	O
(	O
50	O
and	O
100	O
mg	O
/	O
kg	O
)	O
or	O
VPA	O
(	O
300	O
and	O
600	O
mg	O
/	O
kg	O
)	O
completely	O
abolished	O
pilocarpine	O
-	O
evoked	O
increases	O
in	O
extracellular	O
glutamate	O
and	O
aspartate	O
.	O

In	O
addition	O
,	O
a	O
statistically	O
significant	O
reduction	O
was	O
also	O
observed	O
on	O
the	O
level	O
of	O
GABA	O
and	O
glycine	O
but	O
less	O
than	O
a	O
drastic	O
reduction	O
of	O
glutamate	O
and	O
aspartate	O
level	O
.	O

Based	O
on	O
the	O
finding	O
that	O
VPU	O
and	O
VPA	O
could	O
protect	O
the	O
animals	O
against	O
pilocarpine	O
-	O
induced	O
seizure	B-Disease
it	O
is	O
suggested	O
that	O
the	O
reduction	O
of	O
inhibitory	O
amino	O
acid	O
neurotransmitters	O
was	O
comparatively	O
minor	O
and	O
offset	O
by	O
a	O
pronounced	O
reduction	O
of	O
glutamate	O
and	O
aspartate	O
.	O

Therefore	O
,	O
like	O
VPA	O
,	O
the	O
finding	O
that	O
VPU	O
could	O
drastically	O
reduce	O
pilocarpine	O
-	O
induced	O
increases	O
in	O
glutamate	O
and	O
aspartate	O
should	O
account	O
,	O
at	O
least	O
partly	O
,	O
for	O
its	O
anticonvulsant	O
activity	O
observed	O
in	O
pilocarpine	O
-	O
induced	O
seizure	B-Disease
in	O
experimental	O
animals	O
.	O

Some	O
other	O
mechanism	O
than	O
those	O
being	O
reported	O
herein	O
should	O
be	O
further	O
investigated	O
.	O


Delirium	B-Disease
in	O
a	O
patient	O
with	O
toxic	O
flecainide	O
plasma	O
concentrations	O
:	O
the	O
role	O
of	O
a	O
pharmacokinetic	O
drug	O
interaction	O
with	O
paroxetine	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
a	O
case	O
of	O
flecainide	O
-	O
induced	O
delirium	B-Disease
associated	O
with	O
a	O
pharmacokinetic	O
drug	O
interaction	O
with	O
paroxetine	O
.	O

CASE	O
SUMMARY	O
:	O
A	O
69	O
-	O
year	O
-	O
old	O
white	O
female	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
a	O
history	O
of	O
confusion	B-Disease
and	O
paranoia	B-Disease
over	O
the	O
past	O
several	O
days	O
.	O

On	O
admission	O
the	O
patient	O
was	O
taking	O
carvedilol	O
12	O
mg	O
twice	O
daily	O
,	O
warfarin	O
2	O
mg	O
/	O
day	O
,	O
folic	O
acid	O
1	O
mg	O
/	O
day	O
,	O
levothyroxine	O
100	O
microg	O
/	O
day	O
,	O
pantoprazole	O
40	O
mg	O
/	O
day	O
,	O
paroxetine	O
40	O
mg	O
/	O
day	O
,	O
and	O
flecainide	O
100	O
mg	O
twice	O
daily	O
.	O

Flecainide	O
had	O
been	O
started	O
2	O
weeks	O
prior	O
for	O
atrial	B-Disease
fibrillation	I-Disease
.	O

Laboratory	O
test	O
findings	O
on	O
admission	O
were	O
notable	O
only	O
for	O
a	O
flecainide	O
plasma	O
concentration	O
of	O
1360	O
microg	O
/	O
L	O
(	O
reference	O
range	O
200	O
-	O
1000	O
).	O

A	O
metabolic	O
drug	O
interaction	O
between	O
flecainide	O
and	O
paroxetine	O
,	O
which	O
the	O
patient	O
had	O
been	O
taking	O
for	O
more	O
than	O
5	O
years	O
,	O
was	O
considered	O
.	O

Paroxetine	O
was	O
discontinued	O
and	O
the	O
dose	O
of	O
flecainide	O
was	O
reduced	O
to	O
50	O
mg	O
twice	O
daily	O
.	O

Her	O
delirium	B-Disease
resolved	O
3	O
days	O
later	O
.	O

DISCUSSION	O
:	O
Flecainide	O
and	O
pharmacologically	O
similar	O
agents	O
that	O
interact	O
with	O
sodium	O
channels	O
may	O
cause	O
delirium	B-Disease
in	O
susceptible	O
patients	O
.	O

A	O
MEDLINE	O
search	O
(	O
1966	O
-	O
January	O
2009	O
)	O
revealed	O
one	O
in	O
vivo	O
pharmacokinetic	O
study	O
on	O
the	O
interaction	O
between	O
flecainide	O
,	O
a	O
CYP2D6	O
substrate	O
,	O
and	O
paroxetine	O
,	O
a	O
CYP2D6	O
inhibitor	O
,	O
as	O
well	O
as	O
3	O
case	O
reports	O
of	O
flecainide	O
-	O
induced	O
delirium	B-Disease
.	O

According	O
to	O
the	O
Naranjo	O
probability	O
scale	O
,	O
flecainide	O
was	O
the	O
probable	O
cause	O
of	O
the	O
patient	O
'	O
s	O
delirium	B-Disease
;	O
the	O
Horn	O
Drug	O
Interaction	O
Probability	O
Scale	O
indicates	O
a	O
possible	O
pharmacokinetic	O
drug	O
interaction	O
between	O
flecainide	O
and	O
paroxetine	O
.	O

CONCLUSIONS	O
:	O
Supratherapeutic	O
flecainide	O
plasma	O
concentrations	O
may	O
cause	O
delirium	B-Disease
.	O

Because	O
toxicity	B-Disease
may	O
occur	O
when	O
flecainide	O
is	O
prescribed	O
with	O
paroxetine	O
and	O
other	O
potent	O
CYP2D6	O
inhibitors	O
,	O
flecainide	O
plasma	O
concentrations	O
should	O
be	O
monitored	O
closely	O
with	O
commencement	O
of	O
CYP2D6	O
inhibitors	O
.	O


Depression	B-Disease
,	O
impulsiveness	B-Disease
,	O
sleep	O
,	O
and	O
memory	O
in	O
past	O
and	O
present	O
polydrug	O
users	O
of	O
3	O
,	O
4	O
-	O
methylenedioxymethamphetamine	O
(	O
MDMA	O
,	O
ecstasy	O
).	O

RATIONALE	O
:	O
Ecstasy	O
(	O
3	O
,	O
4	O
-	O
methylenedioxymethamphetamine	O
,	O
MDMA	O
)	O
is	O
a	O
worldwide	O
recreational	O
drug	O
of	O
abuse	O
.	O

Unfortunately	O
,	O
the	O
results	O
from	O
human	O
research	O
investigating	O
its	O
psychological	O
effects	O
have	O
been	O
inconsistent	O
.	O

OBJECTIVES	O
:	O
The	O
present	O
study	O
aimed	O
to	O
be	O
the	O
largest	O
to	O
date	O
in	O
sample	O
size	O
and	O
5HT	O
-	O
related	O
behaviors	O
;	O
the	O
first	O
to	O
compare	O
present	O
ecstasy	O
users	O
with	O
past	O
users	O
after	O
an	O
abstinence	O
of	O
4	O
or	O
more	O
years	O
,	O
and	O
the	O
first	O
to	O
include	O
robust	O
controls	O
for	O
other	O
recreational	O
substances	O
.	O

METHODS	O
:	O
A	O
sample	O
of	O
997	O
participants	O
(	O
52	O
%	O
male	O
)	O
was	O
recruited	O
to	O
four	O
control	O
groups	O
(	O
non	O
-	O
drug	O
(	O
ND	O
),	O
alcohol	O
/	O
nicotine	O
(	O
AN	O
),	O
cannabis	O
/	O
alcohol	O
/	O
nicotine	O
(	O
CAN	O
),	O
non	O
-	O
ecstasy	O
polydrug	O
(	O
PD	O
)),	O
and	O
two	O
ecstasy	O
polydrug	O
groups	O
(	O
present	O
(	O
MDMA	O
)	O
and	O
past	O
users	O
(	O
EX	O
-	O
MDMA	O
).	O

Participants	O
completed	O
a	O
drug	O
history	O
questionnaire	O
,	O
Beck	O
Depression	O
Inventory	O
,	O
Barratt	O
Impulsiveness	O
Scale	O
,	O
Pittsburgh	O
Sleep	O
Quality	O
Index	O
,	O
and	O
Wechsler	O
Memory	O
Scale	O
-	O
Revised	O
which	O
,	O
in	O
total	O
,	O
provided	O
13	O
psychometric	O
measures	O
.	O

RESULTS	O
:	O
While	O
the	O
CAN	O
and	O
PD	O
groups	O
tended	O
to	O
record	O
greater	O
deficits	O
than	O
the	O
non	O
-	O
drug	O
controls	O
,	O
the	O
MDMA	O
and	O
EX	O
-	O
MDMA	O
groups	O
recorded	O
greater	O
deficits	O
than	O
all	O
the	O
control	O
groups	O
on	O
ten	O
of	O
the	O
13	O
psychometric	O
measures	O
.	O

Strikingly	O
,	O
despite	O
prolonged	O
abstinence	O
(	O
mean	O
,	O
4	O
.	O
98	O
;	O
range	O
,	O
4	O
-	O
9	O
years	O
),	O
past	O
ecstasy	O
users	O
showed	O
few	O
signs	O
of	O
recovery	O
.	O

Compared	O
with	O
present	O
ecstasy	O
users	O
,	O
the	O
past	O
users	O
showed	O
no	O
change	O
for	O
ten	O
measures	O
,	O
increased	O
impairment	O
for	O
two	O
measures	O
,	O
and	O
improvement	O
on	O
just	O
one	O
measure	O
.	O

CONCLUSIONS	O
:	O
Given	O
this	O
record	O
of	O
impaired	B-Disease
memory	I-Disease
and	O
clinically	O
significant	O
levels	O
of	O
depression	B-Disease
,	O
impulsiveness	B-Disease
,	O
and	O
sleep	B-Disease
disturbance	I-Disease
,	O
the	O
prognosis	O
for	O
the	O
current	O
generation	O
of	O
ecstasy	O
users	O
is	O
a	O
major	O
cause	O
for	O
concern	O
.	O


A	O
comparison	O
of	O
severe	O
hemodynamic	O
disturbances	O
between	O
dexmedetomidine	O
and	O
propofol	O
for	O
sedation	O
in	O
neurocritical	O
care	O
patients	O
.	O

OBJECTIVE	O
:	O
Dexmedetomidine	O
and	O
propofol	O
are	O
commonly	O
used	O
sedatives	O
in	O
neurocritical	O
care	O
as	O
they	O
allow	O
for	O
frequent	O
neurologic	O
examinations	O
.	O

However	O
,	O
both	O
agents	O
are	O
associated	O
with	O
significant	O
hemodynamic	O
side	O
effects	O
.	O

The	O
primary	O
objective	O
of	O
this	O
study	O
is	O
to	O
compare	O
the	O
prevalence	O
of	O
severe	O
hemodynamic	O
effects	O
in	O
neurocritical	O
care	O
patients	O
receiving	O
dexmedetomidine	O
and	O
propofol	O
.	O

DESIGN	O
:	O
Multicenter	O
,	O
retrospective	O
,	O
propensity	O
-	O
matched	O
cohort	O
study	O
.	O

SETTING	O
:	O
Neurocritical	O
care	O
units	O
at	O
two	O
academic	O
medical	O
centers	O
with	O
dedicated	O
neurocritical	O
care	O
teams	O
and	O
board	O
-	O
certified	O
neurointensivists	O
.	O

PATIENTS	O
:	O
Neurocritical	O
care	O
patients	O
admitted	O
between	O
July	O
2009	O
and	O
September	O
2012	O
were	O
evaluated	O
and	O
then	O
matched	O
1	O
:	O
1	O
based	O
on	O
propensity	O
scoring	O
of	O
baseline	O
characteristics	O
.	O

INTERVENTIONS	O
:	O
Continuous	O
sedation	O
with	O
dexmedetomidine	O
or	O
propofol	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
A	O
total	O
of	O
342	O
patients	O
(	O
105	O
dexmedetomidine	O
and	O
237	O
propofol	O
)	O
were	O
included	O
in	O
the	O
analysis	O
,	O
with	O
190	O
matched	O
(	O
95	O
in	O
each	O
group	O
)	O
by	O
propensity	O
score	O
.	O

The	O
primary	O
outcome	O
of	O
this	O
study	O
was	O
a	O
composite	O
of	O
severe	O
hypotension	B-Disease
(	O
mean	O
arterial	O
pressure	O
<	O
60	O
mm	O
Hg	O
)	O
and	O
bradycardia	B-Disease
(	O
heart	O
rate	O
<	O
50	O
beats	O
/	O
min	O
)	O
during	O
sedative	O
infusion	O
.	O

No	O
difference	O
in	O
the	O
primary	O
composite	O
outcome	O
in	O
both	O
the	O
unmatched	O
(	O
30	O
%	O
vs	O
30	O
%,	O
p	O
=	O
0	O
.	O
94	O
)	O
or	O
matched	O
cohorts	O
(	O
28	O
%	O
vs	O
34	O
%,	O
p	O
=	O
0	O
.	O
35	O
)	O
could	O
be	O
found	O
.	O

When	O
analyzed	O
separately	O
,	O
no	O
differences	O
could	O
be	O
found	O
in	O
the	O
prevalence	O
of	O
severe	O
hypotension	B-Disease
or	O
bradycardia	B-Disease
in	O
either	O
the	O
unmatched	O
or	O
matched	O
cohorts	O
.	O

CONCLUSIONS	O
:	O
Severe	O
hypotension	B-Disease
and	O
bradycardia	B-Disease
occur	O
at	O
similar	O
prevalence	O
in	O
neurocritical	O
care	O
patients	O
who	O
receive	O
dexmedetomidine	O
or	O
propofol	O
.	O

Providers	O
should	O
similarly	O
consider	O
the	O
likelihood	O
of	O
hypotension	B-Disease
or	O
bradycardia	B-Disease
before	O
starting	O
either	O
sedative	O
.	O


Effects	O
of	O
dehydroepiandrosterone	O
in	O
amphetamine	O
-	O
induced	O
schizophrenia	B-Disease
models	O
in	O
mice	O
.	O

OBJECTIVE	O
:	O
To	O
examine	O
the	O
effects	O
of	O
dehydroepiandrosterone	O
(	O
DHEA	O
)	O
on	O
animal	O
models	O
of	O
schizophrenia	B-Disease
.	O

METHODS	O
:	O
Seventy	O
Swiss	O
albino	O
female	O
mice	O
(	O
25	O
-	O
35	O
g	O
)	O
were	O
divided	O
into	O
4	O
groups	O
:	O
amphetamine	O
-	O
free	O
(	O
control	O
),	O
amphetamine	O
,	O
50	O
,	O
and	O
100	O
mg	O
/	O
kg	O
DHEA	O
.	O

The	O
DHEA	O
was	O
administered	O
intraperitoneally	O
(	O
ip	O
)	O
for	O
5	O
days	O
.	O

Amphetamine	O
(	O
3	O
mg	O
/	O
kg	O
ip	O
)	O
induced	O
hyper	B-Disease
locomotion	I-Disease
,	O
apomorphine	O
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
subcutaneously	O
[	O
sc	O
])	O
induced	O
climbing	O
,	O
and	O
haloperidol	O
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
sc	O
)	O
induced	O
catalepsy	B-Disease
tests	O
were	O
used	O
as	O
animal	O
models	O
of	O
schizophrenia	B-Disease
.	O

The	O
study	O
was	O
conducted	O
at	O
the	O
Animal	O
Experiment	O
Laboratories	O
,	O
Department	O
of	O
Pharmacology	O
,	O
Medical	O
School	O
,	O
Eskisehir	O
Osmangazi	O
University	O
,	O
Eskisehir	O
,	O
Turkey	O
between	O
March	O
and	O
May	O
2012	O
.	O

Statistical	O
analysis	O
was	O
carried	O
out	O
using	O
Kruskal	O
-	O
Wallis	O
test	O
for	O
hyper	B-Disease
locomotion	I-Disease
,	O
and	O
one	O
-	O
way	O
ANOVA	O
for	O
climbing	O
and	O
catalepsy	B-Disease
tests	O
.	O

RESULTS	O
:	O
In	O
the	O
amphetamine	O
-	O
induced	O
locomotion	O
test	O
,	O
there	O
were	O
significant	O
increases	O
in	O
all	O
movements	O
compared	O
with	O
the	O
amphetamine	O
-	O
free	O
group	O
.	O

Both	O
DHEA	O
50	O
mg	O
/	O
kg	O
(	O
p	O
<	O
0	O
.	O
5	O
),	O
and	O
100	O
mg	O
/	O
kg	O
(	O
p	O
<	O
0	O
.	O
1	O
)	O
significantly	O
decreased	O
all	O
movements	O
compared	O
with	O
the	O
amphetamine	O
-	O
induced	O
locomotion	O
group	O
.	O

There	O
was	O
a	O
significant	O
difference	O
between	O
groups	O
in	O
the	O
haloperidol	O
-	O
induced	O
catalepsy	B-Disease
test	O
(	O
p	O
<	O
0	O
.	O
5	O
).	O

There	O
was	O
no	O
significant	O
difference	O
between	O
groups	O
in	O
terms	O
of	O
total	O
climbing	O
time	O
in	O
the	O
apomorphine	O
-	O
induced	O
climbing	O
test	O
(	O
p	O
>	O
0	O
.	O
5	O
).	O

CONCLUSION	O
:	O
We	O
observed	O
that	O
DHEA	O
reduced	O
locomotor	O
activity	O
and	O
increased	O
catalepsy	B-Disease
at	O
both	O
doses	O
,	O
while	O
it	O
had	O
no	O
effect	O
on	O
climbing	O
behavior	O
.	O

We	O
suggest	O
that	O
DHEA	O
displays	O
typical	O
neuroleptic	O
-	O
like	O
effects	O
,	O
and	O
may	O
be	O
used	O
in	O
the	O
treatment	O
of	O
schizophrenia	B-Disease
.	O


Aconitine	O
-	O
induced	O
Ca2	O
+	O
overload	O
causes	O
arrhythmia	B-Disease
and	O
triggers	O
apoptosis	O
through	O
p38	O
MAPK	O
signaling	O
pathway	O
in	O
rats	O
.	O

Aconitine	O
is	O
a	O
major	O
bioactive	O
diterpenoid	O
alkaloid	O
with	O
high	O
content	O
derived	O
from	O
herbal	O
aconitum	O
plants	O
.	O

Emerging	O
evidence	O
indicates	O
that	O
voltage	O
-	O
dependent	O
Na	O
(+)	O
channels	O
have	O
pivotal	O
roles	O
in	O
the	O
cardiotoxicity	B-Disease
of	O
aconitine	O
.	O

However	O
,	O
no	O
reports	O
are	O
available	O
on	O
the	O
role	O
of	O
Ca	O
(	O
2	O
+)	O
in	O
aconitine	O
poisoning	B-Disease
.	O

In	O
this	O
study	O
,	O
we	O
explored	O
the	O
importance	O
of	O
pathological	O
Ca	O
(	O
2	O
+)	O
signaling	O
in	O
aconitine	O
poisoning	B-Disease
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
found	O
that	O
Ca	O
(	O
2	O
+)	O
overload	O
lead	O
to	O
accelerated	O
beating	O
rhythm	O
in	O
adult	O
rat	O
ventricular	O
myocytes	O
and	O
caused	O
arrhythmia	B-Disease
in	O
conscious	O
freely	O
moving	O
rats	O
.	O

To	O
investigate	O
effects	O
of	O
aconitine	O
on	O
myocardial	B-Disease
injury	I-Disease
,	O
we	O
performed	O
cytotoxicity	B-Disease
assay	O
in	O
neonatal	O
rat	O
ventricular	O
myocytes	O
(	O
NRVMs	O
),	O
as	O
well	O
as	O
measured	O
lactate	O
dehydrogenase	O
level	O
in	O
the	O
culture	O
medium	O
of	O
NRVMs	O
and	O
activities	O
of	O
serum	O
cardiac	O
enzymes	O
in	O
rats	O
.	O

The	O
results	O
showed	O
that	O
aconitine	O
resulted	O
in	O
myocardial	B-Disease
injury	I-Disease
and	O
reduced	O
NRVMs	O
viability	O
dose	O
-	O
dependently	O
.	O

To	O
confirm	O
the	O
pro	O
-	O
apoptotic	O
effects	O
,	O
we	O
performed	O
flow	O
cytometric	O
detection	O
,	O
cardiac	O
histology	O
,	O
transmission	O
electron	O
microscopy	O
and	O
terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
dUTP	O
-	O
biotin	O
nick	O
end	O
labeling	O
assay	O
.	O

The	O
results	O
showed	O
that	O
aconitine	O
stimulated	O
apoptosis	O
time	O
-	O
dependently	O
.	O

The	O
expression	O
analysis	O
of	O
Ca	O
(	O
2	O
+)	O
handling	O
proteins	O
demonstrated	O
that	O
aconitine	O
promoted	O
Ca	O
(	O
2	O
+)	O
overload	O
through	O
the	O
expression	O
regulation	O
of	O
Ca	O
(	O
2	O
+)	O
handling	O
proteins	O
.	O

The	O
expression	O
analysis	O
of	O
apoptosis	O
-	O
related	O
proteins	O
revealed	O
that	O
pro	O
-	O
apoptotic	O
protein	O
expression	O
was	O
upregulated	O
,	O
and	O
anti	O
-	O
apoptotic	O
protein	O
BCL	O
-	O
2	O
expression	O
was	O
downregulated	O
.	O

Furthermore	O
,	O
increased	O
phosphorylation	O
of	O
MAPK	O
family	O
members	O
,	O
especially	O
the	O
P	O
-	O
P38	O
/	O
P38	O
ratio	O
was	O
found	O
in	O
cardiac	O
tissues	O
.	O

Hence	O
,	O
our	O
results	O
suggest	O
that	O
aconitine	O
significantly	O
aggravates	O
Ca	O
(	O
2	O
+)	O
overload	O
and	O
causes	O
arrhythmia	B-Disease
and	O
finally	O
promotes	O
apoptotic	O
development	O
via	O
phosphorylation	O
of	O
P38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
.	O
